

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 2014218599 C1

(54) Title
Guanylate cyclase receptor agonists for use in colonic cleansing

(51) International Patent Classification(s)
C07K 14/245 (2006.01) **A61K 47/36** (2006.01)
A61K 9/48 (2006.01) **A61K 47/38** (2006.01)
A61K 31/53 (2006.01) **A61P 1/10** (2006.01)
A61K 38/04 (2006.01)

(21) Application No: **2014218599** (22) Date of Filing: **2014.02.25**

(87) WIPO No: **WO14/131024**

(30) Priority Data

(31) Number (32) Date (33) Country
61/768,902 **2013.02.25** **US**

(43) Publication Date: **2014.08.28**
(44) Accepted Journal Date: **2018.05.17**
(44) Amended Journal Date: **2018.09.06**

(71) Applicant(s)
Synergy Pharmaceuticals Inc.

(72) Inventor(s)
Riff, Dennis;Jacob, Gary S.;Shailubhai, Kunwar;Griffin, Patrick H.

(74) Agent / Attorney
Spruson & Ferguson, GPO Box 3898, Sydney, NSW, 2001, AU

(56) Related Art
WO 2010/065751 A2
US 2012/0237593 A1
WO 2008/151257 A2
US 2007/0010450 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2014/131024 A3

(43) International Publication Date

28 August 2014 (28.08.2014)

(51) International Patent Classification:

A61K 38/04 (2006.01) *A61K 31/53* (2006.01)
A61K 47/36 (2006.01) *C07K 14/245* (2006.01)
A61K 47/38 (2006.01) *A61P 1/10* (2006.01)
A61K 9/48 (2006.01)

(21) International Application Number:

PCT/US2014/018383

(22) International Filing Date:

25 February 2014 (25.02.2014)

(25) Filing Language:

English

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(26) Publication Language:

English

(30) Priority Data:

61/768,902 25 February 2013 (25.02.2013) US

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

24 December 2014

(72) Inventors: **RIFF, Dennis**; 2 Lagunipa, Laguna Beach, CA 92651 (US). **JACOB, Gary, S.**; 171 East 84th Street, #16J, New York, NY 10028 (US). **SHAILUBHAI, Kunwar**; 2707 Bald Eagle Circle, Audubon, PA 19403 (US). **GRiffin, Patrick, H.**; 143 Bennett Avenue, Apartment 5j, New York, NY (US).

(74) Agents: **KOZAKIEWICZ, Cynthia** et al.; Cooley LLP, 1299 Pennsylvania Avenue, Suite 700, Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,



WO 2014/131024 A3

(54) Title: GUANYLATE CYCLASE RECEPTOR AGONISTS FOR USE IN COLONIC CLEANSING

(57) Abstract: This invention provides a method of colonic cleansing.

AGONISTS OF GUANYLATE CYCLASE AND THEIR USES

5

RELATED APPLICATIONS

This application claims priority to, and benefit of, the U.S. Provisional Application No. 61/768,902, filed on February 25, 2013, the contents of which are incorporated herein by reference in their entireties.

10

INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING

The contents of the text file named “40737-513001WO_ST25.txt”, which was created on February 21, 2014 and is 150 KB in size, are hereby incorporated by reference in their entireties.

FIELD OF THE INVENTION

15 The present invention relates to colon cleansing compositions and methods of use of such compositions.

BACKGROUND OF THE INVENTION

Colon cleansing is important prior to numerous diagnostic and surgical procedures, for 20 example before colonoscopy, barium enema examination or colon surgery. It is also useful for preventing infection after surgery on the lower intestine. Colon cleansing is also known as colon clearing.

A variety of methods for colon cleansing are known. Dietary manipulation, laxatives, cathartics and enemas were traditionally used (Thomas, G. et al., *Gastroenterology*, 1982, 82, 25 435 437). Sodium phosphate solutions (Clarkston, W. K. et al., *Gastrointestinal Endoscopy*, 1996, 43, 43 48) and magnesium citrate/sodium picosulphate solutions (Regev, A. et al., *Am. J. Gastroenterol.*, 1998, 93, 1478 1482) have also been used.

Those methods suffer from various drawbacks. Dietary manipulation and laxatives are time consuming; enemas are unpleasant for the patient; and dangerous salt and water losses may 30 occur with cathartics, enemas and with sodium phosphate solutions.

Therefore, there is a great need to identify novel colon cleansing compositions and methods without these drawbacks.

SUMMARY OF THE INVENTION

5 The present invention provides a method of colonic cleansing by administering to a subject in need thereof an effective amount of a guanylate cyclase receptor agonist (GCRA) peptide or its derivative or analog.

In some embodiments, the peptide is bicyclic GCRA peptide.

10 In some embodiments, the method further comprises administering to the subject an effective amount of an osmotic colonic evacuant. Preferably, the osmotic colonic evacuant is magnesium citrate or a phosphate salt laxative.

15 In some embodiment, the method further comprises administering to the subject an effective amount of L-glucose, lubiprostone (Amitiza), prucalopride, an agent for treating chronic constipation, or any combination thereof. The effective amount of L-glucose is a unit dose of 20g-200g. Preferably, the GCRA peptide or its derivative or analog of the present invention is used in combination with an osmotic liquid prep, such as SUPREP® Bowel Prep Kit (sodium sulfate potassium sulfate, magnesium sulfate).

20 In some embodiment, the method further comprises administering to the subject an effective amount of a cGMP-specific phosphodiesterase inhibitor. The cGMP-specific phosphodiesterase inhibitor is selected from the group consisting of sulindac sulfone, zaprinast, motapizone, vardenafil, and sildenafil.

The effective amount of a GCRA peptide is a unit dose of 0.01 mg to 60 mg. Preferably, the effective amount of a GCRA peptide is a unit dose of 6.0 mg.

25 The present invention provides a formulation that comprises a mixture of (1) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at pH5.0; and (2) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at pH6.0 or pH 7.0.

In some embodiments, the inert carrier is a selected from mannitol, lactose, a microcrystalline cellulose, or starch.

In some embodiments, the amount of GCRA peptide per unit dose is from 1 mg to 60 mg when the GCRA peptide is SP-304 (SEQ ID NO: 1) or SP-333 (SEQ ID NO: 9) or their derivatives or analogs.

In some embodiments, the amount of GCRA peptide per unit dose is from 0.3 mg to 3.0 mg when the GCRA peptide is an *E. coli* ST peptide, linaclotide derivative or analog.

The present invention further provides a method of colonic cleansing by administering to a subject in need thereof any formulations described herein.

In any methods or any formulations described herein, the GCRA peptide consists essentially of the sequence of any one of SEQ ID NO: 1-346. For example, the peptide is bicyclic consisting essentially of the sequence of any one of SEQ ID NO: 1-54, 99-241, and 253-346. Preferably, the GCRA peptide is SEQ ID NO: 1, 9, 55 or 56.

Definitions of the specific embodiments of the invention as claimed herein follow.

According to a first embodiment of the invention, there is provided a method of colonic cleansing, comprising administering to a subject in need thereof an effective amount of a guanylate cyclase receptor agonist (GCRA) peptide consisting essentially of the sequence of SEQ ID NO: 9.

According to a second embodiment of the invention, there is provided a formulation comprising a mixture of:

- a. a composition comprising an inert carrier coated with GCRA peptides consisting essentially of the sequence of SEQ ID NO: 9 wherein said composition comprising an enteric coating that releases the peptides at pH5.0; and
- b. a composition comprising an inert carrier coated with GCRA peptides consisting essentially of the sequence of SEQ ID NO: 9 wherein said composition comprising an enteric coating that releases the peptides at pH6.0 or pH 7.0.

According to a third embodiment of the invention, there is provided a method of colonic cleansing, comprising administering to a subject in need thereof the formulation of the second embodiment.

According to a fourth embodiment of the invention, there is provided a use of a guanylate cyclase receptor agonist (GCRA) peptide consisting essentially of the sequence of SEQ ID NO: 9 in the manufacture of a medicament for colonic cleansing.

According to a fifth embodiment of the invention, there is provided use of a GCRA peptide consisting essentially of the sequence of SEQ ID NO: 9 in the manufacture of the formulation of the second embodiment for colonic cleansing.

The term 'comprise' and variants of the term such as 'comprises' or 'comprising' are used herein to denote the inclusion of a stated integer or stated integers but not to exclude any other integer or any other integers, unless in the context or usage an exclusive interpretation of the term is required.

Any reference to publications cited in this specification is not an admission that the disclosures constitute common general knowledge in Australia.

Other features and advantages of the invention will be apparent from and are encompassed by the following detailed description and claims.

DETAILED DESCRIPTION

The present invention is based upon the development of agonists of guanylate cyclase-C (GC-C). The agonists are analogs of uroguanylin, guanylin, lymphoguanylin and ST peptides.

Physicians and surgeons have developed a variety of means to achieve the desired level of colon cleansing. The use of dietary restrictions, laxatives, enemas, and whole-bowel lavage solutions, alone or in combinations has been employed.

However, these preparations have several drawbacks. For example, because most of commercially available solutions are isotonic, patients are required to ingest a significant amount of volume of these solutions, up to one eight ounce glass every ten minutes for a total of one gallon of fluid, to achieve effective purging. Sodium sulfate and phosphate salts have been used as laxatives. However, because of their small volumes, when used in this fashion they do not sufficiently clean the colon for diagnostic or surgical procedures. Another drawback of these preparations is their unpleasant, bitter, saline taste. This can promote nausea and vomiting in sensitive patients--thereby preventing ingestion.

The guanylate cyclase-C agonists of the present invention provide unexpected and superior effect than previous means for colon cleansing. These agonists are very specific and are relatively more stable in gastrointestinal (GI) tract, because they have relatively higher resistance

to degradation at the N-terminus and C-terminus from carboxypeptidases and/or by other proteolytic enzymes such as those present in the stimulated human intestinal fluid (SIF). In addition, these agonists can significantly increase intestinal motility and decrease water absorption. Therefore, they are excellent colon cleansing compositions with high specificity, 5 high efficiency, low volume/dosage, and no unpleasant taste, thus providing improved patients compliance. This is particularly true when the GCRA peptide or its derivative or analog of the present invention or any composition/formulation described herein is used in combination with a colon cleansing agent.

Preferably, the GCRA peptide or its derivative or analog of the present invention or any 10 composition/formulation described herein is used in combination with L-glucose, cholera toxin, osmotic colonic evacuants, cathartic, laxatives, agents for treating chronic constipation and/or an osmotic liquid prep. For example, an osmotic liquid prep is SUPREP® Bowel Prep Kit (sodium sulfate potassium sulfate, magnesium sulfate).

Accordingly, the present invention provides compositions comprising at least one GCRA 15 peptide (*i.e.*, GCC agonist peptide), at least one enteric coating which releases the peptide at a specific pH (*e.g.*, pH 4.0, pH 5.0, pH 6.0, or pH 7) and an inert carrier.

The present invention also provides a formulation comprising a mixture of (1) a 20 composition having an inert carrier coated with GCRA and an enteric coating that releases the peptides at pH5.0 and (2) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at pH6.0 or pH7.0.

In some embodiments, the GCRA peptide is any one of SEQ ID NO: 1-346. In some 25 embodiments, the GCRA peptide is SEQ ID NO: 1, 9, 55 or 56. In some embodiments, the inert carrier is selected from the group consisting of sorbitol, mannitol, EMDEX, and starch. In some embodiments, the carrier is mannitol (*e.g.*, MANNOGEM) or microcrystalline cellulose (*e.g.* PROSOLV, CELPHERE®, CELPHERE® beads). In a preferred embodiment, the carrier is 30 microcrystalline cellulose sphere or spherical microcrystalline cellulose, such as Celphere® SCP-100.

A composition may comprise an enteric coating which releases drug at pH 5 and an inert carrier coated with GCRA peptides.

A composition may comprise an enteric coating which releases drug at pH 6 and an inert 35 carrier coated with GCRA peptides.

A composition may comprise an enteric coating which releases drug at pH 7 and an inert carrier coated with GCRA peptides.

A composition may comprise an enteric coating which releases drug in a pH range of 4.5 to 5.5 or in a pH range of 5.5 to 6.5 at duodenum or jejunum and an inert carrier coated with 5 GCRA peptides.

A composition may comprise an enteric coating which releases drug in a pH range of 5.5 to 6.5 or in a pH range of 6.5 to 7.5 at ileum, terminal ileum, or ascending colon and an inert carrier coated with GCRA peptides.

A composition may comprise a mixture of enteric coatings which release drug at pH 5 10 and pH 6 or pH 7 and an inert carrier coated with GCRA peptides.

The present invention further provides compositions comprising a mixture of compositions that contain different peptides and/or that release the peptides at different pH levels, so that a specific composition can be released at a specific region of the GI tract (e.g., duodenum, jejunum, ileum, terminal ileum, or ascending colon) at a specific amount and time to 15 maximize the cleansing effect. Preferred pH for duodenum or jejunum release is pH 4.5-5.5 or pH 5.5-6.5. Preferred pH for ileum, terminal ileum, or ascending colon release is pH 5.5-6.5 or pH 6.5-7.5.

The mixture may comprise at least 2, 3, 4 or more compositions that release the peptides at different pH levels (e.g., pH5, pH6, or pH7). The mixture may comprise at least 2, 3, 4 or 20 more compositions that contain different GCRA peptides. A skilled artisan can determine the ratio of these compositions within the mixture, for example, according to the activity of each peptide, solubility of each peptide, and/or the targeting region of the GI tract.

The present invention also provides methods for colonic cleansing by administering to a subject in need thereof an effective amount of a GCRA peptide.

25 The GCRA peptides (*i.e.*, gualylate cyclase-C agonists) according to the invention include amino acid sequences represented by Formulae I-XXI, their corresponding α -amino adipic acid (Aad) derivatives (*e.g.*, Formulae I-Aad, II-Aad, III-Aad, IV-Aad, V-Aad, VI-Aad, VII-a-Aad, VII-b-Aad, VIII-Aad, IX-Aad, XVIII-Aad or XXI-Aad), as well as those amino acid sequence summarized below in Tables 1-8. The gualylate cyclase-C agonists according to 30 the invention are collectively referred to herein as “GCRA peptides”.

Table 1. GCRA Peptides (SP-304 and Derivatives)

Name	Position of Disulfide bonds	Structure	SEQ ID NO
SP-304	C4:C12, C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	1
SP-326	C3:C11, C6:C14	Asp ¹ -Glu ² -Cys ³ -Glu ⁴ -Leu ⁵ -Cys ⁶ -Val ⁷ -Asn ⁸ -Val ⁹ -Ala ¹⁰ -Cys ¹¹ -Thr ¹² -Gly ¹³ -Cys ¹⁴ -Leu ¹⁵	2
SP-327	C3:C11, C6:C14	Asp ¹ -Glu ² -Cys ³ -Glu ⁴ -Leu ⁵ -Cys ⁶ -Val ⁷ -Asn ⁸ -Val ⁹ -Ala ¹⁰ -Cys ¹¹ -Thr ¹² -Gly ¹³ -Cys ¹⁴	3
SP-328	C2:C10, C5:C13	Glu ¹ -Cys ² -Glu ³ -Leu ⁴ -Cys ⁵ -Val ⁶ -Asn ⁷ -Val ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -Leu ¹⁴	4
SP-329	C2:C10, C5:C13	Glu ¹ -Cys ² -Glu ³ -Leu ⁴ -Cys ⁵ -Val ⁶ -Asn ⁷ -Val ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³	5
SP-330	C1:C9, C4:C12	Cys ¹ -Glu ² -Leu ³ -Cys ⁴ -Val ⁵ -Asn ⁶ -Val ⁷ -Ala ⁸ -Cys ⁹ -Thr ¹⁰ -Gly ¹¹ -Cys ¹² -Leu ¹³	6
SP-331	C1:C9, C4:C12	Cys ¹ -Glu ² -Leu ³ -Cys ⁴ -Val ⁵ -Asn ⁶ -Val ⁷ -Ala ⁸ -Cys ⁹ -Thr ¹⁰ -Gly ¹¹ -Cys ¹²	7
SP-332	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	8
SP-333	C4:C12,C7:C15	dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	9
SP-334	C4:C12,C7:C15	dAsn ¹ -dAsp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	10
SP-335	C4:C12,C7:C15	dAsn ¹ -dAsp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	11
SP-336	C4:C12,C7:C15	dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	12
SP-337	C4:C12,C7:C15	dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -dLeu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	13
SP-338	C4:C12, C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵	14
SP-342	C4:C12, C7:C15	PEG3-Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	15
SP-343	C4:C12, C7:C15	PEG3-dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	16
SP-344	C4:C12, C7:C15	PEG3-dAsn ¹ -dAsp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	17
SP-347	C4:C12, C7:C15	dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	18
SP-348	C4:C12, C7:C15	PEG3-Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	19
SP-350	C4:C12, C7:C15	PEG3-dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	20

SP-352	C4:C12, C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	21
SP-358	C4:C12,C7:C15	PEG3-dAsn ¹ -dAsp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	22
SP-359	C4:C12,C7:C15	PEG3-dAsn ¹ -dAsp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	23
SP-360	C4:C12, C7:C15	dAsn ¹ -dAsp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	24
SP-361	C4:C12, C7:C15	dAsn ¹ -dAsp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	25
SP-362	C4:C12, C7:C15	PEG3-dAsn ¹ -dAsp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	26
SP-368	C4:C12, C7:C15	dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dNaI ¹⁶	27
SP-369	C4:C12, C7:C15	dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	28
SP-370	C4:C12, 7:15	dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Asp[Lactam] ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Orn ¹⁵ -dLeu ¹	29
SP-371	C4:C12,C7:C15	dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	30
SP-372	C4:C12,C7:C15	dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	31
N1	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	32
N2	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	33
N3	C4:C12,C7:C15	dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	34
N4	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	35
N5	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	36
N6	C4:C12,C7:C15	dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	37
N7	C4:C12,C7:C15	Asn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	38
N8	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	39
N9	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	40
N10	C4:C12,C7:C15	Asn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	41
N11	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	42
N12	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	43
N13	C4:C12,C7:C15	Asn ¹ -Asp ² -dGlu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	44

Formula I	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -Xaa ¹⁶	45
Formula II	C4:C12,C7:C15	Xaa _{n1} -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -Xaa _{n2} ¹⁶	46
Formula III	4:12,7:15	Xaa _{n1} -Maa ⁴ -Glu ⁵ -Xaa ⁶ -Maa ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Maa ¹² -Thr ¹³ -Gly ¹⁴ -Maa ¹⁵ -Xaa _{n2}	47
Formula IV	4:12,7:15	Xaa _{n1} -Maa ⁴ -Xaa ⁵ -Maa ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Maa ¹² -Xaa ¹³ -Xaa ¹⁴ -Maa ¹⁵ -Xaa _{n2}	48
Formula V	C4:C12,C7:C15	Asn ¹ -Asp ² -Asp ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Asn ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -Xaa ¹⁶	49
Formula VI	C4:C12,C7:C15	dAsn ¹ -Glu ² -Glu ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -X3 ⁸ -Asn ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -d-Xaa ¹⁶	50
Formula VII-a	C4:C12,C7:C15	dAsn ¹ -dGlu ² -Asp ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Asn ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -d-Xaa ¹⁶	51
Formula VII-b	C4:C12,C7:C15	dAsn ¹ -dAsp ² -Glu ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Asn ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -d-Xaa ¹⁶	52
Formula VIII	C4:C12,C7:C15	dAsn ¹ -dAsp ² -dGlu ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Tyr ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -d-Xaa ¹⁶	53
Formula IX	C4:C12,C7:C15	dAsn ¹ -dGlu ² -dGlu ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Tyr ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -d-Xaa ¹⁶	54
Formula XXI	C4:C12,C7:C15	Xaa _{n1} -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Xaa ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Xaa ¹⁵ -Xaa _{n2} ¹⁶	250

Table 2. Linaclotide and Derivatives

Name	Position of Disulfide Bonds	Structure	SEQIDNO:
SP-339(linaclotide)	C1:C6, C2:C10, C5:C13	Cys ¹ -Cys ² -Glu3-Tyr ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -Tyr ¹⁴	55
SP-340	C1:C6, C2:C10, C5:C13	Cys ¹ -Cys ² -Glu ³ -Tyr ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³	56
SP-349	C1:C6, C2:C10, C5:C13	PEG3-Cys ¹ -Cys ² -Glu ³ -Tyr ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -Tyr ¹⁴ -PEG3	57
SP-353	C3:C8, C4:C12, C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶	58
SP-354	C3:C8, C4:C12, C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Phe ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶	59
SP-355	C1:C6, C2:C10, C5:C13	Cys ¹ -Cys ² -Glu ³ -Tyr ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -dTyr ¹⁴	60
SP-357	C1:C6, C2:C10, C5:C13	PEG3-Cys ¹ -Cys ² -Glu ³ -Tyr ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -Tyr ¹⁴	61
SP-374	C3:C8, C4:C12, C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶	62
SP-375	C3:C8, C4:C12, C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr ¹⁶	63
SP-376	C3:C8, C4:C12, C7:C15	dAsn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶	64
SP-377	C3:C8, C4:C12, C7:C15	dAsn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr ¹⁶	65
SP-378	C3:C8, C4:C12, C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr ¹⁶	66
SP-379	C3:C8, C4:C12, C7:C15	dAsn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶	67
SP-380	C3:C8, C4:C12, C7:C15	dAsn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr ¹⁶	68
SP-381	C3:C8, C4:C12, C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Phe ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -	69

		dTyr ¹⁶	
SP-382	C3:C8, C4:C12, C7:15	dAsn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Phe ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶	70
SP-383	C3:C8, C4:C12, C7:15	dAsn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Phe ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr ¹⁶	71
SP384	C1:C6, C2:C10, C5:C13	Cys ¹ -Cys ² -Glu ³ -Tyr ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -Tyr ¹⁴ -PEG3	72
N14	C1:C6, C2:C10, C5:C13	PEG3-Cys ¹ -Cys ² -Glu ³ -Tyr ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -PEG3	73
N15	C1:C6, C2:C10, C5:C13	PEG3-Cys ¹ -Cys ² -Glu ³ -Tyr ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³	74
N16	C1:C6, C2:C10, C5:C13	Cys ¹ -Cys ² -Glu ³ -Tyr ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -PEG3	75
N17	C3:C8, C4:C12, C7:C15	PEG3-Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶ -PEG3	76
N18	C3:C8, C4:C12, C7:C15	PEG3-Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶ -PEG3	77
N19	C3:C8, C4:C12, C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁶ -PEG3	78
N20	C3:C8, C4:C12, C7:C15	PEG3-Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Phe ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶ -PEG3	79
N21	C3:C8, C4:C12, C7:C15	PEG3-Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Phe ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶ -PEG3	80
N22	C3:C8, C4:C12, C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Phe ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶ -PEG3	81
N23	C3:C8, C4:C12, C7:C15	PEG3-Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶ -PEG3	82

N24	C3:C8, C4:C12, C7:C15	PEG3-Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶	83
N25	C3:C8, C4:C12, C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶ -PEG3	84
N26	C1:C6, C2:C10, C5:C13	Cys ¹ -Cys ² -Glu3-Ser ⁴ -Cys ⁵ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -Tyr ¹⁴	85
N27	C1:C6, C2:C10, C5:C13	Cys ¹ -Cys ² -Glu3-Phe ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -Tyr ¹⁴	86
N28	C1:C6, C2:C10, C5:C13	Cys ¹ -Cys ² -Glu3-Ser ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -	87
N29	C1:C6, C2:C10, C5:C13	Cys ¹ -Cys ² -Glu3-Phe ⁴ -Cys ⁵ -Cys ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³	88
N30	1:6, 2:10, 5:13	Pen ¹ -Pen ² -Glu3-Tyr ⁴ -Pen ⁵ -Pen ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Pen ¹⁰ -Thr ¹¹ -Gly ¹² -Pen ¹³ -Tyr ¹⁴	89
N31	1:6, 2:10, 5:13	Pen ¹ -Pen ² -Glu3-Tyr ⁴ -Pen ⁵ -Pen ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Pen ¹⁰ -Thr ¹¹ -Gly ¹² -Pen ¹³	90
Formula X	C9:C14, C10:C18, C13:C21	Xaa ¹ -Xaa ² -Xaa ³ -Xaa ⁴ -Xaa ⁵ -Xaa ⁶ -Asn ⁷ -Tyr ⁸ -Cys ⁹ -Cys ¹⁰ -Xaa ¹¹ -Tyr ¹² -Cys ¹³ -Cys ¹⁴ -Xaa ¹⁵ -Xaa ¹⁶ -Xaa ¹⁷ -Cys ¹⁸ -Xaa ¹⁹ -Xaa ²⁰ -Cys ²¹ -Xaa ²²	91
Formula XI	C9:C14, C10:C18, C13:C21	Xaa ¹ -Xaa ² -Xaa ³ -Xaa ⁴ -Xaa ⁵ -Xaa ⁶ -Asn ⁷ -Phe ⁸ -Cys ⁹ -Cys ¹⁰ -Xaa ¹¹ -Phe ¹² -Cys ¹³ -Cys ¹⁴ -Xaa ¹⁵ -Xaa ¹⁶ -Xaa ¹⁷ -Cys ¹⁸ -Xaa ¹⁹ -Xaa ²⁰ -Cys ²¹ -Xaa ²²	92
Formula XII	C3:C8, C4:C12, C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Xaa ⁵ -Phe ⁶ -Cys ⁷ -Cys ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -Xaa ¹⁶	93
Formula XIII	3:8, 4:12, 7:15	Asn ¹ -Phe ² -Pen ³ -Cys ⁴ -Xaa ⁵ -Phe ⁶ -Cys ⁷ -Pen ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -Xaa ¹⁶	94
Formula XIV	3:8, 4:12, 7:15	Asn ¹ -Phe ² -Maa ³ -Maa ⁴ -Xaa ⁵ -Xaa ⁶ -Maa ⁷ -Maa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Maa ¹² -Xaa ¹³ -Xaa ¹⁴ -Maa ¹⁵ -Xaa ¹⁶	95
Formula XV	1:6, 2:10, 5:13	Maa ¹ -Maa ² -Glu3-Xaa ⁴ -Maa ⁵ -Maa ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Maa ¹⁰ -Thr ¹¹ -Gly ¹² -Maa ¹³ -Tyr ¹⁴	96
Formula XVI	1:6, 2:10, 5:13	Maa ¹ -Maa ² -Glu3-Xaa ⁴ -Maa ⁵ -Maa ⁶ -Asn ⁷ -Pro ⁸ -Ala ⁹ -Maa ¹⁰ -Thr ¹¹ -Gly ¹² -Maa ¹³	97
Formula XVII	1:6, 2:10, 5:13	Xaa _{n3} -Maa ¹ -Maa ² -Xaa ³ -Xaa ⁴ -Maa ⁵ -Maa ⁶ -Xaa ⁷ -Xaa ⁸ -Maa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Maa ¹² -Xaa ¹³ -Xaa _{n2}	98

Table 3.GCRA Peptides

Name	Position of Disulfide bonds	Structure	SEQIDNO:
SP-363	C4:C12,C7:C15	dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu-AMIDE ¹⁶	99
SP-364	C4:C12,C7:C15	dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dSer ¹⁶	100
SP-365	C4:C12,C7:C15	dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dSer-AMIDE ¹⁶	101
SP-366	C4:C12,C7:C15	dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr ¹⁶	102
SP-367	C4:C12,C7:C15	dAsn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr-AMIDE ¹⁶	103
SP-373	C4:C12,C7:C15	Pyglu ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu-AMIDE ¹⁶	104
/	C4:C12,C7:C15	Pyglu ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	251
SP-304diPEG	C4:C12,C7:C15	PEG3-Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶ -PEG3	105
SP-304N-PEG	C4:C12,C7:C15	PEG3-Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	106
SP-304C-PEG	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶ -PEG3	107

Table 4. SP-304 Analogs, Uroguanylin, and Uroguanylin Analogs

Name	Position of Disulfide bonds	Structure	SEQID NO
Formula XVIII	C4:C12, C7:C15	Xaa ¹ -Xaa ² -Xaa ³ -Maa ⁴ -Xaa ⁵ -Xaa ⁶ -Maa ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Val ¹¹ -Maa ¹² -Xaa ¹³ -Xaa ¹⁴ -Maa ¹⁵ -Xaa ¹⁶	108
Uroguanylin	C4:C12, C7:C15	Asn ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	109
N32	C4:C12,C7:C15	Glu ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	110
N33	C4:C12,C7:C15	Glu ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	111
N34	C4:C12,C7:C15	Glu ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	112
N35	C4:C12,C7:C15	Glu ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	113
N36	C4:C12,C7:C15	Asp ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	114
N37	C4:C12,C7:C15	Asp ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	115
N38	C4:C12,C7:C15	Asp ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	116
N39	C4:C12,C7:C15	Asp ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	117
N40	C4:C12,C7:C15	Gln ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	118
N41	C4:C12,C7:C15	Gln ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	119
N42	C4:C12,C7:C15	Gln ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	120
N43	C4:C12,C7:C15	Gln ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	121
N44	C4:C12,C7:C15	Lys ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	122
N45	C4:C12,C7:C15	Lys ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	123
N46	C4:C12,C7:C15	Lys ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	124
N47	C4:C12,C7:C15	Lys ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	125
N48	C4:C12,C7:C15	Glu ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	126
N49	C4:C12,C7:C15	Glu ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	127

Table 5. Guanylin and Analogs

Name	Position of Disulfide bonds	Structure	SEQIDNO
Formula XIX	4:12,7:15	Xaa ¹ -Xaa ² -Xaa ³ -Maa ⁴ -Xaa ⁵ -Xaa ⁶ -Maa ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Maa ¹² -Xaa ¹³ -Xaa ¹⁴ -Maa ¹⁵	174
Guanylin	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Phe ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	175
Guanylin	C4:C12,C7:C15	Pro ¹ -Gly ² -Thr ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Tyr ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵	252
Human Guanylin	C4:C12, C7:C15	Pro ¹ -Gly ² -Thr ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Tyr ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵	
N97	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	176
N98	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	177
N99	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Val ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	178
N100	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	179
N101	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	180
N102	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	181
N103	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Val ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	182
N104	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	183
N105	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	184
N106	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	185
N107	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Val ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	186
N108	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	187
N109	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	188
N110	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	189
N111	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Val ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	190
N112	C4:C12,C7:C15	Ser ¹ -His ² -Thr ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	191
N113	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	192
N114	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	193
N115	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Val ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	194
N116	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	195
N117	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	196
N118	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	197
N119	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Val ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	198
N120	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	199
N121	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	200
N122	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	201

N123	C4:Cl12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Val ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	202
N124	C4:Cl12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	203
N125	C4:Cl12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	204
N126	C4:Cl12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	205
N127	C4:Cl12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Val ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	206
N128	C4:Cl12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ala ⁸ -Asn ⁹ -Ala ¹⁰ -Ala ¹¹ -Cys ¹² -Ala ¹³ -Gly ¹⁴ -Cys ¹⁵	207

Table 6. Lymphoguanylin and Analogs

Name	Position of Disulfide bonds	Structure	SEQID NO
FormulaXX	4:12	Xaa ¹ -Xaa ² -Xaa ³ -Maa ⁴ -Xaa ⁵ -Xaa ⁶ -Maa ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Maa ¹² -Xaa ¹³ -Xaa _{nl} ¹⁴ -Xaa _{nl} ¹⁵	208
<u>Lymphoguanylin</u>	C4:C12	Gln ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	209
N129	C4:C12	Gln ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	210
N130	C4:C12	Gln ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	211
N131	C4:C12	Gln ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	212
N132	C4:C12	Gln ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	213
N133	C4:C12	Gln ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Glu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	214
N134	C4:C12	Gln ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Glu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	215
N135	C4:C12	Gln ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Glu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	216
N136	C4:C12	Gln ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Glu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	217
N137	C4:C12	Gln ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Glu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	218
N138	C4:C12	Gln ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	219
N139	C4:C12	Gln ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	220
N140	C4:C12	Gln ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	221
N141	C4:C12	Gln ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	222
N142	C4:C12	Gln ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	223
N143	C4:C12	Gln ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	224
N144	C4:C12	Gln ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Tyr ¹⁵	225
N145	C4:C12,C7	Gln ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	226

N146	:C15	Gln ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	227
N147	:C15	Gln ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	228
N148	:C15	Gln ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	229
N149	:C15	Gln ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Glu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	230
N150	:C15	Gln ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Glu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser	231
N151	:C15	Gln ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Glu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	232
N152	:C15	Gln ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Glu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	233
N153	:C15	Gln ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	234
N154	:C15	Gln ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	235
N155	:C15	Gln ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	236
N156	:C15	Gln ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	237
N157	:C15	Gln ¹ -Glu ² -Glu ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	238
N158	:C15	Gln ¹ -Asp ² -Glu ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	239
N159	:C15	Gln ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	240
N160	:C15	Gln ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Ile ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	241

Table 7. ST Peptide and Analogues

Name	Position of Disulfide bonds	Structure	SEQIDNO
STPeptide	C9:C14,C10:C18,C13:C21	Asn ¹ -Ser ² -Ser ³ -Asn ⁴ -Ser ⁵ -Ser ⁶ -Asn ⁷ -Tyr ⁸ -Cys ⁹ -Cys ¹⁰ -Glu ¹¹ -Lys ¹² -Cys ¹³ -Cys ¹⁴ -Asn ¹⁵ -Pro ¹⁶ -Ala ¹⁷ -Cys ¹⁸ -Thr ¹⁹ -Gly ²⁰ -Cys ²¹ -Tyr ²²	242
N161	C3:C8,C4:C12,C7:C15	PEG3-Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶ -PEG3	243
N162	C3:C8,C4:C12,C7:C15	PEG3-Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶	244
N163	C3:C8,C4:C12,C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶ -PEG3	245
N164	C3:C8,C4:C12,C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶	246
N165	C3:C8,C4:C12,C7:C15	dAsn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr ¹⁶	247
N166	C3:C8,C4:C12,C7:C15	Asn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr ¹⁶	248
N167	C3:C8,C4:C12,C7:C15	dAsn ¹ -Phe ² -Cys ³ -Cys ⁴ -Glu ⁵ -Thr ⁶ -Cys ⁷ -Cys ⁸ -Asn ⁹ -Pro ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Tyr ¹⁶	249

Table 8. Alpha-aminoadipic acid derivatives of GCRA Peptides

Corresponds to:	Position of Disulfide bond	Structure	SEQ ID NO
SP-304	C4:C12, C7:C15	Asn ¹ -Asp ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	253
SP-326	C3:C11, C6:C14	Asp ¹ -Ad ² -Cys ³ -Glu ⁴ -Leu ⁵ -Cys ⁶ -Val ⁷ -Asn ⁸ -Val ⁹ -Ala ¹⁰ -Cys ¹¹ -Thr ¹² -Gly ¹³ -Cys ¹⁴ -Leu ¹⁵	254
SP-327	C3:C11, C6:C14	Asp ¹ -Ad ² -Cys ³ -Glu ⁴ -Leu ⁵ -Cys ⁶ -Val ⁷ -Asn ⁸ -Val ⁹ -Ala ¹⁰ -Cys ¹¹ -Thr ¹² -Gly ¹³ -Cys ¹⁴	255
SP-328	C2:C10, C5:C13	Ad ¹ -Cys ² -Glu ³ -Leu ⁴ -Cys ⁵ -Val ⁶ -Asn ⁷ -Val ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³ -Leu ¹⁴	256

SP-329	C2:C10, C5:C13	Aad ¹ -Cys ² -Glu ³ -Leu ⁴ -Cys ⁵ -Val ⁶ -Asn ⁷ -Val ⁸ -Ala ⁹ -Cys ¹⁰ -Thr ¹¹ -Gly ¹² -Cys ¹³	257
SP332	C4:C12,C7:C15	Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	258
SP-333	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	259
SP-334	C4:C12,C7:C15	dAsn ¹ -dAsp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	260
SP-336	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	261
SP-337	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	262
SP-338	C4:C12, C7:C15	Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵	263
SP-342	C4:C12, C7:C15	PEG3-Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	264
SP-343	C4:C12, C7:C15	PEG3-dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	265
SP-344	C4:C12, C7:C15	PEG3-dAsn ¹ -dAsp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	266
SP-347	C4:C12, C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	267
SP-348	C4:C12, C7:C15	PEG3-Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	268
SP-350	C4:C12, C7:C15	PEG3-dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	269
SP-352	C4:C12, C7:C15	Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	270
SP-359	C4:C12,C7:C15	PEG3-dAsn ¹ -dAsp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	271
SP-360	C4:C12, C7:C15	dAsn ¹ -dAsp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	272
SP-368	C4:C12, C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	273
SP-369	C4:C12, C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -AIB ⁸ -Asn ⁹ -AIB ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	274
SP-370	C4:C12, 7:15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Asp[Lactam] ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Orn ¹⁵ -dLeu ¹⁶	275
SP-371	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	276
SP-372	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	277
N1	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	278
N2	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	279
N3	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Tyr ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	280

N4	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	281
N5	C4:C12,C7:C15	PEG3-dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	282
N6	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Ser ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	283
N7	C4:C12,C7:C15	Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	284
N8	C4:C12,C7:C15	PEG3-Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu ¹⁶ -PEG3	285
N9	C4:C12,C7:C15	PEG3-Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	286
N10	C4:C12,C7:C15	Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	287
N11	C4:C12,C7:C15	PEG3-Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶ -PEG3	288
N12	C4:C12,C7:C15	PEG3-Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dSer ¹⁶ -PEG3	289
N13	C4:C12,C7:C15	Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dSer ¹⁶ -PEG3	290
Formula I (I-Aad)	C4:C12,C7:C15	Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -Xaa ¹⁶	291
Formula II (II-Aad)	C4:C12,C7:C15	Xaa _{n1} -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -Xaa _{n2}	292
Formula III (III-Aad)	4:12,7:15	Xaa _{n1} -Maa ⁴ -Glu ⁵ -Xaa ⁶ -Maa ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Maa ¹² -Thr ¹³ -Gly ¹⁴ -Maa ¹⁵ -Xaa _{n2}	293
Formula IV (IV-Aad)		Xaa _{n1} -Maa ⁴ -Xaa ⁵ -Maa ⁶ -Xaa ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Maa ¹² -Xaa ¹³ -Maa ¹⁴ -Maa ¹⁵ -Xaa _{n2}	294
Formula V (V-Aad)	C4:C12,C7:C15	Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Asn ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Cys ¹⁵ -Xaa ¹⁶	295
Formula VI (VI-Aad)	C4:C12,C7:C15	dAsn ¹ -Glu ² -Aad ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Asn ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -dLeu ¹⁶	296
Formula VII-a (VI-a-Aad)	C4:C12,C7:C15	dAsn ¹ -dGlu ² -Aad ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Asn ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -d-Xaa ¹⁶	297

Formula VII-b (VI-b- Aad)	C4:C12,C7:C15	dAsn ¹ -dAsp ² -Aad ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Tyr ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -d-Xaa ¹⁶	298
Formula VIII (VIII-Aad)	C4:C12,C7:C15	dAsn ¹ -dAsp ² -Aad ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Tyr ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -d-Xaa ¹⁶	299
Formula IX (IX-Aad)	C4:C12,C7:C15	dAsn ¹ -dGlu ² -Aad ³ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Cys ⁷ -Xaa ⁸ -Tyr ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Cys ¹⁵ -d-Xaa ¹⁶	300
Formula XXI (XXI- Aad)	C4:C12,C7:C15	Xaa ₁₁ -Cys ⁴ -Xaa ⁵ -Xaa ⁶ -Xaa ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Cys ¹² -Xaa ¹³ -Xaa ¹⁴ -Xaa ¹⁵ -Xaa ₁₂ ¹⁶	301
SP-363	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu-AMIDE ¹⁶	302
SP-364	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dSer ¹⁶	303
SP-365	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dSer-AMIDE ¹⁶	304
SP-366	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr ¹⁶	305
SP-367	C4:C12,C7:C15	dAsn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dTyr-AMIDE ¹⁶	306
SP-373	C4:C12,C7:C15	Pyglu ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -dLeu-AMIDE ¹⁶	307
/	C4:C12,C7:C15	Pyglu ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	308
SP- 304diPEG	C4:C12,C7:C15	PEG3-Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶ -PEG3	309
SP-304N- PEG	C4:C12,C7:C15	PEG3-Asn ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	310
SP-304C- PEG	C4:C12,C7:C15	Asn ¹ -Asp ² -Glu ³ -Cys ⁴ -Ad ⁵ -Cys ⁶ -Glu ⁷ -Leu ⁸ -Cys ⁹ -Val ¹⁰ -Asn ¹¹ -Val ¹² -Ala ¹³ -Cys ¹⁴ -Gly ¹⁵ -Cys ¹⁶ -Leu ¹⁶	311
Formula XVII (XVII- Aad)	C4:C12,C7:C15	Xaa ¹ -Xaa ² -Ad ³ -Maa ⁴ -Xaa ⁵ -Xaa ⁶ -Maa ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Maa ¹¹ -Xaa ¹² -Maa ¹³ -Xaa ¹⁴ -Maa ¹⁵ -Xaa ¹⁶	312
N32	C4:C12,C7:C15	Glu ¹ -Asp ² -Ad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Val ⁸ -Asn ⁹ -Val ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Leu ¹⁶	313

N83	C4:C12,C7:C15	Glu ¹ -Glu ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	338
N85	C4:C12,C7:C15	Asp ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	339
N87	C4:C12,C7:C15	Asp ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	340
N88	C4:C12,C7:C15	Asp ¹ -Glu ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	341
N89	C4:C12,C7:C15	Gln ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	342
N91	C4:C12,C7:C15	Gln ¹ -Glu ² -Asp ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	343
N92	C4:C12,C7:C15	Gln ¹ -Glu ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	344
N93	C4:C12,C7:C15	Lys ¹ -Asp ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	345
N95	C4:C12,C7:C15	Lys ¹ -Glu ² -Aad ³ -Cys ⁴ -Glu ⁵ -Leu ⁶ -Cys ⁷ -Ile ⁸ -Asn ⁹ -Met ¹⁰ -Ala ¹¹ -Cys ¹² -Thr ¹³ -Gly ¹⁴ -Cys ¹⁵ -Ser ¹⁶	346

The GCRA peptides and derivative or analogs thereof described herein bind the guanylate cyclase C (GC-C) and stimulate intracellular production of cyclic guanosine monophosphate (cGMP). In some aspects, the GCRA peptides stimulate intracellular cGMP production at higher levels than naturally occurring GC-C agonists (*e.g.*, uroguanylin, guanylin, 5 lymphoguanylin and ST peptides).

For example, the GCRA peptides of the invention stimulate 5, 10%, 20%, 30%, 40%, 50%, 75%, 90% or more intracellular cGMP compared to naturally occurring GC-C agonists. The terms induced and stimulated are used interchangeably throughout the specification. The GCRA peptides described herein are more stable than naturally occurring GC-C agonists. By 10 more stable it is meant that the peptide degrades less and/or more slowly in simulated gastrointestinal fluid and/or simulated intestinal fluid compared to naturally occurring GC-C agonists. For example, the GCRA peptide of the invention degrade 2%, 3%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 75%, 90% or less compared to naturally occurring GC-C agonists.

As used herein, the term “guanylate cyclase receptor (GCR)” refers to the class of 15 guanylate cyclase C receptor on any cell type to which the inventive agonist peptides or natural agonists described herein bind. As used herein, “intestinal guanylate cyclase receptor” is found exclusively on epithelial cells lining the GI mucosa. Uroguanylin, guanylin, and ST peptides are expected to bind to these receptors and may induce apoptosis. The possibility that there may be different receptors for each agonist peptide is not excluded. Hence, the term refers to the class of 20 guanylate cyclase receptors on epithelial cells.

As used herein, the term “GCC agonist” is meant to refer to peptides and/or other compounds that bind to an intestinal guanylate cyclase receptor and stimulate fluid and electrolyte transport. This term also covers fragments and pro-peptides that bind to GCR and stimulate fluid and water secretion.

As used herein, the term “substantially equivalent” is meant to refer to a peptide that has 25 an amino acid sequence equivalent to that of the binding domain where certain residues may be deleted or replaced with other amino acids without impairing the peptide’s ability to bind to an intestinal guanylate cyclase receptor and stimulate fluid and electrolyte transport.

Addition of carriers (*e.g.*, phosphate-buffered saline or PBS) and other components to the 30 composition of the present invention is well within the level of skill in this art. In addition to the compound, such compositions may contain pharmaceutically acceptable carriers and other

ingredients known to facilitate administration and/or enhance uptake. Other formulations, such as microspheres, nanoparticles, liposomes, and immunologically-based systems may also be used in accordance with the present invention. Other examples include formulations with polymers (e.g., 20% w/v polyethylene glycol) or cellulose, or enteric formulations.

5

GCRA PEPTIDES

In one aspect, the invention provides a GCRA peptide. The GCRA peptides are analogues uroguanylin, guanylin, lymphoguanylin and ST peptides. No particular length is implied by the term “peptide”. In some embodiments, the GCRA peptide is less than 25 amino acids in length, e.g., less than or equal to 20, 15, 14, 13, 12, 11, 10, or 5 amino acid in length.

The GCRA peptides can be polymers of L-amino acids, D-amino acids, or a combination of both. For example, in various embodiments, the peptides are D retro-inverso peptides. The term “retro-inverso isomer” refers to an isomer of a linear peptide in which the direction of the sequence is reversed and the chirality of each amino acid residue is inverted. *See, e.g.,* Jameson *et al.*, *Nature*, 368, 744-746 (1994); Brady *et al.*, *Nature*, 368, 692-693 (1994). The net result of combining D-enantiomers and reverse synthesis is that the positions of carbonyl and amino groups in each amide bond are exchanged, while the position of the side-chain groups at each alpha carbon is preserved. Unless specifically stated otherwise, it is presumed that any given L-amino acid sequence of the invention may be made into a D retro-inverso peptide by synthesizing a reverse of the sequence for the corresponding native L-amino acid sequence. For example a GCRA peptide includes the sequence defined by Formulae I-XXI, their corresponding α -amino adipic acid (Aad) derivatives (e.g., Formula I-Aad, II-Aad, III-Aad, IV-Aad, V-Aad, VI-Aad, VII-a-Aad, VII-b-Aad, VIII-Aad, IX-Aad, XVIII-Aad or XXI-Aad), as well as those amino acid sequence summarized below in Tables 1-8.

By inducing cGMP production is meant that the GCRA peptide induces the production of intracellular cGMP. Intracellular cGMP is measured by methods known in the art. For example, the GCRA peptide of the invention stimulate 5%, 10%, 20%, 30%, 40%, 50%, 75%, 90% or more intracellular cGMP compared to naturally occurring GC-C agonists. In some embodiments the GCRA peptides described herein are more stable than naturally occurring GC-C agonists. By more stable it is meant that the peptide degrade less and/or more slowly in simulated gastric fluid and/or simulated intestinal fluid compared to naturally occurring GC-C

agonists. For example, the GCRA peptide of the invention degrade 2%, 3%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 75%, 90% or less compared to naturally occurring GC-C agonists.

As used herein PEG3, 3 PEG, is meant to denote polyethylene glycol such as include aminoethoxy-ethyloxy-acetic acid (AeeA).

5 As used herein, the term “AMIDE” is meant to denote that the terminal carboxylic acid is replaced with an amide group, i.e., the terminal COOH is replaced with CONH₂.

As used herein (e.g., in Formulae I- XXI, their corresponding α -amino adipic acid (Aad) derivatives represented by Formulae I-Aad, II-Aad, III-Aad, IV-Aad, V-Aad, VI-Aad, VII-a-Aad, VII-b-Aad, VIII-Aad, IX-Aad, XVIII-Aad or XXI-Aad), X_{aa} is any natural, unnatural 10 amino acid or amino acid analogue; M_{aa} is a Cysteine (Cys), Penicillamine (Pen), homocysteine, or 3-mercaptoproline. Xaa_{n1} is meant to denote an amino acid sequence of any natural, unnatural amino acid or amino acid analogue that is one, two or three residues in length; Xaa_{n2} is meant to denote an amino acid sequence of any natural, unnatural amino acid or amino acid analogue that is zero or one residue in length; and Xaa_{n3} is meant to denote an amino acid 15 sequence of any natural, unnatural amino acid or amino acid analogue that is zero, one, two, three, four, five or six residues in length. Additionally, any amino acid represented by Xaa, may be an L-amino acid, a D-amino acid, a methylated amino acid, a fluorinated amino acid or any combination of thereof. Preferably the amino acid at the N- terminus, C-terminus or both is a D-amino acid. Optionally, any GCRA peptide represented by Formulae I-XXI and their 20 corresponding α -amino adipic acid (Aad) derivatives represented by Formulae I-Aad, II-Aad, III-Aad, IV-Aad, V-Aad, VI-Aad, VII-a-Aad, VII-b-Aad, VIII-Aad, IX-Aad, XVIII-Aad or XXI-Aad may contain one or more polyethylene glycol residues at the N- terminus, C-terminus or both. An exemplary polyethylene glycol includes aminoethoxy-ethyloxy-acetic acid and polymers thereof. In some embodiments, any GCRA peptide represented by Formulae I-XXI 25 and their corresponding α -amino adipic acid (Aad) derivatives represented by Formulae I-Aad, II-Aad, III-Aad, IV-Aad, V-Aad, VI-Aad, VII-a-Aad, VII-b-Aad, VIII-Aad, IX-Aad, XVIII-Aad or XXI-Aad may contain AMIDE at the c-terminus.

Specific examples of GCRA peptides that can be used in the methods and formulations of the invention include a peptide selected from the group designated by SEQ ID NOs: 1-346.

30 In some embodiments, GCRA peptides include peptides having the amino acid sequence of Formula I. In some embodiments, at least one amino acid of Formula I is a D-amino acid or a

methylated amino acid and/or the amino acid at position 16 is a serine. Preferably, the amino acid at position 16 of Formula I is a D-amino acid or a methylated amino acid. For example, the amino acid at position 16 of Formula I is a d-leucine or a d-serine. Optionally, one or more of the amino acids at positions 1-3 of Formula I are D-amino acids or methylated amino acids or a 5 combination of D-amino acids or methylated amino acids. For example, Asn¹, Asp² or Glu³ (or a combination thereof) of Formula I is a D-amino acid or a methylated amino acid. Preferably, the amino acid at position Xaa⁶ of Formula I is a leucine, serine or tyrosine.

In alternative embodiments, GCRA peptides include peptides having the amino acid sequence of Formula II. In some embodiments, at least one amino acid of Formula II is a D-amino acid or a methylated amino acid. Preferably, the amino acid denoted by Xaa_{n2} of Formula II is a D-amino acid or a methylated amino acid. In some embodiments, the amino acid denoted by Xaa_{n2} of Formula II is a leucine, a d-leucine, a serine, or a d-serine. Preferably, the one or more amino acids denoted by Xaa_{n1} of Formula II are D-amino acids or methylated amino acids. Preferably, the amino acid at position Xaa⁶ of Formula II is a leucine, a serine, or a tyrosine. In 15 some embodiments, Xaa¹ is a pyroglutamic acid. In some embodiments, Xaa² is glutamic acid or d-glutamic acid. In some embodiments, Xaa³ is an aspartic acid or d-aspartic acid. In some embodiments, Xaa⁸ and Xaa¹⁰ are AIB. In some embodiments, Xaa⁹ is tyrosine. In some embodiments, Xaa¹⁶ is dNal.

In some embodiments, GCRA peptides include peptides having the amino acid sequence of Formula III. In some embodiments, at least one amino acid of Formula III is a D-amino acid or a methylated amino acid and/or Maa is not a cysteine. Preferably, the amino acid denoted by Xaa_{n2} of Formula III is a D-amino acid or a methylated amino acid. In some embodiments the amino acid denoted by Xaa_{n2} of Formula III is a leucine, a d-leucine, a serine, or a d-serine. Preferably, the one or more amino acids denoted by Xaa_{n1} of Formula III are D-amino acids or methylated amino acids. Preferably, the amino acid at position Xaa⁶ of Formula III is a leucine, a serine, or a tyrosine. In some embodiments, Xaa¹ is a pyroglutamic acid. In some 25 embodiments, Xaa² is glutamic acid or d-glutamic acid. In some embodiments, Xaa³ is an aspartic acid or d-aspartic acid. In some embodiments, Xaa¹⁶ is dNal.

In other embodiments, GCRA peptides include peptides having the amino acid sequence of Formula IV. In some embodiments, at least one amino acid of Formula IV is a D-amino acid or a methylated amino acid, and/or Maa is not a cysteine. Preferably, the Xaa_{n2} of Formula IV is

a D-amino acid or a methylated amino acid. In some embodiments, the amino acid denoted by Xaa_{n2} of Formula IV is a leucine, a d-leucine, a serine, or a d-serine. Preferably, the one or more of the amino acids denoted by Xaa_{n1} of Formula IV is a D-amino acid or a methylated amino acid. Preferably, the amino acid denoted Xaa^6 of Formula IV is a leucine, a serine, or a tyrosine.

5 In some embodiments, Xaa^1 is a pyroglutamic acid. In some embodiments, Xaa^2 is glutamic acid or d-glutamic acid. In some embodiments, Xaa^3 is an aspartic acid or d-aspartic acid. In some embodiments, Xaa^8 and Xaa^{10} are AIB. In some embodiments, Xaa^9 is tyrosine. In some embodiments, Xaa^{16} is dNal.

In further embodiments, GCRA peptides include peptides having the amino acid sequence of Formula V. In some embodiments, at least one amino acid of Formula V is a D-amino acid or a methylated amino acid. Preferably, the amino acid at position 16 of Formula V is a D-amino acid or a methylated amino acid. For example, the amino acid at position 16 (i.e., Xaa^{16}) of Formula V is a d-leucine or a d-serine. Optionally, one or more of the amino acids at position 1-3 of Formula V are D-amino acids or methylated amino acids or a combination of D-amino acids or methylated amino acids. For example, Asn^1 , Asp^2 or Glu^3 (or a combination thereof) of Formula V is a D-amino acids or a methylated amino acid. Preferably, the amino acid denoted at Xaa^6 of Formula V is a leucine, a serine, or a tyrosine.

In additional embodiments, GCRA peptides include peptides having the amino acid sequence of Formula VI, VII, VIII, or IX. Preferably, the amino acid at position 6 of Formula VI, VII, VIII, or IX is a leucine, a serine, or a tyrosine. In some aspects the amino acid at position 16 of Formula VI, VII, VIII, or IX is a leucine or a serine. Preferably, the amino acid at position 16 of Formula V is a D-amino acid or a methylated amino acid.

In additional embodiments, GCRA peptides include peptides having the amino acid sequence of Formula X, XI, XII, XIII, XIV, XV, XVI or XVII. Optionally, one or more amino acids of Formulae X, XI, XII, XIII, XIV, XV, XVI or XVII are D-amino acids or methylated amino acids. Preferably, the amino acid at the carboxyl terminus of the peptides according to Formulae X, XI, XII, XIII, XIV, XV, XVI or XVII is a D-amino acid or a methylated amino acid. For example the amino acid at the carboxyl terminus of the peptides according to Formulae X, XI, XII, XIII, XIV, XV, XVI or XVII is a D-tyrosine.

30 Preferably, the amino acid denoted by Xaa^6 of Formula XIV is a tyrosine, phenylalanine or a serine. Most preferably the amino acid denoted by Xaa^6 of Formula XIV is a phenylalanine

or a serine. Preferably, the amino acid denoted by Xaa^4 of Formula XV, XVI or XVII is a tyrosine, a phenylalanine, or a serine. Most preferably, the amino acid position Xaa^4 of Formula V, XVI or XVII is a phenylalanine or a serine.

In some embodiments, GCRA peptides include peptides containing the amino acid sequence of Formula XVIII. Preferably, the amino acid at position 1 of Formula XVIII is a glutamic acid, aspartic acid, glutamine or lysine. Preferably, the amino acid at position 2 and 3 of Formula XVIII is a glutamic acid, or an aspartic acid. Preferably, the amino acid at position 5 is a glutamic acid. Preferably, the amino acid at position 6 of Formula XVIII is an isoleucine, valine, serine, threonine or tyrosine. Preferably, the amino acid at position 8 of Formula XVIII is a valine or isoleucine. Preferably, the amino acid at position 9 of Formula XVIII is an asparagine. Preferably, the amino acid at position 10 of Formula XVIII is a valine or a methionine. Preferably, the amino acid at position 11 of Formula XVIII is an alanine. Preferably, the amino acid at position 13 of Formula XVIII is a threonine. Preferably, the amino acid at position 14 of Formula XVIII is a glycine. Preferably, the amino acid at position 16 of Formula XVIII is a leucine, serine or threonine

In alternative embodiments, GCRA peptides include peptides containing the amino acid sequence of Formula XIX. Preferably, the amino acid at position 1 of Formula XIX is a serine or asparagine. Preferably, the amino acid at position 2 of Formula XIX is a histidine or an aspartic acid. Preferably, the amino acid at position 3 of Formula XIX is a threonine or a glutamic acid. Preferably, the amino acid at position 5 of Formula XIX is a glutamic acid. Preferably, the amino acid at position 6 of Formula XIX is an isoleucine, leucine, valine or tyrosine. Preferably, the amino acid at position 8, 10, 11, or 13 of Formula XIX is an alanine. Preferably, the amino acid at position 9 of Formula XIX is an asparagine or a phenylalanine. Preferably, the amino acid at position 14 of Formula XIX is a glycine.

In further embodiments, GCRA peptides include peptides containing the amino acid sequence of Formula XX. Preferably, the amino acid at position 1 of Formula XX is a glutamine. Preferably, the amino acid at position 2 or 3 of Formula XX is a glutamic acid or an aspartic acid. Preferably, the amino acid at position 5 of Formula XX is a glutamic acid. Preferably, the amino acid at position 6 of Formula XX is threonine, glutamine, tyrosine, isoleucine, or leucine. Preferably, the amino acid at position 8 of Formula XX is isoleucine or valine. Preferably, the amino acid at position 9 of Formula XX is asparagine. Preferably, the

amino acid at position 10 of Formula XX is methionine or valine. Preferably, the amino acid at position 11 of Formula XX is alanine. Preferably, the amino acid at position 13 of Formula XX is a threonine. Preferably, the amino acid at position 1 of Formula XX is a glycine. Preferably, the amino acid at position 15 of Formula XX is a tyrosine. Optionally, the amino acid at position 5 15 of Formula XX is two-amino acid in length and is Cysteine (Cys), Penicillamine (Pen) homocysteine, or 3-mercaptoproline and serine, leucine or threonine.

In some embodiments, GCRA peptides include peptides having the amino acid sequence of Formula XXI. In some embodiments, at least one amino acid of Formula XXI is a D-amino acid or a methylated amino acid. Preferably, the amino acid denoted by Xaa_{n2} of Formula XXI is 10 a D-amino acid or a methylated amino acid. In some embodiments, the amino acid denoted by Xaa_{n2} of Formula XXI is a leucine, a d-leucine, a serine, or a d-serine. Preferably, the one or more amino acids denoted by Xaa_{n1} of Formula XXI are D-amino acids or methylated amino acids. Preferably, the amino acid at position Xaa^6 of Formula XXI is a leucine, a serine, or a tyrosine. In some embodiments, Xaa^1 is a pyroglutamic acid. In some embodiments, Xaa^2 is 15 glutamic acid or d-glutamic acid. In some embodiments, Xaa^3 is an aspartic acid or d-aspartic acid. In some embodiments, Xaa^7 is an aspartic acid and forms a lactam bridge with Xaa^{15} . In some embodiments, Xaa^8 and Xaa^{10} are AIB. In some embodiments, Xaa^9 is tyrosine. In some embodiments, Xaa^{15} is an Orn. In some embodiments, Xaa^{16} is dNal.

The GCRA peptides of the invention also include analogs that contain an α -amino adipic acid (Aad), preferably at the 3rd position from the N-terminus of each peptide or at the position to the N-terminal side next to the first cysteine (“Cys”) residue. In some embodiments, the GCRA peptide Aad derivatives include peptides having the amino acid sequences of Formula I-Aad, II-Aad, III-Aad, IV-Aad, V-Aad, VI-Aad, VII-a-Aad, VII-b-Aad, VIII-Aad, IX-Aad, XVIII-Aad or XXI-Aad (Table 8). Except the Aad replacement described herein, variations of 20 amino acid at each position of each Formula are the same as those described above in its corresponding Formula sequence without Aad. In some embodiments, when Xaa_{n1} represents one amino acid, Xaa_{n1} is an α -amino adipic acid (Aad). In some embodiments, when Xaa_{n1} represents two amino acids, the second residue from the N-terminus is an α -amino adipic acid (Aad). In some embodiments, when Xaa_{n1} represents three amino acids, the third residue from 25 the N-terminus is an α -amino adipic acid (Aad). Exemplary Ad analogs are listed in Table 8.

In certain embodiments, one or more amino acids of the GCRA peptides can be replaced by a non-naturally occurring amino acid or a naturally or non-naturally occurring amino acid analog. There are many amino acids beyond the standard 20 (Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val). Some are naturally-
5 occurring others are not. (See, for example, Hunt, The Non-Protein Amino Acids: In Chemistry and Biochemistry of the Amino Acids, Barrett, Chapman and Hall, 1985). For example, an aromatic amino acid can be replaced by 3,4-dihydroxy-L-phenylalanine, 3-iodo-L-tyrosine, triiodothyronine, L-thyroxine, phenylglycine (Phg) or nor-tyrosine (norTyr). Phg and norTyr and other amino acids including Phe and Tyr can be substituted by, e.g., a halogen, -CH₃, -OH, -
10 CH₂NH₃, -C(O)H, -CH₂CH₃, -CN, -CH₂CH₂CH₃, -SH, or another group. Any amino acid can be substituted by the D-form of the amino acid.

With regard to non-naturally occurring amino acids or naturally and non-naturally occurring amino acid analogs, a number of substitutions in the polypeptide and agonists described herein are possible alone or in combination.

15 For example, glutamine residues can be substituted with gamma-Hydroxy-Glu or gamma- Carboxy-Glu. Tyrosine residues can be substituted with an alpha substituted amino acid such as L-alpha-methylphenylalanine or by analogues such as: 3-Amino-Tyr; Tyr(CH₃);
Tyr(PO₃(CH₃)₂); Tyr(SO₃H); beta-Cyclohexyl-Ala; beta-(1-Cyclopentenyl)-Ala; beta-
Cyclopentyl-Ala; beta-Cyclopropyl-Ala; beta-Quinolyl-Ala; beta-(2-Thiazolyl)-Ala; beta-
20 (Triazole-1-yl)-Ala; beta-(2-Pyridyl)-Ala; beta-(3-Pyridyl)-Ala; Amino-Phe; Fluoro-Phe;
Cyclohexyl-Gly; tBu-Gly; beta-(3-benzothienyl)-Ala; beta-(2-thienyl)-Ala; 5-Methyl-Trp; and
A- Methyl-Trp. Proline residues can be substituted with homopro (L-pipecolic acid); hydroxy-
Pro; 3,4-Dehydro-Pro; 4-fluoro-Pro; or alpha-methyl-Pro or an N(alpha)-C(alpha) cyclized
amino acid analogues with the structure: n = 0, 1, 2, 3 Alanine residues can be substituted with
25 alpha-substituted or N-methylated amino acid such as alpha-amino isobutyric acid (aib), L/D-
alpha-ethylalanine (L/D-isovaline), L/D-methylvaline, or L/D-alpha-methylleucine or a non-
natural amino acid such as beta-fluoro-Ala. Alanine can also be substituted with: n = 0, 1, 2, 3
Glycine residues can be substituted with alpha-amino isobutyric acid (aib) or L/D-alpha-
ethylalanine (L/D-isovaline).

30 Further examples of unnatural amino acids include: an unnatural analog of tyrosine; an unnatural analogue of glutamine; an unnatural analogue of phenylalanine; an unnatural analogue

of serine; an unnatural analogue of threonine; an alkyl, aryl, acyl, azido, cyano, halo, hydrazine, hydrazide, hydroxyl, alkenyl, alkynl, ether, thiol, sulfonyl, seleno, ester, thioacid, borate, boronate, phospho, phosphono, phosphine, heterocyclic, enone, imine, aldehyde, hydroxylamine, keto, or amino substituted amino acid, or any combination thereof; an amino acid with a

5 photoactivatable cross-linker; a spin-labeled amino acid; a fluorescent amino acid; an amino acid with a novel functional group; an amino acid that covalently or noncovalently interacts with another molecule; a metal binding amino acid; an amino acid that is amidated at a site that is not naturally amidated, a metal-containing amino acid; a radioactive amino acid; a photocaged and/or photoisomerizable amino acid; a biotin or biotin-analogue containing amino acid; a

10 glycosylated or carbohydrate modified amino acid; a keto containing amino acid; amino acids comprising polyethylene glycol or polyether; a heavy atom substituted amino acid (*e.g.*, an amino acid containing deuterium, tritium, ¹³C, ¹⁵N, or ¹⁸O); a chemically cleavable or photocleavable amino acid; an amino acid with an elongated side chain; an amino acid containing a toxic group; a sugar substituted amino acid, *e.g.*, a sugar substituted serine or the

15 like; a carbon-linked sugar-containing amino acid; a redox-active amino acid; an α -hydroxy containing acid; an amino thio acid containing amino acid; an α , α disubstituted amino acid; a β -amino acid; a cyclic amino acid other than proline; an O-methyl-L-tyrosine; an L-3-(2-naphthyl)alanine; a 3-methyl-phenylalanine; a p-acetyl-L-phenylalanine; an O-4-allyl-L-tyrosine; a 4-propyl-L-tyrosine; a tri-O-acetyl-GlcNAc β -serine; an L-Dopa; a fluorinated phenylalanine;

20 an isopropyl-L-phenylalanine; a p-azido-L-phenylalanine; a p-acyl-L-phenylalanine; a p-benzoyl-L-phenylalanine; an L-phosphoserine; a phosphonoserine; a phosphonotyrosine; a p-iodo-phenylalanine; a 4-fluorophenylglycine; a p-bromophenylalanine; a p-amino-L-phenylalanine; an isopropyl-L-phenylalanine; L-3-(2-naphthyl)alanine; D- 3-(2-naphthyl)alanine (dNal); an amino-, isopropyl-, or O-allyl-containing phenylalanine analogue; a dopa, 0-methyl-L-tyrosine; a glycosylated amino acid; a p-(propargyloxy)phenylalanine; dimethyl-Lysine; hydroxy-proline; mercaptopropionic acid; methyl-lysine; 3-nitro-tyrosine; norleucine; pyro-glutamic acid; Z (Carbobenzoxyl); ϵ - Acetyl-Lysine; β -alanine; aminobenzoyl derivative; aminobutyric acid (Abu); citrulline; aminohexanoic acid; aminoisobutyric acid (AIB); cyclohexylalanine; d-cyclohexylalanine; hydroxyproline; nitro-arginine; nitro-phenylalanine;

25 nitro-tyrosine; norvaline; octahydroindole carboxylate; ornithine (Orn); penicillamine (PEN); tetrahydroisoquinoline; acetamidomethyl protected amino acids and pegylated amino acids.

Further examples of unnatural amino acids and amino acid analogs can be found in U.S. 20030108885, U.S. 20030082575, US20060019347 (paragraphs 410-418) and the references cited therein. The polypeptides of the invention can include further modifications including those described in US20060019347, paragraph 589.

5 In some embodiments, an amino acid can be replaced by a naturally-occurring, non-essential amino acid, *e.g.*, taurine.

Alternatively, the GCRA peptides are cyclic peptides. GCRA cyclic peptides are prepared by methods known in the art. For example, macrocyclization is often accomplished by forming an amide bond between the peptide N- and C-termini, between a side chain and the N-
10 or C-terminus [*e.g.*, with $K_3Fe(CN)_6$ at pH 8.5] (Samson *et al.*, *Endocrinology*, 137: 5182-5185 (1996)), or between two amino acid side chains, such as cysteine. See, *e.g.*, DeGrado, *Adv Protein Chem*, 39: 51-124 (1988). In various aspects the GCRA peptides are [4,12; 7,15] bicycles.

15 In some GCRA peptides one or both members of one or both pairs of Cys residues which normally form a disulfide bond can be replaced by homocysteine, penicillamine, 3-mercaptoprolidine (Kolodziej *et al.* 1996 *Int J Pept Protein Res* 48:274); β , β dimethylcysteine (Hunt *et al.* 1993 *Int J Pept Protein Res* 42:249) or diaminopropionic acid (Smith *et al.* 1978 *J Med Chem* 21:117) to form alternative internal cross-links at the positions of the normal disulfide bonds.

20 In addition, one or more disulfide bonds can be replaced by alternative covalent cross-links, *e.g.*, an amide linkage (-CH₂CH(O)NHCH₂- or -CH₂NHCH(O)CH₂-), an ester linkage, a thioester linkage, a lactam bridge, a carbamoyl linkage, a urea linkage, a thiourea linkage, a phosphonate ester linkage, an alkyl linkage (-CH₂CH₂CH₂CH₂-), an alkenyl linkage(-CH₂CH=CHCH₂-), an ether linkage (-CH₂CH₂OCH₂- or -CH₂OCH₂CH₂-), a thioether linkage (-CH₂CH₂SCH₂- or -CH₂SCH₂CH₂-), an amine linkage (-CH₂CH₂NHCH₂- or -CH₂NHCH₂-) or a thioamide linkage (-CH₂CH(S)HNHCH₂- or -CH₂NHCH(S)CH₂-). For example, Ledu *et al.* (Proc Nat'l Acad. Sci. 100:11263-78, 2003) describe methods for preparing lactam and amide cross-links. Exemplary GCRA peptides which include a lactam bridge include for example SP-370.

25 The GCRA peptides can have one or more conventional polypeptide bonds replaced by an alternative bond. Such replacements can increase the stability of the polypeptide. For

example, replacement of the polypeptide bond between a residue amino terminal to an aromatic residue (*e.g.* Tyr, Phe, Trp) with an alternative bond can reduce cleavage by carboxy peptidases and may increase half-life in the digestive tract. Bonds that can replace polypeptide bonds include: a retro-inverso bond (C(O)-NH instead of NH-C(O)); a reduced amide bond (NH-CH2);
5 a thiomethylene bond (S-CH2 or CH2-S); an oxomethylene bond (O-CH2 or CH2-O); an ethylene bond (CH2-CH2); a thioamide bond (C(S)-NH); a trans-olefine bond (CH=CH); a fluoro substituted trans-olefme bond (CF=CH); a ketomethylene bond (C(O)-CHR or CHR-C(O) wherein R is H or CH3; and a fluoro-ketomethylene bond (C(O)-CFR or CFR-C(O) wherein R is H or F or CH3.

10 The GCRA peptides can be modified using standard modifications. Modifications may occur at the amino (N-), carboxyl (C-) terminus, internally or a combination of any of the preceding. In one aspect described herein, there may be more than one type of modification on the polypeptide. Modifications include but are not limited to: acetylation, amidation, biotinylation, cinnamoylation, farnesylation, formylation, myristoylation, palmitoylation,
15 phosphorylation (Ser, Tyr or Thr), stearoylation, succinylation, sulfurylation and cyclisation (via disulfide bridges or amide cyclisation), and modification by Cys3 or Cys5. The GCRA peptides described herein may also be modified by 2, 4-dinitrophenyl (DNP), DNP-lysine, modification by 7-Amino-4-methyl- coumarin (AMC), flourescein, NBD (7-Nitrobenz-2-Oxa-1,3-Diazole), p-nitro-anilide, rhodamine B, EDANS (5-((2-aminoethyl)amino)naphthalene-1- sulfonic acid),
20 dabcyl, dabsyl, dansyl, texas red, FMOC, and Tamra (Tetramethylrhodamine). The GCRA peptides described herein may also be conjugated to, for example, polyethylene glycol (PEG); alkyl groups (*e.g.*, C1-C20 straight or branched alkyl groups); fatty acid radicals; combinations of PEG, alkyl groups and fatty acid radicals (*See*, U.S. Patent 6,309,633; Soltero et al., 2001 Innovations in Pharmaceutical Technology 106-110); BSA and KLH (Keyhole Limpet
25 Hemocyanin). The addition of PEG and other polymers which can be used to modify polypeptides of the invention is described in US2006019347 section IX.

Also included in the invention are peptides that biologically or functional equivalent to the peptides described herein. The term "biologically equivalent" or functional equivalent" is intended to mean that the compositions of the present invention are capable of demonstrating some or all of the cGMP production modulatory effects.

GCRA peptides can also include derivatives of GCRA peptides which are intended to include hybrid and modified forms of GCRA peptides in which certain amino acids have been deleted or replaced and modifications such as where one or more amino acids have been changed to a modified amino acid or unusual amino acid and modifications such as glycosylation so long 5 the modified form retains the biological activity of GCRA peptides. By retaining the biological activity, it is meant that cGMP and or apoptosis is induced by the GCRA peptide, although not necessarily at the same level of potency as that of a naturally-occurring GCRA peptide identified.

Preferred variants are those that have conservative amino acid substitutions made at one 10 or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic 15 side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side 20 chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a GCRA polypeptide is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a GCRA coding 25 sequence, such as by saturation mutagenesis, and the resultant mutants can be screened to identify mutants that retain activity.

Also included within the meaning of substantially homologous is any GCRA peptide which may be isolated by virtue of cross-reactivity with antibodies to the GCRA peptide.

25

PREPARATION OF GCRA PEPTIDES

GCRA peptides are easily prepared using modern cloning techniques, or may be synthesized by solid state methods or by site-directed mutagenesis. A GCRA peptide may include dominant negative forms of a polypeptide.

30

Chemical synthesis may generally be performed using standard solution phase or solid phase peptide synthesis techniques, in which a peptide linkage occurs through the direct

condensation of the amino group of one amino acid with the carboxyl group of the other amino acid with the elimination of a water molecule. Peptide bond synthesis by direct condensation, as formulated above, requires suppression of the reactive character of the amino group of the first and of the carboxyl group of the second amino acid. The masking substituents must permit their 5 ready removal, without inducing breakdown of the labile peptide molecule.

In solution phase synthesis, a wide variety of coupling methods and protecting groups may be used (See, Gross and Meienhofer, eds., "The Peptides: Analysis, Synthesis, Biology," Vol. 1-4 (Academic Press, 1979); Bodansky and Bodansky, "The Practice of Peptide Synthesis," 2d ed. (Springer Verlag, 1994)). In addition, intermediate purification and linear scale up are 10 possible. Those of ordinary skill in the art will appreciate that solution synthesis requires consideration of main chain and side chain protecting groups and activation method. In addition, careful segment selection is necessary to minimize racemization during segment condensation. Solubility considerations are also a factor. Solid phase peptide synthesis uses an insoluble 15 polymer for support during organic synthesis. The polymer-supported peptide chain permits the use of simple washing and filtration steps instead of laborious purifications at intermediate steps. Solid-phase peptide synthesis may generally be performed according to the method of Merrifield et al., J. Am. Chem. Soc., 1963, 85:2149, which involves assembling a linear peptide chain on a resin support using protected amino acids. Solid phase peptide synthesis typically utilizes either the Boc or Fmoc strategy, which is well known in the art.

20 Those of ordinary skill in the art will recognize that, in solid phase synthesis, deprotection and coupling reactions must go to completion and the side-chain blocking groups must be stable throughout the synthesis. In addition, solid phase synthesis is generally most suitable when peptides are to be made on a small scale.

25 Acetylation of the N-terminal can be accomplished by reacting the final peptide with acetic anhydride before cleavage from the resin. C-amidation is accomplished using an appropriate resin such as methylbenzhydrylamine resin using the Boc technology.

30 Alternatively the GCRA peptides are produced by modern cloning techniques. For example, the GCRA peptides are produced either in bacteria including, without limitation, *E. coli*, or in other existing systems for polypeptide or protein production (e.g., *Bacillus subtilis*, *baculovirus* expression systems using *Drosophila Sf9* cells, yeast or filamentous fungal expression systems, mammalian cell expression systems), or they can be chemically synthesized.

If the GCRA peptide or variant peptide is to be produced in bacteria, *e.g.*, *E. coli*, the nucleic acid molecule encoding the polypeptide may also encode a leader sequence that permits the secretion of the mature polypeptide from the cell. Thus, the sequence encoding the polypeptide can include the pre sequence and the pro sequence of, for example, a naturally-occurring bacterial ST polypeptide. The secreted, mature polypeptide can be purified from the culture medium.

The sequence encoding a GCRA peptide described herein can be inserted into a vector capable of delivering and maintaining the nucleic acid molecule in a bacterial cell. The DNA molecule may be inserted into an autonomously replicating vector (suitable vectors include, for example, pGEM3Z and pcDNA3, and derivatives thereof). The vector nucleic acid may be a bacterial or bacteriophage DNA such as bacteriophage lambda or M13 and derivatives thereof. Construction of a vector containing a nucleic acid described herein can be followed by transformation of a host cell such as a bacterium. Suitable bacterial hosts include but are not limited to, *E. coli*, *B subtilis*, *Pseudomonas*, *Salmonella*. The genetic construct also includes, in addition to the encoding nucleic acid molecule, elements that allow expression, such as a promoter and regulatory sequences. The expression vectors may contain transcriptional control sequences that control transcriptional initiation, such as promoter, enhancer, operator, and repressor sequences.

A variety of transcriptional control sequences are well known to those in the art. The expression vector can also include a translation regulatory sequence (*e.g.*, an untranslated 5' sequence, an untranslated 3' sequence, or an internal ribosome entry site). The vector can be capable of autonomous replication or it can integrate into host DNA to ensure stability during polypeptide production.

The protein coding sequence that includes a GCRA peptide described herein can also be fused to a nucleic acid encoding a polypeptide affinity tag, *e.g.*, glutathione S-transferase (GST), maltose E binding protein, protein A, FLAG tag, hexa-histidine, myc tag or the influenza HA tag, in order to facilitate purification. The affinity tag or reporter fusion joins the reading frame of the polypeptide of interest to the reading frame of the gene encoding the affinity tag such that a translational fusion is generated. Expression of the fusion gene results in translation of a single polypeptide that includes both the polypeptide of interest and the affinity tag. In some instances

where affinity tags are utilized, DNA sequence encoding a protease recognition site will be fused between the reading frames for the affinity tag and the polypeptide of interest.

Genetic constructs and methods suitable for production of immature and mature forms of the GCRA peptides and variants described herein in protein expression systems other than 5 bacteria, and well known to those skilled in the art, can also be used to produce polypeptides in a biological system.

The peptides disclosed herein may be modified by attachment of a second molecule that confers a desired property upon the peptide, such as increased half-life in the body, for example, pegylation. Such modifications also fall within the scope of the term "variant" as used herein.

10

COMPOSITIONS

The present invention also provides compositions comprising at least one GCRA peptide (*i.e.*, GCC agonist peptide) described herein, at least one enteric coating which releases the peptide at a specific pH (*e.g.*, about pH 4.0, pH 5.0, pH 6.0 or pH 7.0) and an inert carrier.

15 A composition may comprise an enteric coating which releases the peptide at pH5 and an inert carrier coated with GCRA peptides.

A composition may comprise an enteric coating which releases the peptide at pH6 and an inert carrier coated with GCRA peptides.

20 A composition may comprise an enteric coating which releases the peptide at pH7 and an inert carrier coated with GCRA peptides.

The present invention further provides a formulation comprising a mixture of compositions that contain different peptides and/or that release the peptides at different pH levels. The mixture may comprise at least 2, 3, 4 or more compositions that release the peptides at different pH levels. The mixture may comprise at least 2, 3, 4 or more compositions that 25 contain different GCRA peptides. A skilled artisan can determine the ratio of these compositions within the mixture, for example, according to the activity of each peptide, solubility of each peptide, and/or the targeting region of the GI tract.

In some embodiments, a formulation comprises a mixture of (1) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at 30 pH5.0 ("pH5.0 composition") and (2) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at pH6.0 ("pH6.0 composition").

The ratio of pH5.0 composition to pH6.0 composition can be any value between 100:1 (v/v) and 1: 100 (v/v) and can be determined, for example, by the activity of each peptide, solubility of each peptide, and/or the targeting region of the GI tract. In some embodiments, the ratio of pH5.0 composition to pH6.0 composition is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2: 1, 1: 5, 1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10.

In some embodiments, a formulation comprises a mixture of (1) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at pH5.0 (“pH5.0 composition”) and (2) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at pH7.0 (“pH7.0 composition”).

10 The ratio of pH5.0 composition to pH7.0 composition can be any value between 100:1 (v/v) and 1: 100 (v/v) and can be determined, for example, by the activity of each peptide, solubility of each peptide, and/or the targeting region of the GI tract. In some embodiments, the ratio of pH5.0 composition to pH7.0 composition is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2: 1, 1: 1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10.

15 In some embodiments, a formulation comprises a mixture of (1) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at pH6.0 (“pH6.0 composition”) and (2) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at pH7.0 (“pH7.0 composition”).

20 The ratio of pH6.0 composition to pH7.0 composition can be any value between 100:1 (v/v) and 1: 100 (v/v) and can be determined, for example, by the activity of each peptide, solubility of each peptide, and/or the targeting region of the GI tract. In some embodiments, the ratio of pH6.0 composition to pH7.0 composition is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2: 1, 1: 1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10.

25 In some embodiments, a formulation comprises a mixture of (1) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at pH5.0 (“pH5.0 composition”); (2) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at pH6.0 (“pH6.0 composition”) and (3) a composition having an inert carrier coated with GCRA and an enteric coating that releases the peptides at pH7.0 (“pH7.0 composition”).

The ratio of pH5.0 composition to pH6.0 composition to pH7.0 composition can be determined, for example, by the activity of each peptide, solubility of each peptide, and/or the targeting region of the GI tract.

In some embodiments, a formulation comprises a mixture of (1) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at duodenum or jejunum (“duodenum composition”) and (2) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides at ileum, terminal ileum, or ascending colon (“ileum composition”).

In some embodiments, a formulation comprises a mixture of (1) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides in a pH range of 4.5 to 5.5 or in a pH range of 5.5 to 6.5 at duodenum or jejunum (“duodenum composition”); and (2) a composition having an inert carrier coated with GCRA peptides and an enteric coating that releases the peptides in a pH range of 5.5 to 6.5 or in a pH range of 6.5 to 7.5 at ileum, terminal ileum, or ascending colon (“ileum composition”).

The ratio of duodenum composition to ileum composition can be any value between 100:1 (v/v) and 1: 100 (v/v) and can be determined, for example, by the activity of each peptide, solubility of each peptide, and/or the targeting region of the GI tract. In some embodiments, the ratio of duodenum composition to ileum composition is 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1: 1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10.

The targeting region of the GI tract includes, but is not limited to, duodenum, jejunum, ileum, terminal ileum, and ascending colon.

The GCRA peptides that can be used in the methods and formulations of the invention include a peptide selected from the group designated by SEQ ID NOs: 1-346. Preferably, the GCRA peptide is SEQ ID NO: 1, 9, 55 or 56. In some embodiments, the inert carrier is selected from the group consisting of sorbitol, mannitol, EMDEX, and starch. In some embodiments, the carrier is mannitol (*e.g.*, MANNOGEM) or microcrystalline cellulose (*e.g.*, PROSOLV, CELPHERE®, CELPHERE® beads). In a preferred embodiment, the carrier is microcrystalline cellulose spheres or spherical microcrystalline cellulose, such as Celphere® SCP-100.

The enteric coating material is chosen to target the release of the composition of the present invention to a specific region of the gastrointestinal tract. The enteric coating material

preferably comprises one of the following: (1) a pH dependent polymer; (2) a swellable polymer; or (3) a degradable composition.

In some embodiments, the enteric coating material is an enteric coating which releases the peptides at pH5.

5 In some embodiments, the enteric coating material is an enteric coating which releases the peptides at pH6.

In some embodiments, the enteric coating material is an enteric coating which releases the peptides at pH 7.

In accordance with the invention, the enteric coating chosen for the formulation is any 10 coating which will achieve the targeting objective of the formulation. Examples of suitable enteric coatings include, but are not limited to, the following: (1) acrylic polymers (anionic polymers of methacrylic acid and methacrylates polymers with methacrylic acid as a functional group) such as the EUDRAGIT® (Degussa) polymers, *e.g.*, for release in the duodenum (dissolution above pH 5.5), EUDRAGIT® L 100-55 and EUDRAGIT® L 30 D-55; for release in 15 the jejunum (dissolution above pH 6.0), EUDRAGIT® L 100; for release in the ileum (dissolution above pH 7), EUDRAGIT® S 100 and EUDRAGIT® FS 30, and COLORCON ACRYL-EZE®; (2) polyvinyl Acetate Phthalate (PVAP) including the COLORCON SURETERIC® Aqueous Enteric Coating System, and the COLORCON OPADRY® Enteric Coating System; (3) hypromellose Phthalate, NF (Hydroxy Propyl Methyl Cellulose Phthalate; 20 HPMCP; HP-55 Shin-Etsu); (4) cellulose acetate phthalate (CAP), such as AQUACOAT® CPD; and (5) cellulose acetate trimellitate (CAT). Further examples of suitable enteric coatings include, without limitation, sustained release blends such as EUDRACOL, EUDRAPULSE, and EUDRAMODE, as well as sustained release polymers such as the EUDRAGIT® RL, RS, and NE polymers.

25 In certain embodiments, the formulations of the invention comprise a pH-dependent targeting material that is pharmacologically inactive, meaning that it is excreted without being absorbed or metabolized. In some embodiments, the GCRA peptide-loaded composition is coated with a pH-dependent material. In some embodiments, the GCRA peptide-loaded composition is formed as a matrix with a pH-dependent material. Preferably, the pH-dependent 30 material comprises a pH-dependent polymer.

Preferably, the pH-dependent polymer is stable in the low pH environment of the stomach (*i.e.*, at pH 1-2) and begins to disintegrate at the higher pH of the small intestine (pH 6-7) or distal ileum (pH 7-8). In certain embodiments, the polymer begins to disintegrate at pH 4.5-4.8, pH 4.8-5.0, pH 5.0-5.2, pH 5.2-5.4, pH 5.4-5.8, pH 5.8-6.0, pH 6.0-6.2, pH 6.2-6.4, pH 5 6.4-6.6, pH 6.6-6.8, pH 6.8-7.0, pH 7.0-7.2, or pH 7.2-7.4. In certain embodiments, the polymer begins to disintegrate at pH 4.5-5.5, pH 5.5-6.5, or pH 6.5-7.5. The pH at which a pH-sensitive polymer begins to disintegrate is also referred to herein as the “threshold pH” of the polymer.

In certain embodiments, the pH-dependent polymer is a methacrylic acid copolymer, a polyvinyl acetate phthalate, a hydroxypropylmethylcellulose phthalate, a cellulose acetate trimellitate, a cellulose acetate phthalate, or a hydroxypropyl methyl cellulose acetate succinate.

In a preferred embodiment, the pH-dependent polymer is a methacrylic acid copolymer selected from among the EUDRAGIT® polymers. EUDRAGIT® polymers are available in a wide range of different concentrations and physical forms, including aqueous solutions, aqueous dispersion, organic solutions, and solid substances. The pharmaceutical properties of the polymers are determined by the chemical properties of their functional groups. For example, EUDRAGIT® L, S, FS and E polymers have acidic or alkaline groups that are pH-dependent. Enteric EUDRAGIT® coatings provide protection against release of the GCRA peptide in the stomach and enable controlled release in the intestine. In certain embodiments, anionic EUDRAGIT® grades containing carboxyl groups are mixed with each other to provide pH-dependent release of the GCRA peptide. In certain embodiments, EUDRAGIT® L and S grades are used for enteric coatings. In one embodiment, EUDRAGIT® FS 30D is used for controlled release in the colon. The various EUDRAGIT® polymers are further described in international pharmacopeias such as Ph.Eur., USP/NF, DMF and JPE.

In specific embodiments, the pH-dependent polymer is a methacrylic acid copolymer selected from EUDRAGIT® L100, having a threshold pH of 6.0; EUDRAGIT® S100, having a threshold pH of 7.0; EUDRAGIT® L-30D, having a threshold pH of 5.6; EUDRAGIT® FS 30D, having a threshold pH of 6.8; or EUDRAGIT® L100-55, having a threshold pH of 5.5, or a combination thereof.

In one embodiment, the GCRA peptide formulation comprises a targeting material which provides a controlled (time-dependent) release of the GCRA peptide. Controlled release in this

context includes delayed sustained release, delayed controlled release, delayed slow release, delayed prolonged release, delayed extended release, and a sudden release or “burst.”

Preferably, the controlled release formulation comprises a slowly disintegrating composition comprising the GCRA peptide surrounded by the targeting material. The targeting material preferably comprises at least one swellable polymer. Non-limiting examples of swellable polymers for use in a controlled release formulation of the invention include acrylic copolymers, *e.g.*, EUDRAGIT® RL, EUDRAGIT® RS, or EUDRAGIT® NE; polyvinylacetate, *e.g.*, KOLlicoat® SR 30D; and cellulose derivatives such as ethylcellulose or cellulose acetate, *e.g.*, SURELEASE® and AQUACOAT® ECD. In a preferred embodiment, the targeting material comprises one or more of EUDRAGIT® RL, EUDRAGIT® RS, or EUDRAGIT® NE to provide controlled time release of the GCRA peptide by pH-independent swelling. In a particular embodiment, the targeting material comprises EUDRAGIT® RL:RS (2:8) and an outer coating comprising EUDRAGIT® FS.

Further non-limiting examples of swellable polymers that can be used in the sustained release formulations of the invention include poly(hydroxalkyl methacrylate) having a molecular weight of from 30,000 to 5,000,000; kappa-carrageenan; polyvinylpyrrolidone having a molecular weight of from 10,000 to 360,000; anionic and cationic hydrogels; polyelectrolyte complexes; poly(vinyl alcohol) having low amounts of acetate, cross-linked with glyoxal, formaldehyde, or glutaraldehyde and having a degree of polymerization from 200 to 30,000; a mixture comprising methyl cellulose, cross-linked agar and carboxymethyl cellulose; a water-insoluble, water-swellable copolymer produced by forming a dispersion of finely divided maleic anhydride with styrene, ethylene, propylene, butylene or isobutylene; water-swellable polymers of N-vinyl lactams; polysaccharide, water swellable gums, high viscosity hydroxylpropylmethyl cellulose and/or mixtures thereof. In certain embodiments, the swellable polymer is selected from the group consisting of calcium pectinate, cross-linked polysaccharide, water insoluble starch, microcrystalline cellulose, water insoluble cross-linked peptide, water insoluble cross-linked protein, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen, modified cellulose, and cross-linked polyacrylic acid. Non-limiting examples of a cross-linked polysaccharide include insoluble metal salts or cross-linked derivatives of alginate, pectin, xantham gum, guar gum, tragacanth gum, and locust bean gum, carrageenan, metal salts thereof, and covalently cross-linked derivatives thereof.

Non-limiting examples of modified cellulose include cross-linked derivatives of hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose, carboxymethylcellulose, and metal salts of carboxymethylcellulose.

In certain embodiments, the swellable composition also comprises a wicking agent such as silicon dioxide. The wicking agent may also be selected from a disintegrant such as 5 microcrystalline cellulose to enhance the speed of water uptake. Other suitable wicking agents include, but are not limited to, kaolin, titanium dioxide, fumed silicon dioxide, alumina, niacinamide, sodium lauryl sulfate, low molecular weight polyvinyl pyrrolidone, m-pyrol, bentonite, magnesium aluminum silicate, polyester, polyethylene, and mixtures thereof.

10 In certain embodiments, the targeting material, which may comprise part of the composition and/or form one or more layers coating the composition, optionally further comprises at least one of a lubricant, a flow promoting agent, a plasticizer, an anti-sticking agent, surfactant, wetting agent, suspending agent and dispersing agent.

15 In certain embodiments, the targeting material comprises a water insoluble polymer and a pore-forming agent. Non-limiting examples of pore forming agents include saccharose, sodium chloride, potassium chloride, polyvinylpyrrolidone, and/or polyethyleneglycol, water soluble organic acids, sugars and sugar alcohol. In certain embodiments, the pore forming agent forms part of an outer layer or coating. In other embodiments, the pore forming agent is distributed uniformly throughout the water insoluble polymer.

20 In one embodiment, the targeting material comprises a compression coating. Non-limiting examples of materials that can be used as a compression coating include a gum selected from the group consisting of xanthan gum, locust bean gum, galactans, mannans, alginates, gum karaya, pectin, agar, tragacanth, accacia, carrageenan, tragacanth, chitosan, agar, alginic acid, hydrocolloids acacia catechu, salai guggal, indian boddellum, copaiba gum, asafetida, cambi gum, 25 Enterolobium cyclocarpum, mastic gum, benzoin gum, sandarac, gambier gum, butea frondosa (Flame of Forest Gum), myrrh, konjak mannan, guar gum, welan gum, gellan gum, tara gum, locust bean gum, carageenan gum, glucomannan, galactan gum, sodium alginate, tragacanth, chitosan, xanthan gum, deacetylated xanthan gum, pectin, sodium polypectate, gluten, karaya gum, tamarind gum, ghatti gum, Accaroid/Yacca/Red gum, dammar gum, juniper gum, ester 30 gum, ipil-ipil seed gum, gum talha (acacia seyal), and cultured plant cell gums including those of the plants of the genera: acacia, actinidia, aptenia, carobrotus, chickorium, cucumis, glycine,

hibiscus, hordeum, letuca, lycopersicon, malus, medicago, mesembryanthemum, oryza, panicum, phalaris, phleum, poliathus, polycarbophil, sida, solanum, trifolium, trigonella, Afzelia africana seed gum, Treculia africana gum, detarium gum, cassia gum, carob gum, Prosopis africana gum, Colocassia esculenta gum, Hakea gibbosa gum, khaya gum, scleroglucan, and zea, as well as 5 mixtures of any of the foregoing.

In some embodiments, the targeting material further comprises a plasticizer, a stiffening agent, a wetting agent, a suspending agent, or a dispersing agent, or a combination thereof. Non-limiting examples of a plasticizer include dibutyl sebacate, polyethylene glycol and polypropylene glycol, dibutyl phthalate, diethyl phthalate, triethyl citrate, tributyl citrate, 10 acetylated monoglyceride, acetyl tributyl citrate, triacetin, dimethyl phthalate, benzyl benzoate, butyl and/or glycol esters of fatty acids, refined mineral oils, oleic acid, castor oil, corn oil, camphor, glycerol and sorbitol or a combination thereof. In one embodiment, the stiffening agent comprises cetyl alcohol. Non-limiting examples of wetting agents include a poloxamer, polyoxyethylene ethers, polyoxyethylene sorbitan fatty acid esters, polyoxymethylene stearate, 15 sodium lauryl sulfate, sorbitan fatty acid esters, benzalkonium chloride, polyethoxylated castor oil, and docusate sodium. Non-limiting examples of suspending agents include alginic acid, bentonite, carbomer, carboxymethylcellulose, carboxymethylcellulose calcium, hydroxyethylcellulose, hydroxypropylcellulose, microcrystalline cellulose, colloidal silicon dioxide, dextrin, gelatin, guar gum, xanthan gum, kaolin, magnesium aluminum silicate, maltitol, 20 medium chain triglycerides, methylcellulose, polyoxyethylene sorbitan fatty acid esters, polyvinylpyrrolidinone, propylene glycol alginate, sodium alginate, sorbitan fatty acid esters, and tragacanth. Non-limiting examples of dispersing agents include poloxamer, polyoxyethylene sorbitan fatty acid esters and sorbitan fatty acid esters.

In certain embodiments, the targeted release formulation further comprises an outer 25 enteric coating over the targeted release material. Preferably, the outer enteric coating is selected from the group consisting of cellulose acetate phthalate, hydroxy propyl methyl cellulose acetate succinate, EUDRAGIT® L100 and EUDRAGIT® L30D-55.

In one embodiment, the GCRA peptide formulation is a time-delayed formulation 30 designed to release the GCRA peptide in a fast burst in the colon or small intestine (“burst formulation”). The formulation comprises a core and an outer layer. The composition comprises at least one GCRA peptide and at least one burst controlling agent. In certain embodiments, the

composition further comprises at least one disintegrant selected from the group consisting of croscarmellose sodium, crospovidone (cross-linked PVP), sodium carboxymethyl starch (sodium starch glycolate), cross-linked sodium carboxymethyl cellulose (Croscarmellose), pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, and magnesium aluminum silicate, or a combination thereof. In other embodiments, the composition further comprises at least one of an absorption enhancer, a binder, a hardness enhancing agent, a buffering agent, a filler, a flow regulating agent, a lubricant, a synergistic agent, a chelator, an antioxidant, a stabilizer and a preservative. Optionally, the composition also comprises one or more other excipients.

The burst controlling agent in the composition preferably comprises a water insoluble polymer for controlling the rate of penetration of water into the composition and raising the internal pressure (osmotic pressure) inside the composition. Such a burst controlling agent is preferably able to swell upon contact with liquid. Non-limiting examples of suitable water insoluble polymers include cross-linked polysaccharide, water insoluble starch, microcrystalline cellulose, water insoluble cross-linked peptide, water insoluble cross-linked protein, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen modified cellulose, and cross-linked polyacrylic acid. In one embodiment, the water insoluble polymer is a cross-linked polysaccharide selected from the group consisting of insoluble metal salts or cross-linked derivatives of alginate, pectin, xanthan gum, guar gum, tragacanth gum, and locust bean gum, carrageenan, metal salts thereof, and covalently cross-linked derivatives thereof. In one embodiment, the water insoluble polymer is modified cellulose selected from the group consisting of cross-linked derivatives of hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, methylcellulose, carboxymethylcellulose, and metal salts of carboxymethylcellulose. In another embodiment, the water insoluble polymer is selected from calcium pectinate, microcrystalline cellulose, or a combination thereof.

The outer layer comprises a water insoluble hydrophobic carrier and a pore forming agent comprised of a water insoluble hydrophilic particular matter. The pore forming agent is a water permeable agent which allows entry of liquid into the core. Optionally, the outer layer further comprises at least one of a wetting agent, a suspending agent, a dispersing agent, a stiffening agent and a plasticizer.

In certain embodiments, the water insoluble hydrophobic carrier is selected from the group consisting of a dimethylaminoethylacrylate/ethylmethacrylate copolymer, the copolymer being based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups, wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is approximately 1:20, the polymer corresponding to USP/NF "Ammonio Methacrylate Copolymer Type A", an ethylmethacrylate/chlorotrimethylammoniummethyl methacrylate copolymer, the copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:40, the polymer corresponding to USP/NF "Ammonio Methacrylate Copolymer Type B", a dimethylaminoethylmethacrylate /methylmethacrylate and butylmethacrylate copolymer, a copolymer based on neutral methacrylic acid esters and dimethylaminoethyl methacrylate esters wherein the polymer is cationic in the presence of acids, an ethylacrylate and methylacrylate/ethylmethacrylate and methyl methylacrylate copolymer, the copolymer being a neutral copolymer based on neutral methacrylic acid and acrylic acid esters, ethylcellulose, shellac, zein, and waxes.

In certain embodiments, the water insoluble particulate matter is a hydrophilic yet water insoluble polymer, preferably selected from the group consisting of a water insoluble cross-linked polysaccharide, a water insoluble cross-linked protein, a water insoluble cross-linked peptide, water insoluble cross-linked gelatin, water insoluble cross-linked hydrolyzed gelatin, water insoluble cross-linked collagen, water insoluble cross linked polyacrylic acid, water insoluble cross-linked cellulose derivatives, water insoluble cross-linked polyvinyl pyrrolidone, micro crystalline cellulose, insoluble starch, micro crystalline starch and a combination thereof. Most preferably, the water insoluble particulate matter is microcrystalline cellulose.

In another embodiment, the GCRA peptide containing composition comprises a GCRA peptide covalently conjugated to a carrier molecule such that the covalent bond between the GCRA peptide and the carrier is stable in the stomach and small intestine but labile in the lower gastrointestinal tract, especially the colon. The GCRA peptide covalently linked to a carrier molecule is referred to as the "GCC prodrug." In certain embodiments, the GCC prodrug comprises a GCRA peptide covalently conjugated to a carrier molecule via an azo bond or a glycosidic bond. In other embodiments, the GCC prodrug comprises a glucuronide, a cyclodextrin, a dextran ester, or a polar amino acid. In certain embodiments, the GCC prodrug is

a polymeric prodrug. In one embodiment, the polymeric prodrug comprises polyamides containing azo groups.

FORMULATIONS

The formulations of the invention contain one or more GCRA peptides described herein, in combination with one or more pharmaceutically acceptable carriers (also referred to as diluents) and/or excipients. In a preferred embodiment, the formulations of the invention include an inert carrier. The inert carrier is preferably non-hygroscopic. In one embodiment, the carrier in the formulation contains few or no reducing sugars and is substantially free of contaminants including, but not limited to, iron, peroxide, and formaldehyde. In one embodiment, the carrier is selected from the group consisting of sorbitol, mannitol, EMDEX, and starch. In one embodiment, the carrier is mannitol (*e.g.*, MANNOGEM) or microcrystalline cellulose (*e.g.* PROSOLV, CELPHERE®, CELPHERE® beads).

The formulations of the invention comprise a mixture of the compositions described herein and one or more pharmaceutically acceptable carriers (also referred to as diluents) and/or excipients.

The remainder of the formulation is comprised of the carrier and one or more optional excipients. In one embodiment, the amount of carrier is at least 90% of the total weight of the formulation. In another embodiment, the amount of carrier is at least 95% or at least 98% of the total weight of the formulation. In one embodiment, the amount of carrier is between 90 and 99.9% of the total weight of the formulation. In one embodiment, the one or more optional excipients comprise a disintegrant which is present at 1 to 5% of the total weight of the formulation. In one embodiment, the one or more optional excipients comprise a lubricant which is present at 0.02 to 5% of the total weight of the formulation. In one embodiment, the one or more optional excipients comprise an amino acid such as leucine, isoleucine, valine, histidine, phenylalanine, alanine, glutamic acid, aspartic acid, glutamine, methionine, asparagine, tyrosine, threonine, tryptophan, or glycine, which is present at 0.1 to 4% (*e.g.*, 0.1-1%) of the total weight of the formulation. In one embodiment, the molar ratio between the amino acid and the GCRA peptide is from about 2:1 to about 20:1 (*e.g.*, 5:1). In one embodiment, the one or more optional excipients comprise a stabilizer such as a divalent cation salt, more specifically, a water-soluble divalent cation salt (*e.g.*, calcium chloride, magnesium chloride, zinc chloride, manganese

chloride), which is present at 0.1 to 12% (e.g., 0.1-4%) of the total weight of the formulation. In one embodiment, the molar ratio between the salt and the GCRA peptide is from about 5:1 to about 20:1 (e.g., 10:1).

The formulations may contain other additives as needed, including for example lactose, glucose, fructose, galactose, trehalose, sucrose, maltose, raffnose, maltitol, melezitose, stachyose, lactitol, palatinite, starch, xylitol, mannitol, myoinositol, and the like, and hydrates thereof, and amino acids, for example alanine, glycine and betaine, and polypeptides and proteins, for example albumen.

Further examples of pharmaceutically acceptable carriers and excipients include, but are not limited to binders, fillers, disintegrants, lubricants, anti-microbial agents, and coating agents such as: **BINDERS**: corn starch, potato starch, other starches, gelatin, natural and synthetic gums such as acacia, xanthan, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone (e.g., povidone, crospovidone, copovidone, etc), methyl cellulose, Methocel, pre-gelatinized starch (e.g., STARCH 1500® and STARCH 1500 LM®, sold by Colorcon, Ltd.), hydroxypropyl methyl cellulose, microcrystalline cellulose (FMC Corporation, Marcus Hook, PA, USA), or mixtures thereof, **FILLERS**: talc, calcium carbonate (e.g., granules or powder), dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, dextrose, fructose, honey, lactose anhydrate, lactose monohydrate, lactose and aspartame, lactose and cellulose, lactose and microcrystalline cellulose, maltodextrin, maltose, mannitol, microcrystalline cellulose & guar gum, molasses, sucrose, or mixtures thereof, **DISINTEGRANTS**: agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, clays, other algin, other celluloses, gums (like gellan), low-substituted hydroxypropyl cellulose, or mixtures thereof, **LUBRICANTS**: calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, sodium stearyl fumarate, vegetable based fatty acids lubricant, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil), zinc stearate, ethyl

oleate, ethyl laurate, agar, syloid silica gel (AEROSIL 200, W.R. Grace Co., Baltimore, MD USA), a coagulated aerosol of synthetic silica (Deaussa Co., Piano, TX USA), a pyrogenic silicon dioxide (CAB-O-SIL, Cabot Co., Boston, MA USA), or mixtures thereof, ANTI-CAKING AGENTS: calcium silicate, magnesium silicate, silicon dioxide, colloidal silicon dioxide, talc, or mixtures thereof, ANTIMICROBIAL AGENTS: benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, butyl paraben, cetylpyridinium chloride, cresol, chlorobutanol, dehydroacetic acid, ethylparaben, methylparaben, phenol, phenylethyl alcohol, phenoxyethanol, phenylmercuric acetate, phenylmercuric nitrate, potassium sorbate, propylparaben, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimersol, thymo, or mixtures thereof, and COATING AGENTS: sodium carboxymethyl cellulose, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose), hydroxypropyl methyl cellulose phthalate, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline wax, gellan gum, maltodextrin, methacrylates, microcrystalline cellulose and carrageenan or mixtures thereof.

The formulation can also include other excipients and categories thereof including but not limited to Pluronic®, Poloxamers (such as Lutrol® and Poloxamer 188), ascorbic acid, glutathione, protease inhibitors (e.g. soybean trypsin inhibitor, organic acids), pH lowering agents, creams and lotions (like maltodextrin and carrageenans); materials for chewable tablets (like dextrose, fructose, lactose monohydrate, lactose and aspartame, lactose and cellulose, maltodextrin, maltose, mannitol, microcrystalline cellulose and guar gum, sorbitol crystalline); parenterals (like mannitol and povidone); plasticizers (like dibutyl sebacate, plasticizers for coatings, polyvinylacetate phthalate); powder lubricants (like glyceryl behenate); soft gelatin capsules (like sorbitol special solution); spheres for coating (like sugar spheres); spheronization agents (like glyceryl behenate and microcrystalline cellulose); suspending/gelling agents (like carrageenan, gellan gum, mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, xanthan gum); sweeteners (like aspartame, aspartame and lactose, dextrose, fructose, honey, maltodextrin, maltose, mannitol, molasses, sorbitol crystalline, sorbitol special solution, sucrose); wet granulation agents (like calcium carbonate, lactose anhydrous, lactose monohydrate, maltodextrin, mannitol, microcrystalline cellulose, povidone, starch), caramel, carboxymethylcellulose sodium, cherry cream flavor and cherry flavor, citric acid anhydrous,

citric acid, confectioner's sugar, D&C Red No. 33, D&C Yellow #10 Aluminum Lake, disodium edetate, ethyl alcohol 15%, FD&C Yellow No. 6 aluminum lake, FD&C Blue # 1 Aluminum Lake, FD&C Blue No. 1, FD&C blue no. 2 aluminum lake, FD&C Green No.3, FD&C Red No. 40, FD&C Yellow No. 6 Aluminum Lake, FD&C Yellow No. 6, FD&C Yellow No.10, glycerol palmitostearate, glyceryl monostearate, indigo carmine, lecithin, manitol, methyl and propyl parabens, mono ammonium glycyrrhizinate, natural and artificial orange flavor, pharmaceutical glaze, poloxamer 188, Polydextrose, polysorbate 20, polysorbate 80, polyvidone, pregelatinized corn starch, pregelatinized starch, red iron oxide, saccharin sodium, sodium carboxymethyl ether, sodium chloride, sodium citrate, sodium phosphate, strawberry flavor, synthetic black iron oxide, synthetic red iron oxide, titanium dioxide, and white wax.

Solid oral dosage forms may optionally be treated with coating systems (*e.g.* Opadry® fx film coating system, for example Opadry® blue (OY-LS-20921), Opadry® white (YS-2-7063), Opadry® white (YS- 1-7040), and black ink (S- 1-8 106).

The agents either in their free form or as a salt can be combined with a polymer such as polylactic-glycolic acid (PLGA), poly-(I)-lactic-glycolic-tartaric acid (P(I)LGT) (WO 01/12233), polyglycolic acid (U.S. 3,773,919), polylactic acid (U.S. 4,767,628), poly(ϵ -caprolactone) and poly(alkylene oxide) (U.S. 20030068384) to create a sustained release formulation. Other sustained release formulations and polymers for use in the compositions and methods of the invention are described in EP 0 467 389 A2, WO 93/24150, U.S. 5,612,052, WO 97/40085, WO 03/075887, WO 01/01964A2, U.S. 5,922,356, WO 94/155587, WO 02/074247A2, WO 98/25642, U.S. 5,968,895, U.S. 6,180,608, U.S. 20030171296, U.S. 20020176841, U.S. 5,672,659, U.S. 5,893,985, U.S. 5,134,122, U.S. 5,192,741, U.S. 5,192,741, U.S. 4,668,506, U.S. 4,713,244, U.S. 5,445,832 U.S. 4,931,279, U.S. 5,980,945, WO 02/058672, WO 97/26015, WO 97/04744, and US20020019446. In such sustained release formulations microparticles (Delie and Blanco-Prieto 2005 Molecule 10:65-80) of polypeptide are combined with microparticles of polymer. U.S. 6,011,0 1 and WO 94/06452 describe a sustained release formulation providing either polyethylene glycols (*i.e.* PEG 300 and PEG 400) or triacetin. WO 03/053401 describes a formulation which may both enhance bioavailability and provide controlled release of the agent within the GI tract. Additional controlled release formulations are described in WO 02/38129, EP 326151, U.S. 5,236,704, WO 02/30398, WO 98/13029; U.S. 20030064105, U.S. 20030138488A1, U.S. 20030216307A1, U.S. 6,667,060, WO 01/49249, WO

01/49311, WO 01/49249, WO 01/49311, and U.S. 5,877,224 materials which may include those described in WO04041195 (including the seal and enteric coating described therein) and pH-sensitive coatings that achieve delivery in the colon including those described in US4,910,021 and WO9001329. US4910021 describes using a pH-sensitive material to coat a capsule.

WO9001329 describes using pH-sensitive coatings on beads containing acid, where the acid in the bead core prolongs dissolution of the pH-sensitive coating. U. S. Patent No. 5,175,003 discloses a dual mechanism polymer mixture composed of pH-sensitive enteric materials and film-forming plasticizers capable of conferring permeability to the enteric material, for use in drug-delivery systems; a matrix pellet composed of a dual mechanism polymer mixture permeated with a drug and sometimes covering a pharmaceutically neutral nucleus; a membrane-coated pellet comprising a matrix pellet coated with a dual mechanism polymer mixture envelope of the same or different composition; and a pharmaceutical dosage form containing matrix pellets. The matrix pellet releases acid-soluble drugs by diffusion in acid pH and by disintegration at pH levels of nominally about 5.0 or higher.

The GCC peptides described herein may be formulated in the pH triggered targeted control release systems described in WO04052339. The agents described herein may be formulated according to the methodology described in any of WO03105812 (extruded hydratable polymers); WO0243767 (enzyme cleavable membrane translocators); WO03007913 and WO03086297 (mucoadhesive systems); WO02072075 (bilayer laminated formulation comprising pH lowering agent and absorption enhancer); WO04064769 (amidated polypeptides); WO05063156 (solid lipid suspension with pseudotropic and/or thixotropic properties upon melting); WO03035029 and WO03035041 (erodible, gastric retentive dosage forms); US5007790 and US5972389 (sustained release dosage forms); WO041 1271 1 (oral extended release compositions); WO05027878, WO02072033, and WO02072034 (delayed release compositions with natural or synthetic gum); WO05030182 (controlled release formulations with an ascending rate of release); WO05048998 (microencapsulation system); US Patent 5,952,314 (biopolymer); US5,108,758 (glassy amylose matrix delivery); US 5,840,860 (modified starch based delivery). JP10324642 (delivery system comprising chitosan and gastric resistant material such as wheat gliadin or zein); US 5,866,619 and US 6,368,629 (saccharide containing polymer); US 6,531,152 (describes a drug delivery system containing a water soluble core (Ca pectinate or other water-insoluble polymers) and outer coat which bursts (*e.g.* hydrophobic polymer-

Eudragit)); US 6,234,464; US 6,403,130 (coating with polymer containing casein and high methoxy pectin; WO0174 175 (Maillard reaction product); WO05063206 (solubility increasing formulation); WO040 19872 (transferring fusion proteins).

The GCC peptides described herein may be formulated using gastrointestinal retention system technology (GIRES; Merrion Pharmaceuticals). GIRES comprises a controlled-release dosage form inside an inflatable pouch, which is placed in a drug capsule for oral administration. Upon dissolution of the capsule, a gas-generating system inflates the pouch in the stomach where it is retained for 16-24 hours, all the time releasing agents described herein.

The GCC peptides described herein can also be formulated using the multi matrix system technology (MMX).

The GCC peptides described herein can be formulated in an osmotic device including the ones disclosed in US 4,503,030, US 5,609,590 and US 5,358,502. US 4,503,030 describing an osmotic device for dispensing a drug to certain pH regions of the gastrointestinal tract. More particularly, the invention relates to an osmotic device comprising a wall formed of a semi-

5 permeable pH sensitive composition that surrounds a compartment containing a drug, with a passageway through the wall connecting the exterior of the device with the compartment. The device delivers the drug at a controlled rate in the region of the gastrointestinal tract having a pH of less than 3.5, and the device self- destructs and releases all its drug in the region of the gastrointestinal tract having a pH greater than 3.5, thereby providing total availability for drug 10 absorption. U.S. Patent Nos. 5,609,590 and 5, 358,502 disclose an osmotic bursting device for dispensing a beneficial agent to an aqueous environment. The device comprises a beneficial agent and osmagent surrounded at least in part by a semi-permeable membrane. The beneficial agent may also function as the osmagent. The semi-permeable membrane is permeable to water and substantially impermeable to the beneficial agent and osmagent. A trigger means is attached 15 to the semi-permeable membrane (e.g., joins two capsule halves). The trigger means is activated by a pH of from 3 to 9 and triggers the eventual, but sudden, delivery of the beneficial agent. These devices enable the pH-triggered release of the beneficial agent core as a bolus by osmotic bursting.

20 The composition of the present invention can be formulated in the form of a tablet, a capsule, granules, pellets, or crystals. In certain embodiments, the composition comprises microparticles or microspheres. In one embodiment, the composition comprises a cellulose

acetate butyrate microsphere. In some embodiments, the composition comprises one or more layers of targeting materials. In other embodiments, the composition is formulated in a matrix with a targeting material. In certain embodiments, the matrix is coated with at least one additional targeting material.

5 The GCC-agonist containing composition of the present formulations is formed according to art-recognized methods. In one embodiment, the composition is formed with a pellet-forming agent such as microcrystalline cellulose, low-substituted hydroxypropylcellulose, chitin, chitosan, or any combination or mixture thereof. Generally, an amount of pellet-forming agent that is less than 20% by weight results in poor sphericity and broad particle size
10 distribution. Accordingly, the pellet-forming agent of the present formulations is preferably at least 20% by weight. In certain embodiments, the pellet-forming agent is present at 20% to 95% or 50% to 90% by weight.

15 The formulation may further comprise one or more pharmaceutically acceptable excipients. Preferably, the excipients are present in an amount of 2 to 70% or 5 to 50% by weight. The term excipient broadly refers to a biologically inactive substance used in
20 combination with the active agents of the formulation. An excipient can be used, for example, as a solubilizing agent, a stabilizing agent, a diluent, an inert carrier, a preservative, a binder, a disintegrant, a coating agent, a flavoring agent, or a coloring agent. Preferably, at least one excipient is chosen to provide one or more beneficial physical properties to the formulation, such as increased stability and/or solubility of the active agent(s).

25 A "pharmaceutically acceptable" excipient is one that has been approved by a state or federal regulatory agency for use in animals, and preferably for use in humans, or is listed in the U.S. Pharmacopia, the European Pharmacopia or another generally recognized pharmacopia for use in animals, and preferably for use in humans. Examples of excipients include certain inert proteins such as albumins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as aspartic acid (which may alternatively be referred to as aspartate), glutamic acid (which may alternatively be referred to as glutamate), lysine, arginine, glycine, and histidine; fatty acids and phospholipids such as alkyl sulfonates and caprylate; surfactants such as sodium dodecyl sulphate and polysorbate; nonionic surfactants such as such as TWEEN[®], PLURONICS[®], or
30 polyethylene glycol (PEG); carbohydrates such as glucose, sucrose, mannose, maltose, trehalose, and dextrans, including cyclodextrins; polyols such as sorbitol; chelating agents such as EDTA;

and salt-forming counter-ions such as sodium. Particularly preferred are hydrophilic excipients which reduce the protein binding activity and aggregation of GCRA peptides.

In some embodiments, the GCRA peptide formulation further comprises one or more excipients selected from among an absorption enhancer, a binder, a disintegrant, and a hardness enhancing agent. In other embodiments, the formulation further comprises one or more excipients selected from among a wicking agent, a stabilizer, a flow regulating agent, a lubricant, an antioxidant, a chelating agent, or a sequestrate.

Non-limiting examples of suitable binders include starch, polyvinylpyrrolidone (POVIDONE), low molecular weight hydroxypropylcellulose, low molecular weight hydroxypropylmethylcellulose, low molecular weight carboxymethylcellulose, ethylcellulose, gelatin, polyethylene oxide, acacia, dextrin, magnesium aluminum silicate, and polymethacrylates. Non-limiting examples of a disintegrant include croscarmellose sodium crospovidone (cross-linked PVP), sodium carboxymethyl starch (sodium starch glycolate), pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium 15 carboxymethyl cellulose, and magnesium aluminum silicate (Veegum). In certain embodiments, a binder is selected from polyvinylpyrrolidone and sodium carboxymethylcellulose.

Non-limiting examples of a wicking agent include colloidal silicon dioxide, kaolin, titanium oxide, fumed silicon dioxide, alumina, niacinamide, sodium lauryl sulfate, low molecular weight polyvinyl pyrrolidone, m-pyrol, bentonite, magnesium aluminum silicate, 20 polyester, polyethylene, and mixtures thereof. In certain embodiments, a wicking agent is selected from sodium lauryl sulfate, colloidal silicon dioxide, and low molecular weight polyvinyl pyrrolidone.

Non-limiting examples of a stabilizer include butyl hydroxyanisole, ascorbic acid, citric acid, and mixtures thereof. Preferably, the stabilizer is a basic substance which can elevate the 25 pH of an aqueous solution or dispersion of the formulation to at least about pH 6.8. Examples of such basic substances include, for example, antacids such as magnesium aluminometasilicate, magnesium aluminosilicate, magnesium aluminate, dried aluminum hydroxide, synthetic hydrotalcite, synthetic aluminum silicate, magnesium carbonate, precipitated calcium carbonate, magnesium oxide, aluminum hydroxide, and sodium hydrogencarbonate. Other examples 30 include pH-regulating agents such as L-arginine, sodium phosphate, disodium hydrogen phosphate, sodium dihydrogenphosphate, potassium phosphate, dipotassium hydrogenphosphate,

potassium dihydrogenphosphate, disodium citrate, sodium succinate, ammonium chloride, and sodium benzoate. In certain embodiments, a stabilizer is selected from ascorbic acid and magnesium aluminometasilicate.

In an embodiment where the stabilizer is a basic substance, the basic substance can be an inorganic water-soluble compound or an inorganic water-insoluble compound. Non-limiting examples of an inorganic water-soluble compounds for use as a stabilizer include carbonate salts such as sodium carbonate, potassium carbonate, sodium bicarbonate, or potassium hydrogen carbonate; phosphate salts such as anhydrous sodium phosphate, potassium phosphate, calcium dibasic phosphate, or trisodium phosphate; and alkali metal hydroxides, such as sodium, 5 potassium, or lithium hydroxide. Non-limiting examples of inorganic water-insoluble compounds for use as a stabilizer include suitable alkaline compounds capable of imparting the requisite basicity, such as those commonly employed in antiacid compositions, for example, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium hydrogen carbonate, aluminum hydroxide, calcium hydroxide, or calcium carbonate; composite aluminum-magnesium compounds, such as magnesium aluminum hydroxide; silicate compounds such as 10 magnesium aluminum silicate (Veegum F), magnesium aluminometasilicate (Nesulin FH2), magnesium aluminosilicate (Nisulin A); and pharmaceutically acceptable salts of phosphoric acid such as tribasic calcium phosphate.

Non-limiting examples of a flow regulating agents include a colloidal silicon dioxide and 20 aluminum silicate.

Non-limiting examples of a lubricant include stearate salts, such as magnesium stearate, calcium stearate, and sodium stearate, stearic acid, talc, sodium stearyl fumarate, sodium lauryl sulfate, sodium benzoate, polyethylene glycol, polyvinyl alcohol, glycerol behenate compritol (glycerol behenate), corola oil, glyceryl palmitostearate, hydrogenated vegetable oil, magnesium oxide, mineral oil, poloxamer, and combinations thereof. In certain embodiments, a lubricant is 25 selected from talc and magnesium stearate.

Non-limiting examples of antioxidants include 4,4 (2,3 dimethyl tetramethylene dipyrochatechol), tocopherol-rich extract (natural vitamin E), α -tocopherol, β -tocopherol, γ -tocopherol, δ -tocopherol, butylhydroxytoluene (BHT), butyl hydroxyanisole (BHA), butyl hydroxytoluene (BHT), propyl gallate, octyl gallate, dodecyl gallate, tertiary butylhydroquinone (TBHQ), fumaric acid, malic acid, ascorbic acid (Vitamin C), sodium ascorbate, calcium ascorbate,

potassium ascorbate, ascorbyl palmitate, ascorbyl stearate, citric acid, sodium lactate, potassium lactate, calcium lactate, magnesium lactate, anoxomer, erythorbic acid, sodium erythorbate, erythorbin acid, sodium erythorbin, ethoxyquin, glycine, gum guaiac, sodium citrates (monosodium citrate, disodium citrate, trisodium citrate), potassium citrates (monopotassium citrate, tripotassium citrate), lecithin, polyphosphate, tartaric acid, sodium tartrates (monosodium tartrate, disodium tartrate), potassium tartrates (monopotassium tartrate, dipotassium tartrate), sodium potassium tartrate, phosphoric acid, sodium phosphates (monosodium phosphate, disodium phosphate, trisodium phosphate), potassium phosphates (monopotassium phosphate, dipotassium phosphate, tripotassium phosphate), calcium disodium ethylene diamine tetraacetate (Calcium disodium EDTA), lactic acid, trihydroxy butyrophenone and thiadipropionic acid.

In certain embodiments, the composition of the formulation comprises an antioxidant and both a chelator and a sequestrate. The chelating agent acts to remove trace quantities of metals which might otherwise bind to the GCC agonist and cause loss of activity, for example through oxidation. The sequestrate preferably has several hydroxyl and/or carboxylic acid groups which provide a supply of hydrogen for regeneration of the inactivated antioxidant free radical. Non-limiting examples of chelating agents include antioxidants, dipotassium edentate, disodium edentate, edetate calcium disodium, edetic acid, fumaric acid, malic acid, maltol, sodium edentate, and trisodium edetate. Non-limiting examples of sequestrates include citric acid and ascorbic acid.

In some embodiments, the formulation further comprises a filler. Preferably, the filler is present in an amount of from 10% to 85% by weight. Non-limiting examples of suitable materials for use as a filler include starch, lactitol, lactose, an inorganic calcium salt, microcrystalline cellulose, sucrose, and combinations thereof. In some embodiments, the filler comprises microcrystalline cellulose. Preferably, the microcrystalline cellulose has a particle size of less than about 100 microns, and most preferably the microcrystalline cellulose has a particle size of about 50 microns.

In some embodiments, the composition optionally includes a buffering agent such as an inorganic salt compound and an organic alkaline salt compound. Non-limiting examples of a buffering agent include potassium bicarbonate, potassium citrate, potassium hydroxide, sodium bicarbonate, sodium citrate, sodium hydroxide, calcium carbonate, dibasic sodium phosphate,

monosodium glutamate, tribasic calcium phosphate, monoethanolamine, diethanolamine, triethanolamine, citric acid monohydrate, lactic acid, propionic acid, tartaric acid, fumaric acid, malic acid, and monobasic sodium phosphate.

In some embodiments, the composition described herein further comprises a preservative.

5 Non-limiting examples of a preservative include an antioxidant, dipotassium edentate, disodium edentate, edetate calcium disodium, edetic acid, fumaric acid, malic acid, maltol, sodium edentate, and trisodium edentate.

The formulations of the invention are preferably optimized for oral delivery. However, in some embodiments, the formulations may be prepared in the form of suppositories (e.g., with 10 conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery. Solid oral dosage forms may optionally be treated with coating systems (e.g. Opadry® fx film coating system, for example Opadry® blue (OY-LS-20921), Opadry® white (YS-2-7063), Opadry® white (YS- 1-7040), and black ink (S- 1-8 106).

15 USES

The present invention provides a method of colonic cleansing by administering to a subject in need thereof an effective amount of any compositions of the present invention, for example a GCRA peptide.

The present invention also provides a method of colonic cleansing by administering to a 20 subject in need thereof an effective amount of any formulations of the present invention.

The GCRA peptides that can be used in the methods and formulations of the invention include a peptide selected from the group designated by SEQ ID NOs: 1-346. Preferably, the GCRA peptide is SEQ ID NO: 1, 9, 55 or 56.

This method can be used in cleansing or purging the bowels or colon prior to carrying out 25 a diagnostic, therapeutic or surgical procedure on the colon, rectum or anus or elsewhere in the abdomen. The diagnostic or surgical procedure may, for example, be sigmoidoscopy, colonoscopy, radiographic examination, preparation for patients undergoing bowel surgery, and other medical or diagnostic procedures. It has been believed that profuse, uncontrolled diarrhea was necessary to produce adequate cleansing of the colon. This present invention provides a safe 30 and effective cleansing method for the bowels and colon, without the ingestion of large volumes

of lavage solutions, without the unpleasant, bitter, and dangerous hypertonic salt solutions, thus providing an improved patients compliance.

“Subject”, as used herein, means an individual. In one aspect, the subject is a mammal such as a primate, and, in another aspect, the subject is a human. The term “subject” also includes 5 domesticated animals (e.g., cats, dogs, etc.), and livestock (e.g., cattle, horses, pigs, sheep, goats, etc.). The subject may be a human over 50 years old. In some embodiments, the subject is one who is undergoing colonoscopy for a routinely accepted indication, including, but not limited to routine screening, polyp or neoplasm history, rectal bleeding, other gastrointestinal bleeding, abdominal pain, unknown diarrhea or constipation etiology, anemia of unknown etiology, 10 inflammatory bowel disease, abnormal endosonography or evaluation of barium enema results.

The compositions (e.g., GCRA peptides) or the formulations described herein can be administered with one or more other agents, for example, L-glucose, cholera toxin, osmotic 15 colonic evacuants, cathartic, laxatives and agents for treating chronic constipation. In some embodiments, the compositions (e.g., GCRA peptides) or the formulations described herein can be administered with L-glucose. The compositions or the formulations described herein can be 20 administered prior to, concurrently, or after the administration of one or more such agents.

Preferably, the GCRA peptide or its derivative or analog of the present invention or any composition/formulation described herein is used in combination with L-glucose, cholera toxin, osmotic colonic evacuants, cathartic, laxatives, agents for treating chronic constipation and/or an 25 osmotic liquid prep. For example, an osmotic liquid prep is SUPREP® Bowel Prep Kit (sodium sulfate potassium sulfate, magnesium sulfate).

The term “cathartic”, as used herein, refers to any composition that acts as a colonic evacuant for cleansing or purging the bowels or colon prior to sigmoidoscopy, colonoscopy, radiographic examination, preparation for patients undergoing bowel surgery, and other medical 25 or diagnostic procedures.

The phrase “osmotic colonic evacuant”, as used herein, refers to any composition that induces water infusion and retention into the intestinal lumen when the composition is administered to a subject. Compositions of an osmotic colonic evacuant include solids, powders, gels, or liquids. A liquid composition of an osmotic colonic evacuant may be constituted from a 30 solid, powder, or gel composition using a physiologically acceptable carrier (e.g., water). A liquid composition of an osmotic colonic evacuant suitable for administration also may be

constituted from liquid concentrate form using a physiologically acceptable carrier (e.g., water) as diluent.

An osmotic colonic evacuant may be a phosphate-based cathartic, for example, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium biphosphate, sodium acid

5 pyrophosphate, or mixtures thereof; or a sulfate-based cathartic, for example, sodium picosulfate and sodium sulfate, or mixtures thereof; or magnesium-based cathartic, for example, magnesium citrate, magnesium hydroxide, magnesium sulfate, magnesium oxide, or mixtures thereof; or magnesium sulfate (Epsom salts).

A stimulant laxative can cause rhythmic muscle contractions in the large intestines.

10 Exemplary stimulant laxatives and their effective doses include: Aloe, 250-1000 mg.; bisacodyl, about 5-80 mg.; casanthranol, 30 to 360 mg.; cascara aromatic fluid extract, 2-24 ml.; cascara sagrada bark, 300-4000 mg.; cascada sagrada extract, 300 to 2000 mg.; cascara sagrada fluid extract, 0.5 to 5 ml.; castor oil, 15-240 ml.; danthron, 75-300 mg.; dehydrocholic acid, 250-2000 mg; phenolphthalein, 30-1000 mg.; sennosides A and B, 12-200 mg.; and picosulfate, 1-100 mg.

15 Other laxatives may include glycerin suppositories, sorbitol, lactulose, and polyethylene glycol (PEG).

Exemplary agents for treating chronic constipation include, but are not limited to lubiprostone (Amitiza), prucalopride, SENNA, MIRALAX, LACTULOSE, PEG, or calcium polycarbophil), stool softeners (such as mineral oil or COLACE), bulking agents (such as 20 METAMUCIL or bran), agents such as ZELNORM (also called tegaserod), and anticholinergic medications such as BENTYL and LEVSIN.

The compositions (e.g., GCRA peptides) or the formulations described herein can be used in combination with a phosphodiesterase inhibitor. PDE inhibitors are those compounds which slow the degradation of cyclic AMP (cAMP) and/or cyclic GMP (cGMP) by inhibition of 25 the phosphodiesterases, which can lead to a relative increase in the intracellular concentration of cAMP and/or cGMP. Possible PDE inhibitors are primarily those substances which are to be numbered among the class consisting of the PDE3 inhibitors, the class consisting of the PDE4 inhibitors and/or the class consisting of the PDE5 inhibitors, in particular those substances which can be designated as mixed types of PDE3/4 inhibitors or as mixed types of PDE3/4/5 inhibitors. 30 By way of example, those PDE inhibitors may be mentioned such as are described and/or claimed in the following patent applications and patents: DE1470341, DE2108438, DE2123328,

DE2305339, DE2305575, DE2315801, DE2402908, DE2413935, DE2451417, DE2459090,
DE2646469, DE2727481, DE2825048, DE2837161, DE2845220, DE2847621, DE2934747,
DE3021792, DE3038166, DE3044568, EP000718, EP0008408, EP0010759, EP0059948,
EP0075436, EP0096517, EPO1 12987, EPO1 16948, EP0150937, EP0158380, EP0161632,
5 EP0161918, EP0167121, EP0199127, EP0220044, EP0247725, EP0258191, EP0272910,
EP0272914, EP0294647, EP0300726, EP0335386, EP0357788, EP0389282, EP0406958,
EP0426180, EP0428302, EP0435811, EP0470805, EP0482208, EP0490823, EP0506194,
EP0511865, EP0527117, EP0626939, EP0664289, EP0671389, EP0685474, EP0685475,
EP0685479, JP92234389, JP94329652, JP95010875, U.S. Pat. Nos. 4,963,561, 5,141,931,
10 WO9117991, WO9200968, WO9212961, WO9307146, WO9315044, WO9315045,
WO9318024, WO9319068, WO9319720, WO9319747, WO9319749, WO9319751,
WO9325517, WO9402465, WO9406423, WO9412461, WO9420455, WO9422852,
WO9425437, WO9427947, WO9500516, WO9501980, WO9503794, WO9504045,
WO9504046, WO9505386, WO9508534, WO9509623, WO9509624, WO9509627,
15 WO9509836, WO9514667, WO9514680, WO9514681, WO9517392, WO9517399,
WO9519362, WO9522520, WO9524381, WO9527692, WO9528926, WO9535281,
WO9535282, WO9600218, WO9601825, WO9602541, WO9611917, DE3142982, DE1 116676,
DE2162096, EP0293063, EP0463756, EP0482208, EP0579496, EP0667345 US6,331,543,
US20050004222 (including those disclosed in formulae I-XIII and paragraphs 37-39, 85-0545
20 and 557-577) and WO9307124, EP0163965, EP0393500, EP0510562, EP0553174, WO9501338
and WO9603399. PDE5 inhibitors which may be mentioned by way of example are RX-RA-69,
SCH-51866, KT- 734, vesnarinone, zaprinast, SKF-96231, ER-21355, BF/GP-385, NM-702 and
sildenafil (Viagra®). PDE4 inhibitors which may be mentioned by way of example are RO-20-
1724, MEM 1414 (R1533/R1500; Pharmacia Roche), DENBUFYLLINE, ROLIPRAM,
25 OXAGRELATE, NITRAQUAZONE, Y-590, DH-6471, SKF-94120, MOTAPIZONE,
LIXAZINONE, INDOLIDAN, OLPRINONE, ATIZORAM, KS-506-G, DIPAMFYLLINE,
BMY-43351, ATIZORAM, AROFYLLINE, FILAMINAST, PDB-093, UCB-29646, CDP-840,
SKF- 107806, PICLAMILAST, RS- 17597, RS-25344-000, SB-207499, TIBENELAST, SB-
210667, SB-211572, SB-211600, SB-212066, SB-212179, GW-3600, CDP-840, MOPIDAMOL,
30 ANAGRELIDE, IBUDILAST, AMRINONE, PIMOBENDAN, CILOSTAZOL, QUAZINONE
and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy4-difluoromethoxybenzamide. PDE3

inhibitors which may be mentioned by way of example are SULMAZOLE, AMPIZONE, CILOSTAMIDE, CARBAZERAN, PIROXIMONE, IMAZODAN, CI-930, SIGUAZODAN, ADIBENDAN, SATERINONE, SKF-95654, SDZ-MKS-492, 349-U-85, EMORADAN, EMD-53998, EMD-57033, NSP-306, NSP-307, REVIZINONE, NM-702, WIN-62582 and WIN-
5 63291, ENOXIMONE and MILRINONE. PDE3/4 inhibitors which may be mentioned by way of example are BENAFENTRINE, TREQUINSIN, ORG-30029, ZARDAVERINE, L-686398, SDZ-ISQ-844, ORG-20241, EMD-54622, and TOLAFENTRINE. Other PDE inhibitors include: cilomilast, pentoxyfylline, roflumilast, tadalafil(Cialis®), theophylline, and vardenafil(Levitra®), zaprinast (PDE5 specific). Preferably, the cGMP-specific phosphodiesterase inhibitor is selected
10 from the group consisting of sulindac sulfone, zaprinast, motapizone, vardenafil, and sildenafil.

Prior to consumption, flavorants and/or sweeteners may be added to compositions of the present invention to increase its palatability. Optionally, the flavorant can be present in the mixture or solution that contains the instant compositions. Alternatively, the flavorant and sweetener can be individually packaged apart from the instant compositions. The flavorant may
15 include a citrate-based component. The citrate-based component may include citric acid, salts, such as sodium or potassium citrate, derivatives of citrate, such as a citrate derivatized with ester functionality, and the like. The flavorant also may include natural and/or artificial flavorings, such as natural and/or artificial fruit flavors, to further increase the palatability of the cathartic. Preferred sweeteners include aspartame, sucralose, and acesulfame potassium, among other
20 ingredients. Preferably, the flavorant and sweetener may be combined as a powered mixture. Examples of such combinations include the commercially available aspartame-based drink mixture, such as the CRYSTAL LIGHT®TM powder that is available from Kraft Foods, Northfield, Ill. (USA) or the N&A Pink Lemonade FL System Sugar FAFT523 that is available from WILD Flavors, Inc., Erlanger, Ky. (USA). Both of these powders include aspartame, citric acid, and fruit flavors that result in flavored drinks when the powder is combined with water.
25 Examples of compositions and uses of flavorants and sweeteners in phosphate-based cathartics are described, for example, in ASPARTAME AND CITRATE FLAVORED PHOSPHATE SALT CATHARTIC, U.S. Published Patent Application publication no. US20060051428 to Ayala et al.

30 The GCRA peptides may be in a pharmaceutical composition in unit dose form, together with one or more pharmaceutically acceptable excipients. The term “unit dose form” refers to a

single drug delivery entity, *e.g.*, a tablet, capsule, solution or inhalation formulation. The amount of peptide present should be sufficient to have a positive effect when administered to a patient (typically, between 10 μ g and 3 g). “Positive effect” refers to effective cleansing or purging the bowels or colon prior to carrying out a diagnostic, therapeutic or surgical procedure on the colon, 5 rectum or anus or elsewhere in the abdomen.

The GCRA peptides can be administered alone or in combination with other agents. Combination methods can be achieved by administering two or more agents, *e.g.*, a GCRA peptide described herein and another compound, each of which is formulated and administered separately, or by administering two or more agents in a single formulation. Other combinations 10 are also encompassed by combination therapy. For example, two agents can be formulated together and administered in conjunction with a separate formulation containing a third agent. While the two or more agents in the combination methods can be administered simultaneously, they need not be. For example, administration of a first agent (or combination of agents) can precede administration of a second agent (or combination of agents) by minutes, hours, or days. 15 Thus, the two or more agents can be administered within minutes of each other or within 1, 2, 3, 6, 9, 12, 15, 18, or 24 hours of each other or within 1 or 2 days of each other. In some cases even longer intervals are possible. While in many cases it is desirable that the two or more agents used in a combination therapy be present in within the patient's body at the same time, this need not be so.

20 In some embodiments, a GCRA peptide or its derivative or analog of the present invention is administered 30 minutes before administering an additional colon cleansing agent (*e.g.*, L-glucose, cholera toxin, osmotic colonic evacuants, cathartic, laxatives, agents for treating chronic constipation and/or an osmotic liquid prep).

25 In some embodiments, a GCRA peptide or its derivative or analog of the present invention is administered the evening prior to the colonoscopy (*e.g.*, at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 hours or more before the colonoscopy).

Combination therapy can also include two or more administrations of one or more of the 30 agents used in the combination. For example, if agent X and agent Y are used in a combination, one could administer them sequentially in any combination one or more times, *e.g.*, in the order X-Y- X, X-X-Y, Y-X-Y, Y-Y-X, X-X-Y-Y, etc.

Combination therapy can also include the administration of two or more agents via different routes or locations. For example, (a) one agent is administered orally and another agent is administered intravenously or (b) one agent is administered orally and another is administered locally. In each case, the agents can either simultaneously or sequentially. Approximated 5 dosages for some of the combination therapy agents described herein are found in the "BNF Recommended Dose" column of tables on pages 11-17 of WO01/76632 (the data in the tables being attributed to the March 2000 British National Formulary) and can also be found in other standard formularies and other drug prescribing directories. For some drugs, the customary prescribed dose for an indication will vary somewhat from country to country.

10 In some embodiments, the GCRA peptide or its derivative or analog of the present invention or any composition/formulation described herein and the additional agent (*e.g.*, L-glucose, cholera toxin, osmotic colonic evacuants, cathartic, laxatives, agents for treating chronic constipation and/or an osmotic liquid prep) are administered orally.

15 The GCRA peptides, alone or in combination, can be combined with any pharmaceutically acceptable carrier or medium. Thus, they can be combined with materials that do not produce an adverse, allergic or otherwise unwanted reaction when administered to a patient. The carriers or mediums used can include solvents, dispersants, coatings, absorption promoting agents, controlled release agents, and one or more inert excipients (which include starches, polyols, granulating agents, microcrystalline cellulose (*e.g.* Celphere®, Celphere® 20 beads), diluents, lubricants, binders, disintegrating agents, and the like), etc. If desired, tablet dosages of the disclosed compositions may be coated by standard aqueous or nonaqueous techniques.

25 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl 30 parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for

the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions 5 (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of 10 manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the 15 required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as 20 manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a 25 GCRA agonist) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

30 Oral compositions generally include an inert diluent or an edible carrier, such as mannitol, fructooligosaccharides, polyethylene glycol and other excipients. They can be

5 enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as 10 magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

15 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

20 The compositions described herein can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

25 In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from 30 Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to

those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811, incorporated fully herein by reference.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Compositions of the present invention may also optionally include other therapeutic ingredients, anti-caking agents, preservatives, sweetening agents, colorants, flavors, desiccants, plasticizers, dyes, glidants, anti-adherents, anti-static agents, surfactants (wetting agents), anti-oxidants, film- coating agents, and the like. Any such optional ingredient must be compatible with the compound described herein to insure the stability of the formulation.

DOSAGE

Dosage levels of active ingredients in a pharmaceutical composition can also be varied so as to achieve a transient or sustained concentration of the compound in a subject, and to result in the desired response. It is well within the skill of the art to start doses of the compound at levels lower than required to achieve the desired effect and to gradually increase the dosage until the desired effect is achieved. It will be understood that the specific dose level for any particular subject will depend on a variety of factors, including body weight, general health, diet, natural history of disease, route and scheduling of administration, combination with one or more other drugs, and severity of disease.

An effective dosage of the composition will typically be between about 1 μ g and about 10 mg per kilogram body weight, preferably between about 10 μ g to 5 mg of the compound per kilogram body weight. Adjustments in dosage will be made using methods that are routine in the art and will be based upon the particular composition being used and clinical considerations.

The guanylate cyclase receptor agonists used in the methods described above may be administered orally, systemically or locally. Dosage forms include preparations for inhalation or injection, solutions, suspensions, emulsions, tablets, capsules, topical salves and lotions, transdermal compositions, other known peptide formulations and pegylated peptide analogs.

5 Agonists may be administered as either the sole active agent or in combination with other drugs, *e.g.*, L-glucose, lubiprostone (Amitiza), prucalopride, a laxative, an osmotic colonic evacuant and/or an inhibitor of cGMP-dependent phosphodiesterase. In all cases, additional drugs should be administered at a dosage that is therapeutically effective using the existing art as a guide. Drugs may be administered in a single composition or sequentially.

10 Dosage levels of the GCRA peptide for use in methods of this invention typically are from about 0.001 mg to about 10,000 mg daily, preferably from about 0.005 mg to about 1,000 mg daily. For example, an effective amount of the GCRA peptide for use in methods of this invention is 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 15 40, 45, 50, 55 or 60 mg per unit dose. In some preferred embodiments, an effective amount of the GCRA peptide for use in methods of this invention is 6.0 mg per unit dose. In some embodiments, an effective amount of the GCRA peptide for use in methods of this invention is 1.0 - 60 mg (*e.g.*, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55 or 60 mg) per unit dose, when 20 the GCRA peptide is SP-304 (SEQ ID NO: 1), SP-333 (SEQ ID NO: 9) or their derivatives or analogs. In some embodiments, an effective amount of the GCRA peptide for use in methods of this invention is 0.3 - 3.0 mg (*e.g.*, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, or 3.0 mg) per unit dose, when the GCRA peptide is an *E. coli* ST peptide, linaclotide (SEQ ID NO: 55) or its derivatives or analogs. In a merely illustrative embodiment, the GCRA peptide is given once or 25 twice one day before the procedure (*e.g.*, colonoscopy, surgery etc.) and once or twice on the day of the procedure but before the procedure. In some embodiments a second agent useful for cleansing or purging the bowels or colon prior to carrying out a diagnostic, therapeutic or surgical procedure on the colon, rectum or anus or elsewhere in the abdomen is administered, prior to, concurrently or after the administration of the GCRA peptide. Suitable second agents 30 are described herein (*e.g.*, an osmotic colonic evacuant; L-glucose, lubiprostone (Amitiza), prucalopride; or a cGMP-specific phosphodiesterase inhibitor). In some aspects the second agent

is administered at less than the standard dose for cleansing and purging the bowels and colon because the GCR agonist acts synergistically with the second agent. The dosage of the second agent can be determined by a physician. For example, the amount of L-glucose is a unit dose of 20g-200g, preferably a unit dose of 24g-48g. On the basis of mg/kg daily dose, either given in 5 single or divided doses, dosages typically range from about 0.001/75 mg/kg to about 10,000/75 mg/kg, preferably from about 0.005/75 mg/kg to about 1,000/75 mg/kg.

In some embodiments, subdoses can be administered two to six times in total before the procedure, preferably two to four times before the procedure, and even more preferably two to three times before the procedure. Doses can be in immediate release form or sustained release 10 form sufficiently effective to obtain the desired control over the medical condition.

The dosage regimen to clean or purge the bowels or colon prior to the procedure with the combinations and compositions of the present invention is selected in accordance with a variety of factors. These factors include, but are not limited to, the type, age, weight, sex, diet, and medical condition of the subject, the route of administration, pharmacological considerations 15 such as the activity, efficacy, pharmacokinetics and toxicology profiles of the particular second agent employed, whether a drug delivery system is utilized. Thus, the dosage regimen actually employed may vary widely and therefore deviate from the preferred dosage regimen set forth above.

20

EXAMPLES

Example 1. A Phase 1, Single-Dose, Pilot Clinical Study to Assess the Safety, Tolerability and Efficacy of Oral SP-333 as an Adjunct to SUPREP® Bowel Prep Kit for Cleansing of the Colon Prior to Colonoscopic Examination in Adults

Table 9. PROTOCOL SYNOPSIS

Study Title	A Phase 1, Single-Dose, Pilot Clinical Study to Assess the Safety, Tolerability and Efficacy of Oral SP-333 as an Adjunct to SUPREP® Bowel Prep Kit for Cleansing of the Colon Prior to Colonoscopic Examination in Adults
Objectives	<p>Primary Objective: The primary endpoint of this study is bowel preparation treatment success as determined by the investigator (bowel preparation will be rated by the Investigator as "Excellent", "Good", "Fair" or "Poor").</p> <p>Secondary Objectives: Safety and Tolerability of SP-333 when given as an adjunct to the SUPREP® Bowel Prep</p>

	Kit for cleansing of the colon prior to colonoscopy.
Methodology	Open Label, Exploratory Single Dose Study
Number of Patients and Population	Approximately 10 adult male and female patients scheduled to undergo colonoscopy
Study Drug	SP-333 6.0 mg tablets for oral administration.
Treatment	Patients will take one (1) 6 mg tablet of SP-333 the evening before their scheduled colonoscopy.
Study Design	This is a phase 1, exploratory, open-label, single-dose, single-center study.
Criteria for Evaluation: Efficacy and Safety	<p>Primary efficacy endpoint: Efficacy will be assessed on the basis of a binary outcome of overall bowel preparation treatment success or failure for the Study Population (defined as those patients who took study drug and for whom the colonoscopy was initiated and who did not have an adverse event preventing initiation of the colonoscopy procedure). Bowel preparation treatment success rate will be described; formal hypothesis testing will not be performed.</p> <p>Exploratory Endpoints The exploratory endpoints for this study are:</p> <ul style="list-style-type: none"> Volume of intra-procedural water required to improve visualization during the procedure as determined by the Investigator; and, Proportion of procedures that reach the cecum and allow complete visualization of the right colon and cecum as determined by the Investigator <p>Safety will be assessed by descriptive summary of treatment-emergent adverse events (TEAEs), adverse events leading to withdrawal, and serious adverse events (SAEs).</p>
Data Analysis	<p>Efficacy analysis Bowel preparation treatment success rate will be described for the study population; formal hypothesis testing will not be performed.</p> <p>Safety Data The safety analysis data set will include all randomized subjects who receive at least one dose of study drug. Incidence of treatment emergent adverse events, withdrawals due to adverse events, serious adverse events and concomitant medications will be listed for each patient and summarized by treatment group.</p>

Overall Design of the Study

This clinical study outlined above was designed to assess the effect of a single oral dose of 6 mg SP-333 when given concurrently with a standard pre-colonoscopy bowel prep - the SUPREP® Bowel Prep Kit (Braintree Laboratories, Braintree, MA 02185, USA). The investigator is a highly experienced gastroenterologist and oversaw all study activities and performed all colonoscopies per his usual routine.

SUPREP® Bowel Prep Kit (FDA Approved Split-Dose regimen)

The SUPREP® Bowel Prep Kit is an osmotic laxative approved and indicated for cleansing of the colon as a preparation for colonoscopy in adults. (Note that the Medication Guide that accompanies the SUPREP® Bowel Prep Kit was given to the patient as per standard clinical practice.)

Patient Instructions for SUPREP® Bowel Prep Kit and Study Drug Administration:*Evening before colonoscopy - approximately 6 PM*

1. Take Study Drug approximately 30 minutes before the start of the first bottle of the bowel prep kit.
- 10 2. Take a 6 ounce bottle of study preparation and pour the entire contents into the mixing cup provided. Fill the cup with cool water to the fill line (16 ounces) and drink the entire cup of solution.
3. Drink two (2) 16 ounce glasses of WATER over the next hour. Fill the mixing cup with water up to the fill line (16 ounces) and drink the entire glass.

15

Morning of colonoscopy

At least 3 hours prior to colonoscopy:

1. Take the second 6 ounce bottle of study preparation and pour the entire contents into the mixing cup provided. Fill the cup with cool water to the fill line (16 ounces) and drink the entire cup of solution.
- 20 2. Drink two (2) 16 ounce glasses of WATER over the next hour. Fill the mixing cup with water up to the fill line (16 ounces) and drink the entire glass.

Patient must complete the solution and additional water at least 2 hours before colonoscopy.

25

Introduction**Background**

Colonoscopists rate currently available pre-procedure colon cleansing preparations as “excellent” (i.e., low residual solid and liquid volume allowing improved visualization) in only 30 50% of patients. Increasing the proportion of preps that result in optimal visualization,

especially of the right colon [a segment with traditionally higher miss rates for polyps and flat lesions], will serve to improve the clinical outcome of the colonoscopy.

Orally administered GC-C agonists have been shown to increase bowel movement frequency and improve stool consistency in patients with chronic idiopathic constipation and in patients with 5 irritable bowel syndrome with constipation. The normal physiological response to an orally delivered GC-C receptor agonist is an increase in water transport into the lumen of the proximal small bowel; the increased water content results in more frequent bowel movement with a normalized consistency in these patients.

SP-333 Mechanism of Action

10 SP-333 is a novel investigational medicinal product that has demonstrated potent agonist of the intestinal GC-C receptor in several in vitro and in vivo pharmacology studies and is now in Phase 2 clinical development. It is a synthetic hexadecapeptide designed to mimic the actions of the natriuretic peptide uroguanylin, a member of the guanylin family of enteric peptides.

15 Uroguanylin and guanylin are endogenous agonists for the human GC-C receptor that is expressed on the luminal surface of epithelial cells lining the GI mucosa; this naturally occurring GI hormone stimulates the intracellular production of cyclic guanosine monophosphate (cGMP), resulting in activation of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), and thereby generating water transport into the bowel lumen.

Clinical Experience

20 Two phase 1 clinical studies with SP-333 have been completed to date and a Phase 2 trial in OIC is in progress. In the Phase I single ascending oral dose study, conducted in 64 healthy subjects, the following doses of SP-333 were tested: 0.1, 0.3, 1, 3, 10, 20, 30, and 60 mg.

25 Overall, SP-333 was safe and well tolerated. Diarrhea was the most common adverse event and was generally dose-related, with 1 mg being the threshold dose. The time to onset of diarrhea was variable but tended to decrease with increasing doses from 4 to 2 hours or less. The number of subjects with watery bowel movement rose from none (< 3 mg) to 2 of 6 (3, 10 and 20 mg) to 4 of 6 (30 mg). The majority of these episodes was mild, occurred once, and was associated with urgency and in some cases mild cramping. There were no SAEs. No clinically meaningful 30 changes in clinical laboratory test results, ECG or vital signs were observed, and no serious adverse events were reported.

In the Phase I multiple ascending dose study, 89 subjects received daily doses of 0.3, 1, 3, 10, & 30 mg SP-333 for 14 days or 60 mg SP-333 for 7 days. The maximum tolerated dose was 30 mg with 60 mg deemed an intolerable dose due to 2 instances of fecal incontinence or soiling in the 7 patients dosed with 60 mg SP-333. SP-333 was generally safe and well-tolerated during this study; there were no clinically meaningful changes in hematology, clinical chemistry, or urinalysis parameters, and no clinically meaningful changes in vital sign or ECG parameters with SP-333 dosing at any dose level. Most commonly reported as TEAEs (treatment-emergent adverse events) were gastrointestinal disorders (primarily diarrhea and defecation urgency) of mild or moderate intensity. No clinically meaningful changes in clinical laboratory test results, ECG or vital signs were observed; no subject experienced a serious adverse event (SAE) and no subject withdrew from the study due to a TEAE.

Phase 1 pharmacokinetic sampling indicated no detectable (limit of quantitation = 1 ng/mL) systemic absorption of SP-333 following oral doses < 10 mg; it is therefore highly unlikely that a single oral dose of 6 mg SP-333 will result in any systemic exposure.

15 Detailed information concerning the available pharmacology, toxicology, drug metabolism, clinical studies' data and the adverse event profile of SP-333 can be found in the Investigator's Brochure.

Overall, SP-333 is an ideal agent to enhance the effectiveness of current bowel cleansing regimens by physiologically increasing water content in the intestine thereby facilitating better 20 evacuation of bowel contents prior to colonoscopy.

Rationale and Objectives

Colorectal cancer (CRC) is a leading cause of cancer death. The lifetime risk of developing CRC in the US approaches 6%, and almost half of those affected will die of the disease. Despite the usefulness of screening procedures for its detection, CRC is a major cause 25 of morbidity and mortality. In screening procedures for CRC such as sigmoidoscopy, colonoscopy, and radiography, it is important that the colon be thoroughly purged and cleansed. In particular, it is essential that as much fecal matter and fluids as possible be removed from the colon to permit adequate visualization of the intestinal mucosa. Furthermore, should a planned diagnostic procedure become a therapeutic procedure by virtue of an unexpected pathological 30 finding (e.g., an adenomatous polyp requiring removal), the ease of performance and overall

success of the therapeutic intervention is enhanced when minimal residual fecal matter and fluid are present.

Primary Objective:

The primary objective of this study was to assess the bowel preparation treatment success

5 of 6 mg SP-333 plus SUPREP® Bowel Prep Kit compared to previous bowel preparation treatment success experience of the Investigator using the SUPREP® Bowel Prep Kit used alone.

Secondary Objective:

The secondary objective of this study was to assess the overall safety and tolerability of 6

mg SP-333 when used as an adjunct to SUPREP® Bowel Prep Kit for bowel cleansing prior to
10 colonoscopy.

Exploratory Objectives:

The exploratory objectives of this study were to assess the volume of intra-procedural water required to improve visualization and the proportion of procedures that reach the cecum and allow complete visualization of the right colon and cecum using 6 mg SP-333 plus

15 SUPREP® Bowel Prep Kit compared to the previous experience of the Investigator with the SUPREP® Bowel Prep Kit used alone.

Rationale for the Doses Selected

Dose selection for this trial was based on results of the Phase 1 studies where a 6 mg oral

daily dose of SP-333 was found to result in self-limited diarrhea (watery stools) with mild

20 urgency in healthy volunteers. No additional AEs of note were observed.

Efficacy Endpoints

Primary Endpoint

The primary endpoint of this study was bowel preparation treatment success as

25 determined by the investigator (bowel preparation will be rated by the Investigator as "Excellent", "Good", "Fair" or "Poor"). A successful bowel preparation treatment is defined as bowel cleansing graded either "Excellent" or "Good" by the investigator (See Table 10).

Table 10. Bowel Preparation Treatment Assessment

Score	Grade	Description
1	Poor	Large amounts of fecal residue, additional cleansing required

2	Fair	Enough feces or fluid to prevent a completely reliable exam
3	Good	Small amounts of feces or fluid not interfering with exam
4	Excellent	No more than small bits of adherent feces/fluid

Secondary Endpoints

The secondary endpoints for this study were:

5 • Frequency of Treatment Emergent Adverse Events
 • Frequency of Serious Adverse Events (SAEs)

Exploratory Endpoints

The exploratory endpoints for this study were:

10 • Volume of intra-procedural water required to improve visualization during the procedure as determined by the Investigator; and,
 • Proportion of procedures that reach the cecum and allow complete visualization of the right colon and cecum as determined by the Investigator

15 Safety Endpoints

- Frequency of Treatment Emergent Adverse Events
- Frequency of SAEs
- Number of patients who were not able to initiate colonoscopy due to an adverse event

20 Planned Sample Size and Number of Study Centers

Approximately ten (10) patients requiring routine diagnostic colonoscopy were recruited by the Investigator from his practice.

Duration of Study

Patients were consented for the study at the same time that informed consent was obtained for the colonoscopy procedure. Each successfully consented & recruited patient took a single dose of 6 mg SP-333 in the evening before the colonoscopy - approximately 30 minutes 5 prior to ingestion of the first bottle of the SUPREP® Bowel Prep Kit (See Section entitled “Patient Instructions for SUPREP® Bowel Prep Kit” above).

Study Population

The study population consisted of male and female outpatients who were undergoing 10 colonoscopy for a routinely accepted indication.

Inclusion Criteria

Patients were entered into the study only if they meet all of the following criteria:

1. Male or female outpatients who are undergoing colonoscopy for a routinely accepted 15 indication, including (but not limited to routine screening, polyp or neoplasm history, rectal bleeding, other gastrointestinal bleeding, abdominal pain, unknown diarrhea or constipation etiology, anemia of unknown etiology, inflammatory bowel disease, abnormal endosonography or evaluation of barium enema results
2. At least 18 years of age
3. Females, and of child-bearing potential, and males with female partners of child-bearing 20 potential are using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse). Subjects practicing abstinence must agree to use an acceptable form of birth control should they become sexually active during the study.
- 25 Pharmacologic methods of contraception must be stable for at least one month prior to Visit 1.
4. Females of child bearing potential must have a negative urine pregnancy test within 48 hours of the colonoscopy
5. In the Investigator's judgment, subject is mentally competent to provide informed consent to 30 participate in the study

Exclusion Criteria

Subjects who meet any of the following criteria were excluded from the study:

1. Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon
- 5 2. Subjects who had previous gastrointestinal surgeries (e.g. colostomy, colectomy, gastric bypass, stomach stapling). Any questions regarding the significance of a previous gastrointestinal surgery should be directed to Synergy Pharmaceuticals Inc.
3. Subjects who, in the opinion of the Principal Investigator, have an uncontrolled clinically significant pre-existing medical condition which might put them at undue medical risk for 10 colonoscopy; examples include, but are not limited to:
 - a. Chronic Child-Pugh Grade B or C liver insufficiency
 - b. renal insufficiency
 - c. Abnormal and clinically significant ECG finding within 3 months prior to scheduled colonoscopy
 - 15 d. History of or current New York Heart Association (NYHA) Functional Classification grade III or IV congestive heart failure
4. Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
5. Subjects undergoing colonoscopy for foreign body removal and decompression.
6. Subjects who are pregnant or lactating
- 20 7. Subjects of childbearing potential who refuse a pregnancy test.
8. Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
9. Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.
- 25 10. Subjects who withdraw consent before completion of SUPREP® Bowel Prep Kit

Dietary Restrictions

Subjects may have a light breakfast on the day before colonoscopy, followed by clear liquids until the colonoscopy is completed the following day. Examples of acceptable clear liquids are:

- 30 ▪ Water

- Strained fruit juices (without pulp) including apple, orange, white grape, or white cranberry
- Limeade or lemonade
- Gatorade/ Powerade
- 5 ▪ Ginger ale
- Coffee or tea (do not use any dairy or non-dairy creamer)
- Chicken broth
- Gelatin desserts without added fruit or topping

10 Note: Purple/Red liquids, Milk and Alcoholic beverages are not permitted.

Variables and Methods of Assessment

Demographics

Demographics were assessed at Screening.

15 **Patient Demography**

Patient demography consists of:

- Age at screening (date of birth)
- Ethnicity
- Sex (Gender)

20 Descriptive summaries of demographic characteristics were provided.

Efficacy Variables

Efficacy were assessed on the basis of a binary outcome of overall bowel preparation treatment success or failure for the Study Population (defined as those patients who took study drug and for whom the colonoscopy was initiated and who did not have an adverse event 25 preventing initiation of the colonoscopy procedure). Bowel preparation treatment success rate was described; formal hypothesis testing was not performed.

The volume of intra-procedural water required to improve visualization, the proximal insertion depth of the colonoscope and whether or not the right colon and cecum were completely visualized were recorded in the Colonoscopy Procedure Record.

Safety Variables

All adverse events were collected from the time of informed consent until the end of the study; the SAE reporting period concluded approximately 30 days after completion of the colonoscopy.

5 Treatment emergent adverse events were descriptively presented by preferred term, severity and relationship to treatment.

Procedures by Visit

Visit 1: Screening

10 1. All pre-colonoscopy procedures were performed per the standard of pre-colonoscopy evaluation as determined important and necessary by the Investigator.

2. Proper use of the SUPREP® Bowel Prep Kit was explained per the routine of Investigator.

3. Informed consent for colonoscopy was obtained.

4. Once informed consent was obtained for the colonoscopy:

15 a. Explained SP-333 study and its objectives; allowed subject to ask any questions he or she may have

 b. Obtained informed consent for the study

5. Instructed patient to take study medication in the evening prior to the colonoscopy - approximately 30 minutes before the start of the first bottle of the SUPREP® Bowel Prep

20 Kit.

Visit 2 (Day of Colonoscopy)

Visit 2 (Day of Colonoscopy)

1. When patient arrived for procedure ensured that study drug was taken on the proper timing and assessed patient for continued suitability for performance of colonoscopy per standard routine.

25 2. Ensured that colonoscopy record includes all information as outlined below.

Study Data Recorded in Colonoscopy Procedure Record

The following data were collected and recorded in the colonoscopy procedure record :

30 1) Start time of colonoscopy

 2) Completion time of colonoscopy

- 3) Volume of water used to improve visualization
- 4) Presence/absence of aphthous ulcerations and characterization
- 5) Presence/absence of ischemic colitis and characterization
- 6) Number of polyps identified and post biopsy characterization
- 7) Number of flat lesions identified and post biopsy characterization

5

Drug Accountability

The Investigator, or qualified designee, maintained an accurate record of the receipt of the study medication as shipped by the Sponsor (or designee) and the date received.

In addition, accurate records of study drug dispensed to patients were kept by the Investigator, or 10 qualified designee, including the amount dispensed to each patient, and the date dispensed.

ASSESSMENT, REPORTING, RECORDING AND FOLLOW UP OF ADVERSE EVENTS

Adverse Event Definition and Reporting

15 Study patients were monitored and questioned for TEAEs at each study visit.

An Adverse Event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. Subjects 20 were queried for any problems they experienced during and after preparation by site personnel at all visits. Colonoscopy and biopsy findings are not considered adverse events unless considered by the investigator to be related to the preparation or colonoscopy procedure. Adverse event collection commenced at the time the patient provides informed consent to participate in the study and concluded with the completion of the colonoscopy. Subjects were instructed to promptly report adverse events to the Investigator. The Investigator recorded date/time of report, date/time of onset, description of the adverse event, severity of adverse event, action(s) taken regarding treatment of the event, action(s) taken regarding study participation, duration of adverse event, and the Investigator's assessment of relationship of adverse event to study treatment.

The Investigator assessed the severity of each adverse event using the following categories:

25

Grade	Severity	Description
-------	----------	-------------

Grade	Severity	Description
1	Mild	Barely noticeable, does not influence functioning causing no limitations of usual activities
2	Moderate	Makes participant uncomfortable, influences functioning causing some limitations of usual activities
3	Severe	Severe discomfort, treatment needed Severe and undesirable, causing inability to carry out usual activities
4	Life threatening	Immediate risk of death, Life threatening or disabling (Must be reported as serious adverse event)
5	Fatal	Causes death of the participant (Must be reported as serious adverse event)

The Investigator assessed the relationship to study drug for each adverse event using the following categories:

Categories of Attribution:	Description
UNRELATED	There is <i>no</i> evidence of any causal relationship.
POSSIBLE	There is <i>some</i> evidence to suggest a causal relationship (e.g., the event occurred within a reasonable time after administration of the trial medication). However, the influence of <i>other factors may have contributed</i> to the event (e.g., the subject's clinical condition, other concomitant events).
PROBABLE	There is <i>evidence</i> to suggest a causal relationship, and the influence of other factors is <i>unlikely</i> .
DEFINITE	There is <i>clear</i> evidence to suggest a causal relationship, and other possible contributing factors can be <i>ruled out</i> .

Assessment of Adverse Events

A Serious Adverse Event (SAE) is any untoward medical occurrence that results in at least one of the following outcomes:

- Results in death
- Is life-threatening
- Requires inpatient hospitalization or prolongation of existing hospitalization
- A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- Is a congenital anomaly/birth defect
- Requires medical or surgical intervention to prevent permanent impairment or damage

Statistical Methods

No analyses were carried out other than a descriptive summary of the primary, secondary, safety and exploratory endpoints of this study.

Results

A total of 9 patients received SP-333 according to the study protocol and completed the study. All patients tolerated the combination of SP-333 and the standard colonoscopy preparation very well.

The same gastroenterologist performed all colonoscopy on the 9 patients. The gastroenterologist observed that the addition of SP-333 to the standard colonoscopy cleansing preparation allowed better visualization of the entire colon and ensured a safe and successful procedure. Subjects who had undergone previous colonoscopies concluded that taking the SP-333 along with their colon cleansing preparation made the preparation much easier than their past colon cleansing preparation without SP-333.

CLAIMS

1. A method of colonic cleansing, comprising administering to a subject in need thereof an effective amount of a guanylate cyclase receptor agonist (GCRA) peptide consisting essentially of the sequence of SEQ ID NO: 9.
2. The method of claim 1, wherein said peptide is bicyclic consisting essentially of the sequence of SEQ ID NO: 9.
3. The method of claim 1 or claim 2, further comprising administering to said subject an effective amount of an osmotic colonic evacuant.
4. The method of claim 3, wherein said osmotic colonic evacuant is magnesium citrate.
5. The method of claim 3, wherein said osmotic colonic evacuant is a phosphate salt laxative.
6. The method of any one of claims 1 to 5, further comprising administering to said subject an effective amount of L-glucose, lubiprostone (Amitiza), prucalopride, an agent for treating chronic constipation, or any combination thereof.
7. The method of claim 6, wherein said effective amount of L-glucose is a unit dose of 20g- 200g.
8. The method of any one of claims 1 to 5, further comprising administering to said subject an effective amount of a cGMP- specific phosphodiesterase inhibitor.
9. The method of claim 8, wherein said cGMP- specific phosphodiesterase inhibitor is selected from the group consisting of sulindac sulfone, zaprinast, motapizone, vardenafil, and sildenafil.
10. The method of any one of claims 1 to 9, wherein the effective amount of a GCRA peptide is a unit dose of 0.01 mg to 60 mg.

11. A formulation comprising a mixture of:
 - a. a composition comprising an inert carrier coated with GCRA peptides consisting essentially of the sequence of SEQ ID NO: 9 wherein said composition comprising an enteric coating that releases the peptides at pH5.0; and
 - b. a composition comprising an inert carrier coated with GCRA peptides consisting essentially of the sequence of SEQ ID NO: 9 wherein said composition comprising an enteric coating that releases the peptides at pH6.0 or pH 7.0.
12. The formulation of claim 11, wherein the inert carrier is selected from mannitol, lactose, a microcrystalline cellulose, or starch.
13. The formulation of claim 11, wherein the amount of GCRA peptide per unit dose is from 1 mg to 60 mg.
14. The formulation of claim 11, wherein the amount of GCRA peptide per unit dose is from 0.3 mg to 3.0 mg when the GCRA peptide is an *E. coli* ST peptide or derivative or analog thereof.
15. A method of colonic cleansing, comprising administering to a subject in need thereof the formulation of any one of claims 11-14.
16. Use of a guanylate cyclase receptor agonist (GCRA) peptide consisting essentially of the sequence of SEQ ID NO: 9 in the manufacture of a medicament for colonic cleansing.
17. Use of a GCRA peptide consisting essentially of the sequence of SEQ ID NO: 9 in the manufacture of the formulation of any one of claims 11-14 for colonic cleansing.

40737-513001WO_ST25. txt
SEQUENCE LISTING

<110> Synergy Pharmaceuticals Inc
Riff, Dennis
Shai Lubhai, Kunwar
Jacob, Gary S
Griffin, Patrick H

<120> Agonists of Guanyl ate Cyclase and Their Uses

<130> 40737-513001WO

<150> US 61/768902
<151> 2013-02-25

<160> 346

<170> PatentIn version 3.5

<210> 1
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<400> 1

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 2
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<400> 2

Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 3
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<400> 3

Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys
1 5 10

<210> 4
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

40737-513001W0_ST25. txt

<400> 4

Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10

<210> 5

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemical ly Synthesized

<400> 5

Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys
1 5 10

<210> 6

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemical ly Synthesized

<400> 6

Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10

<210> 7

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemical ly Synthesized

<400> 7

Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys
1 5 10

<210> 8

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemical ly Synthesized

<220>

<221> MI SC_FEATURE

<222> (16)..(16)

<223> wherein LEU is a D amino acid

<400> 8

Asn Asp Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

40737-513001W0_ST25. txt

<210> 9
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<400> 9

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 10
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (2)..(2)
<223> wherein ASP is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<400> 10

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 11
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)

<223> wherein ASN is a D amino acid

<220>

<221> MI SC FEATURE

<222> (2)..(2)

<223> wherein ASP is a D amino acid

<220>

<221> MI SC FEATURE

<222> (3)..(3)

<223> wherein GLU is a D amino acid

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is a D amino acid

<400> 11

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 12

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is a D amino acid

<400> 12

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 13

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is a D amino acid

<220>

<221> MI SC FEATURE

<222> (6)..(6)

<223> wherein LEU is a D amino acid

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is a D amino acid

<400> 13

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 14
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 14

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys
1 5 10 15

<210> 15
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU at position 16 is attached to polyethylene glycol

<400> 15

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 16
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

40737-513001W0_ST25. txt

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU at position 16 is attached to polyethylene glycol

<400> 16

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 17
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (2)..(2)
<223> wherein ASP is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU at position 16 is attached to polyethylene glycol

<400> 17

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 18
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)

40737-513001WO_ST25. txt

<223> wherein ASN is a D amino acid

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU at position 16 is attached to polyethylene glycol

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is a D amino acid

<400> 18

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 19

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is a D amino acid

<400> 19

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 20

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is a D amino acid

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is a D amino acid

<400> 20

40737-513001W0_ST25. txt

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 21
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU at position 16 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D-amino acid

<400> 21

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 22
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D-amino acid

<220>
<221> MI SC FEATURE
<222> (2)..(2)
<223> wherein ASP is a D-amino acid

<220>
<221> MI SC FEATURE
<222> (3)..(3)
<223> wherein GLU is a D-amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D-amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU at position 16 is attached to polyethylene glycol

40737-513001W0_ST25. txt

<400> 22

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Leu
1 5 10 15

<210> 23

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemical Ly Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is a D amino acid

<220>

<221> MI SC FEATURE

<222> (2)..(2)

<223> wherein ASP is a D amino acid

<220>

<221> MI SC FEATURE

<222> (3)..(3)

<223> wherein GLU is a D amino acid

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is a D amino acid

<400> 23

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Leu
1 5 10 15

<210> 24

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemical Ly Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is a D amino acid

<220>

<221> MI SC FEATURE

<222> (2)..(2)

<223> wherein ASP is a D amino acid

<220>

<221> MI SC FEATURE

40737-513001W0_ST25. txt

<222> (3)..(3)
<223> wherein GLU is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU at position 16 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<400> 24

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 25
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (2)..(2)
<223> wherein ASP is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU at position 16 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<400> 25

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 26
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol

40737-513001W0_ST25. txt

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (2)..(2)
<223> wherein ASP is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<400> 26

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 27
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein x is 3-(2-naphthyl)alanine

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein x is a D amino acid

<400> 27

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 28
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (8)..(8)

40737-513001W0_ST25. txt

<223> wherein x at position 8 is al pha-ami no i sobutyric acid

<220>

<221> MI SC FEATURE

<222> (10)..(10)

<223> wherein x at position 10 is al pha-ami no i sobutyric acid

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is a D amino acid

<400> 28

Asn Asp Glu Cys Glu Leu Cys Xaa Asn Xaa Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 29

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is a D amino acid

<220>

<221> MI SC FEATURE

<222> (7)..(7)

<223> wherein ASP at position 7 is attached to a Lactam bridge

<220>

<221> MI SC FEATURE

<222> (15)..(15)

<223> wherein x at position 15 is ornithine

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is a D amino acid

<400> 29

Asn Asp Glu Cys Glu Leu Asp Val Asn Val Ala Cys Thr Gly Xaa Leu
1 5 10 15

<210> 30

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is a D amino acid

<220>

40737-513001WO_ST25. txt

<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<400> 30

Asn Asp Glu Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 31
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<400> 31

Asn Asp Glu Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 32
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU at position 16 is attached to polyethylene glycol

<400> 32

Asn Asp Glu Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 33
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemical Ly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<400> 33

Asn Asp Glu Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Glu Cys Leu
1 5 10 15

<210> 34
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemical Ly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU at position 16 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<400> 34

Asn Asp Glu Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Glu Cys Leu
1 5 10 15

<210> 35
<211> 16
<212> PRT
<213> Artificial Sequence

<220>

<223> Chemical I y Synthesized

<220>
 <221> MI SC FEATURE
 <222> (1)..(1)
 <223> wherein ASN at position 1 is attached to polyethylene glycol

<220>
 <221> MI SC FEATURE
 <222> (1)..(1)
 <223> wherein ASN is a D amino acid

<220>
 <221> MI SC FEATURE
 <222> (16)..(16)
 <223> wherein LEU is a D amino acid

<220>
 <221> MI SC FEATURE
 <222> (16)..(16)
 <223> wherein LEU at position 16 is attached to polyethylene glycol

<400> 35

Asn	Asp	Gl u	Cys	Gl u	Ser	Cys	Val	Asn	Val	Al a	Cys	Thr	Gl y	Cys	Leu
1				5					10				15		

<210> 36
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemical I y Synthesized

<220>
 <221> MI SC FEATURE
 <222> (1)..(1)
 <223> wherein ASN at position 1 is attached to polyethylene glycol

<220>
 <221> MI SC FEATURE
 <222> (1)..(1)
 <223> wherein ASN is a D amino acid

<220>
 <221> MI SC FEATURE
 <222> (16)..(16)
 <223> wherein LEU is a D amino acid

<400> 36

Asn	Asp	Gl u	Cys	Gl u	Ser	Cys	Val	Asn	Val	Al a	Cys	Thr	Gl y	Cys	Leu
1				5					10				15		

<210> 37
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemical I y Synthesized

40737-513001WO_ST25. txt

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU at position 16 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is a D amino acid

<400> 37

Asn Asp Glu Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 38
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 38

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 39
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein SER at position 16 is attached to polyethylene glycol

<400> 39

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 40
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol

<400> 40

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 41
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein SER at position 16 is attached to polyethylene glycol

<400> 41

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 42
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein SER is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein SER at position 16 is attached to polyethylene glycol

<400> 42

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 43
<211> 16
<212> PRT
<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC_FEATURE

<222> (1)..(1)

<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>

<221> MI SC_FEATURE

<222> (16)..(16)

<223> wherein SER is a D amino acid

<400> 43

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Ser
1 5 10 15

<210> 44

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC_FEATURE

<222> (16)..(16)

<223> wherein SER at position 16 is attached to polyethylene glycol

<220>

<221> MI SC_FEATURE

<222> (16)..(16)

<223> wherein SER is a D amino acid

<400> 44

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Ser
1 5 10 15

<210> 45

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC_FEATURE

<222> (5)..(6)

<223> x is natural, unnatural, an analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC_FEATURE

<222> (8)..(11)

<223> x is natural, unnatural, an analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC_FEATURE

<222> (13)..(14)

<223> x is natural, unnatural, an analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> x is natural, unnatural, an analogue, L, D, or methylated amino acid or any combination

<400> 45

Asn	Asp	Gl u	Cys	Xaa	Xaa	Cys	Xaa	Xaa	Xaa	Cys	Xaa	Xaa	Cys	Xaa
1				5				10					15	

<210> 46

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> x is none or a natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid, or any combination.

<220>

<221> MI SC FEATURE

<222> (2)..(2)

<223> x is none or a natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid, or any combination.

<220>

<221> MI SC FEATURE

<222> (3)..(3)

<223> x is any natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid, or any combination.

<220>

<221> MI SC FEATURE

<222> (5)..(6)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (8)..(11)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (13)..(14)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> x is none or one natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid, or any combination

<400> 46

Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
 1 5 10 15

<210> 47
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemical Synthesized

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> x is none or a natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid or any combination thereof

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> x is none or a natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid or any combination thereof

<220>
 <221> MISC_FEATURE
 <222> (3)..(3)
 <223> x is any natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid or any combination thereof

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoprolidine

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoprolidine

<220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoprolidine

<220>
 <221> MISC_FEATURE
 <222> (15)..(15)
 <223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoprolidine

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> x is natural, unnatural or an analogue, zero or one residue in length, may be L, D, or a methylated amino acid or any combination thereof

<400> 47

Xaa	Xaa	Xaa	Xaa	Gl u	Xaa	Xaa	Val	Asn	Val	Al a	Xaa	Thr	Gl y	Xaa	Xaa
1				5					10				15		

<210> 48

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemical Ly Synthesi zed

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> x is none or a natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid or any combination thereof

<220>

<221> MI SC FEATURE

<222> (2)..(2)

<223> x is none or a natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid or any combination thereof

<220>

<221> MI SC FEATURE

<222> (3)..(3)

<223> x is any natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid or any combination thereof

<220>

<221> MI SC FEATURE

<222> (4)..(4)

<223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoproline

<220>

<221> MI SC FEATURE

<222> (5)..(6)

<223> x is any natural, unnatural or an analogue amino acid, may be L, D, or a methylated amino acid or any combination thereof

<220>

<221> MI SC FEATURE

<222> (7)..(7)

<223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoproline

<220>

<221> MI SC FEATURE

<222> (8)..(11)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (12)..(12)

<223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoproline

<220>

<221> MI SC FEATURE

<222> (13)..(14)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (15)..(15)
<223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoproline

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> x is natural, unnatural or an analogue, zero or one residue in length, may be L, D, or a methylated amino acid or any combination thereof

<400> 48

Xaa
1 5 10 15

<210> 49
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (5)..(6)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (8)..(8)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (10)..(11)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (13)..(14)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<400> 49

Asn Asp Asp Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15

<210> 50
<211> 16
<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is a D amino acid

<220>

<221> MI SC FEATURE

<222> (5)..(6)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (8)..(8)

<223> x is any natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (10)..(11)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (13)..(14)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein x is a D amino acid

<400> 50

Asn Glu Glu Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15

<210> 51

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is a D amino acid

<220>

<221> MI SC FEATURE

<222> (2).. (2)
 <223> wherein GLU is a D amino acid

 <220>
 <221> MI SC FEATURE
 <222> (5).. (6)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

 <220>
 <221> MI SC FEATURE
 <222> (8).. (8)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

 <220>
 <221> MI SC FEATURE
 <222> (10).. (11)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

 <220>
 <221> MI SC FEATURE
 <222> (13).. (14)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

 <220>
 <221> MI SC FEATURE
 <222> (16).. (16)
 <223> wherein x is a D amino acid

 <220>
 <221> MI SC FEATURE
 <222> (16).. (16)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<400> 51

Asn	Gl u	Asp	Cys	Xaa	Xaa	Cys	Xaa	Asn	Xaa	Xaa	Cys	Xaa	Xaa	Cys	Xaa
1				5				10				15			

<210> 52
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemical ly Synthesized

<220>
 <221> MI SC FEATURE
 <222> (1).. (1)
 <223> wherein ASN is a D amino acid

<220>
 <221> MI SC FEATURE
 <222> (2).. (2)
 <223> wherein ASP is a D amino acid

<220>
 <221> MI SC FEATURE
 <222> (5).. (6)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
<221> MI SC FEATURE
<222> (8)..(8)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (10)..(11)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (13)..(14)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein x is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<400> 52

Asn Asp Glu Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15

<210> 53
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (2)..(2)
<223> wherein ASP is a D amino acid

<220>
<221> MI SC FEATURE
<222> (3)..(3)
<223> wherein GLU is a D amino acid

<220>
<221> MI SC FEATURE
<222> (5)..(6)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE

<222> (8)..(8)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
 <221> MI SC FEATURE
 <222> (10)..(11)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
 <221> MI SC FEATURE
 <222> (13)..(14)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
 <221> MI SC FEATURE
 <222> (16)..(16)
 <223> wherein x is a D amino acid

<220>
 <221> MI SC FEATURE
 <222> (16)..(16)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<400> 53

Asn Asp Glu Cys Xaa Xaa Cys Xaa Tyr Xaa Xaa Cys Xaa Xaa Cys Xaa
 1 5 10 15

<210> 54
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<220>
 <221> MI SC FEATURE
 <222> (1)..(1)
 <223> wherein ASN is a D amino acid

<220>
 <221> MI SC FEATURE
 <222> (2)..(2)
 <223> wherein GLU is a D amino acid

<220>
 <221> MI SC FEATURE
 <222> (3)..(3)
 <223> wherein GLU is a D amino acid

<220>
 <221> MI SC FEATURE
 <222> (5)..(6)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
 <221> MI SC FEATURE
 <222> (8)..(8)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
<221> MI SC FEATURE
<222> (10)..(11)
<223> x is natural, unnatural, anal ogue, L, D, or methyl ated ami no aci d
or any combi nati on

<220>
<221> MI SC FEATURE
<222> (13)..(14)
<223> x is natural, unnatural, anal ogue, L, D, or methyl ated ami no aci d
or any combi nati on

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein x is a D ami no aci d

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> x is natural, unnatural, anal ogue, L, D, or methyl ated ami no aci d
or any combi nati on

<400> 54

Asn Gl u Gl u Cys Xaa Xaa Cys Xaa Tyr Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15

<210> 55
<211> 14
<212> PRT
<213> Arti fici al Sequence

<220>
<223> Chemi cal ly Synthesi zed

<400> 55

Cys Cys Gl u Tyr Cys Cys Asn Pro Al a Cys Thr Gl y Cys Tyr
1 5 10

<210> 56
<211> 13
<212> PRT
<213> Arti fici al Sequence

<220>
<223> Chemi cal ly Synthesi zed

<400> 56

Cys Cys Gl u Tyr Cys Cys Asn Pro Al a Cys Thr Gl y Cys
1 5 10

<210> 57
<211> 14
<212> PRT
<213> Arti fici al Sequence

<220>
<223> Chemi cal ly Synthesi zed

<220>

40737-513001W0_ST25. txt

<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein CYS at position 1 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (14)..(14)
<223> wherein TYR at position 14 is attached to polyethylene glycol

<400> 57

Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10

<210> 58
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 58

Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 59
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 59

Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 60
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (14)..(14)
<223> wherein TYR is a D amino acid

<400> 60

Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10

<210> 61
<211> 14
<212> PRT
<213> Artificial Sequence

40737-513001W0_ST25. txt

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein CYS at position 1 is attached to polyethylene glycol

<400> 61

Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10

<210> 62
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<400> 62

Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 63
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is a D amino acid

<400> 63

Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 64
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<400> 64

Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

40737-513001W0_ST25. txt

<210> 65
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> ChemicalIy Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is a D amino acid

<400> 65

Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 66
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> ChemicalIy Synthesized

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is a D amino acid

<400> 66

Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 67
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> ChemicalIy Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<400> 67

Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 68
<211> 16

40737-513001W0_ST25. txt

<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is a D amino acid

<400> 68

Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 69
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is a D amino acid

<400> 69

Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 70
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<400> 70

Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 71
<211> 16
<212> PRT
<213> Artificial Sequence

40737-513001W0_ST25. txt

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is a D amino acid

<400> 71

Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 72
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (14)..(14)
<223> wherein TYR at position 14 is attached to polyethylene glycol

<400> 72

Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10

<210> 73
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein CYS at position 1 is attached to polyethylene glycol

<220>
<221> MI SC FEATURE
<222> (13)..(13)
<223> wherein CYS at position 13 is attached to polyethylene glycol

<400> 73

Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys
1 5 10

<210> 74
<211> 13
<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein CYS at position 1 is attached to polyethylene glycol

<400> 74

Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Glu Cys
1 5 10

<210> 75

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC FEATURE

<222> (13)..(13)

<223> wherein CYS at position 13 is attached to polyethylene glycol

<400> 75

Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Glu Cys
1 5 10

<210> 76

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein TYR at position 16 is attached to polyethylene glycol

<400> 76

Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Glu Cys Tyr
1 5 10 15

<210> 77

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemical I y Synthesi zed

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN at position 1 is attached to polyethylene glycol

<400> 77

Asn Phe Cys Cys Gl u Ser Cys Cys Asn Pro Al a Cys Thr Gl y Cys Tyr
1 5 10 15

<210> 78

<211> 16

<212> PRT

<213> Arti ficial Sequence

<220>

<223> Chemical I y Synthesi zed

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein TYR at position 16 is attached to polyethylene glycol

<400> 78

Asn Phe Cys Cys Gl u Ser Cys Cys Asn Pro Al a Cys Thr Gl y Cys Tyr
1 5 10 15

<210> 79

<211> 16

<212> PRT

<213> Arti ficial Sequence

<220>

<223> Chemical I y Synthesi zed

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN at position 1 is attached to polyethylene glycol

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein TYR at position 16 is attached to polyethylene glycol

<400> 79

Asn Phe Cys Cys Gl u Phe Cys Cys Asn Pro Al a Cys Thr Gl y Cys Tyr
1 5 10 15

<210> 80

<211> 16

<212> PRT

<213> Arti ficial Sequence

<220>

<223> Chemical I y Synthesi zed

40737-513001W0_ST25. txt

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol
<400> 80

Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 81
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR at position 16 is attached to polyethylene glycol
<400> 81

Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 82
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN at position 1 is attached to polyethylene glycol
<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR at position 16 is attached to polyethylene glycol
<400> 82

Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 83
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)

40737-513001WO_ST25. txt

<223> wherein ASN at position 1 is attached to polyethylene glycol

<400> 83

Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 84

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<220>

<221> MISCFEATURE

<222> (16)..(16)

<223> wherein TYR at position 16 is attached to polyethylene glycol

<400> 84

Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 85

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 85

Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10

<210> 86

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 86

Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10

<210> 87

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 87

Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys
1 5 10

40737-513001W0_ST25. txt

<210> 88
<211> 13
<212> PRT
<213> Artifical Sequence

<220>
<223> Chemicaly Synthesized

<400> 88

Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys
1 5 10

<210> 89
<211> 14
<212> PRT
<213> Artifical Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(2)
<223> wherein x is penicillamine

<220>
<221> MI SC FEATURE
<222> (5)..(6)
<223> wherein x is penicillamine

<220>
<221> MI SC FEATURE
<222> (10)..(10)
<223> wherein x is penicillamine

<220>
<221> MI SC FEATURE
<222> (13)..(13)
<223> wherein x is penicillamine

<400> 89

Xaa Xaa Glu Tyr Xaa Xaa Asn Pro Ala Xaa Thr Gly Xaa Tyr
1 5 10

<210> 90
<211> 13
<212> PRT
<213> Artifical Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(2)
<223> wherein x is penicillamine

<220>
<221> MI SC FEATURE
<222> (5)..(6)

<223> wherein x is penicillamine

<220>

<221> MI SC FEATURE

<222> (10)..(10)

<223> wherein x is penicillamine

<220>

<221> MI SC FEATURE

<222> (13)..(13)

<223> wherein x is penicillamine

<400> 90

Xaa Xaa Glu Tyr Xaa Xaa Asn Pro Ala Xaa Thr Glu Xaa
1 5 10

<210> 91

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(6)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (11)..(11)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (15)..(17)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (19)..(20)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>

<221> MI SC FEATURE

<222> (22)..(22)

<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<400> 91

Xaa Xaa Xaa Xaa Xaa Xaa Asn Tyr Cys Cys Xaa Tyr Cys Cys Xaa Xaa
1 5 10 15

Xaa Cys Xaa Xaa Cys Xaa
20

<210> 92

<211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<220>
 <221> MI SC FEATURE
 <222> (1)..(6)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
 <221> MI SC FEATURE
 <222> (11)..(11)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
 <221> MI SC FEATURE
 <222> (15)..(17)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
 <221> MI SC FEATURE
 <222> (19)..(20)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
 <221> MI SC FEATURE
 <222> (22)..(22)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<400> 92

Xaa	Xaa	Xaa	Xaa	Xaa	Xaa	Asn	Phe	Cys	Cys	Xaa	Phe	Cys	Cys	Xaa	Xaa
1					5				10					15	

Xaa Cys Xaa Xaa Cys Xaa
 20

<210> 93
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<220>
 <221> MI SC FEATURE
 <222> (5)..(5)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
 <221> MI SC FEATURE
 <222> (9)..(11)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (13)..(14)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<400> 93

Asn Phe Cys Cys Xaa Phe Cys Cys Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15

<210> 94
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (3)..(3)
<223> wherein x is penicillamine

<220>
<221> MI SC FEATURE
<222> (5)..(5)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (8)..(8)
<223> wherein x is penicillamine

<220>
<221> MI SC FEATURE
<222> (9)..(11)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (13)..(14)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<400> 94

Asn Phe Xaa Cys Xaa Phe Cys Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15

<210> 95
 <211> 16
 <212> PRT
 <213> Artifical Sequence

<220>
 <223> Chemical Synthesized

<220>
 <221> MI SC FEATURE
 <222> (3)..(4)
 <223> wherein x is a cysteine, penicillamine homocysteine, or
 3-mercaptoproline

<220>
 <221> MI SC FEATURE
 <222> (5)..(6)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
 <221> MI SC FEATURE
 <222> (7)..(8)
 <223> wherein x is a cysteine, penicillamine homocysteine, or
 3-mercaptoproline

<220>
 <221> MI SC FEATURE
 <222> (9)..(11)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
 <221> MI SC FEATURE
 <222> (12)..(12)
 <223> wherein x is a cysteine, penicillamine homocysteine, or
 3-mercaptoproline

<220>
 <221> MI SC FEATURE
 <222> (13)..(14)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
 <221> MI SC FEATURE
 <222> (15)..(15)
 <223> wherein x is a cysteine, penicillamine homocysteine, or
 3-mercaptoproline

<220>
 <221> MI SC FEATURE
 <222> (16)..(16)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<400> 95

Asn Phe Xaa
 1 5 10 15

<210> 96
 <211> 14
 <212> PRT
 <213> Artifical Sequence

<220>
<223> Chemical Ly Synthesi zed

<220>
<221> MI SC FEATURE
<222> (1)..(2)
<223> wherein x is a cysteine, penicillamine homocysteine, or
3-mercaptoprol i ne

<220>
<221> MI SC FEATURE
<222> (4)..(4)
<223> x is natural , unnatural , anal ogue, L, D, or methyl ated ami no aci d
or any combi nati on

<220>
<221> MI SC FEATURE
<222> (5)..(6)
<223> wherein x is a cysteine, penicillamine homocysteine, or
3-mercaptoprol i ne

<220>
<221> MI SC FEATURE
<222> (10)..(10)
<223> wherein x is a cysteine, penicillamine homocysteine, or
3-mercaptoprol i ne

<220>
<221> MI SC FEATURE
<222> (13)..(13)
<223> wherein x is a cysteine, penicillamine homocysteine, or
3-mercaptoprol i ne

<400> 96

Xaa Xaa Gl u Xaa Xaa Xaa Asn Pro Al a Xaa Thr Gl y Xaa Tyr
1 5 10

<210> 97
<211> 13
<212> PRT
<213> Artifi ci al Sequence

<220>
<223> Chemical Ly Synthesi zed

<220>
<221> MI SC FEATURE
<222> (1)..(2)
<223> wherein x is a cysteine, penicillamine homocysteine, or
3-mercaptoprol i ne

<220>
<221> MI SC FEATURE
<222> (4)..(4)
<223> x is natural , unnatural , anal ogue, L, D, or methyl ated ami no aci d
or any combi nati on

<220>
<221> MI SC FEATURE
<222> (5)..(6)
<223> wherein x is a cysteine, penicillamine homocysteine, or
3-mercaptoprol i ne

<220>

<221> MI SC FEATURE
<222> (10)..(10)
<223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoprolidine

<220>
<221> MI SC FEATURE
<222> (13)..(13)
<223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoprolidine

<400> 97

Xaa Xaa Glu Xaa Xaa Xaa Asn Pro Ala Xaa Thr Glu Xaa
1 5 10

<210> 98
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> x is none or a natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (2)..(2)
<223> x is none or a natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (3)..(3)
<223> x is none or a natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (4)..(4)
<223> x is none or a natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (5)..(5)
<223> x is none or a natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (6)..(6)
<223> x is none or a natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (7)..(8)
<223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoprolidine

<220>
<221> MI SC FEATURE
<222> (9)..(10)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (11)..(12)
<223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoproline

<220>
<221> MI SC FEATURE
<222> (13)..(15)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoproline

<220>
<221> MI SC FEATURE
<222> (17)..(18)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (19)..(19)
<223> wherein x is a cysteine, penicillamine homocysteine, or 3-mercaptoproline

<220>
<221> MI SC FEATURE
<222> (20)..(20)
<223> x is none or a natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<400> 98

Xaa
1 5 10 15

Xaa Xaa Xaa Xaa
20

<210> 99
<211> 16
<212> PRT
<213> Artifical Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE

40737-513001W0_ST25. txt

<222> (16)..(16)
<223> wherein LEU is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is conjugated to an AMIDE

<400> 99

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 100
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein SER is a D amino acid

<400> 100

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 101
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein SER is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein SER is conjugated to an AMIDE

<400> 101

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15

40737-513001W0_ST25. txt

<210> 102
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is a D amino acid

<400> 102

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 103
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is conjugated to an AMIDE

<400> 103

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 104
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)

40737-513001W0_ST25. txt

<223> wherein GLU is conjugated to Py

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is conjugated to an AMIDE

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is a D-amino acid

<400> 104

Gl u Asp Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

<210> 105

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemical ly Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is attached to polyethylene glycol

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein LEU is attached to polyethylene glycol

<400> 105

Asn Asp Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

<210> 106

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemical ly Synthesized

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein ASN is attached to polyethylene glycol

<400> 106

Asn Asp Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

<210> 107

<211> 16

<212> PRT

<213> Artificial Sequence

40737-513001W0_ST25. txt

<220>
<223> Chemical ly Synthesi zed

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein LEU is attached to polyethylene glycol

<400> 107

Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 108
<211> 16
<212> PRT
<213> Artifi cial Sequence

<220>
<223> Chemical ly Synthesi zed

<220>
<221> MI SC FEATURE
<222> (1)..(3)
<223> x is natural, unnatural, anal ogue, L, D, or methyl ated ami no aci d
or any combi nati on

<220>
<221> MI SC FEATURE
<222> (4)..(4)
<223> wherein x is a cysteine, penic ill ami ne homocysteine, or
3-mercaptoprol ine

<220>
<221> MI SC FEATURE
<222> (5)..(6)
<223> x is natural, unnatural, anal ogue, L, D, or methyl ated ami no aci d
or any combi nati on

<220>
<221> MI SC FEATURE
<222> (7)..(7)
<223> wherein x is a cysteine, penic ill ami ne homocysteine, or
3-mercaptoprol ine

<220>
<221> MI SC FEATURE
<222> (8)..(11)
<223> x is natural, unnatural, anal ogue, L, D, or methyl ated ami no aci d
or any combi nati on

<220>
<221> MI SC FEATURE
<222> (12)..(12)
<223> wherein x is a cysteine, penic ill ami ne homocysteine, or
3-mercaptoprol ine

<220>
<221> MI SC FEATURE
<222> (13)..(14)
<223> x is natural, unnatural, anal ogue, L, D, or methyl ated ami no aci d
or any combi nati on

<220>
<221> MI SC FEATURE

40737-513001W0_ST25. txt

<222> (15)..(15)
<223> wherein x is a cysteine, penicillamine homocysteine, or
3-mercaptoproline

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid
or any combination

<400> 108

Xaa
1 5 10 15

<210> 109
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 109

Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Leu
1 5 10 15

<210> 110
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 110

Glu Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Leu
1 5 10 15

<210> 111
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 111

Glu Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Leu
1 5 10 15

<210> 112
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 112

Gl u Gl u Asp Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
 1 5 10 15

<210> 113
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 113

Gl u Gl u Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
 1 5 10 15

<210> 114
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 114

Asp Asp Asp Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
 1 5 10 15

<210> 115
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 115

Asp Asp Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
 1 5 10 15

<210> 116
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 116

Asp Gl u Asp Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
 1 5 10 15

<210> 117
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

40737-513001W0_ST25. txt

<400> 117

Asp Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 118

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 118

Gln Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 119

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 119

Gln Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 120

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 120

Gln Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 121

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 121

Gln Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 122

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<400> 122

Lys	Asp	Asp	Cys	Gl u	Leu	Cys	Val	Asn	Val	Al a	Cys	Thr	Gl y	Cys	Leu
1				5					10				15		

<210> 123

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<400> 123

Lys	Asp	Gl u	Cys	Gl u	Leu	Cys	Val	Asn	Val	Al a	Cys	Thr	Gl y	Cys	Leu
1				5					10				15		

<210> 124

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<400> 124

Lys	Gl u	Asp	Cys	Gl u	Leu	Cys	Val	Asn	Val	Al a	Cys	Thr	Gl y	Cys	Leu
1				5					10				15		

<210> 125

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<400> 125

Lys	Gl u	Gl u	Cys	Gl u	Leu	Cys	Val	Asn	Val	Al a	Cys	Thr	Gl y	Cys	Leu
1				5					10				15		

<210> 126

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<400> 126

Gl u	Asp	Asp	Cys	Gl u	Leu	Cys	Val	Asn	Val	Al a	Cys	Thr	Gl y	Cys	Ser
1				5					10				15		

<210> 127

<211> 16

<212> PRT

<213> Artificial Sequence

40737-513001W0_ST25. txt

<220>

<223> Chemically Synthesized

<400> 127

Gl u Asp Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 128

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 128

Gl u Gl u Asp Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 129

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 129

Gl u Gl u Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 130

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 130

Asp Asp Asp Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 131

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 131

Asp Asp Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 132

<211> 16

<212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 132

Asp Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
 1 5 10 15

<210> 133
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 133

Asp Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
 1 5 10 15

<210> 134
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 134

Gln Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
 1 5 10 15

<210> 135
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 135

Gln Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
 1 5 10 15

<210> 136
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 136

Gln Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
 1 5 10 15

40737-513001W0_ST25. txt

<210> 137
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 137

Gl n Gl u Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 138
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 138

Lys Asp Asp Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 139
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 139

Lys Asp Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 140
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 140

Lys Gl u Asp Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 141
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 141

Lys Gl u Gl u Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 142
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 142

Gl u Asp Asp Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Leu
1 5 10 15

<210> 143
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 143

Gl u Asp Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Leu
1 5 10 15

<210> 144
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 144

Gl u Gl u Asp Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Leu
1 5 10 15

<210> 145
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 145

Gl u Gl u Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Leu
1 5 10 15

<210> 146
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 146

Asp Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
 1 5 10 15

<210> 147
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 147

Asp Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
 1 5 10 15

<210> 148
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 148

Asp Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
 1 5 10 15

<210> 149
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 149

Asp Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
 1 5 10 15

<210> 150
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 150

Gln Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
 1 5 10 15

<210> 151
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

40737-513001W0_ST25. txt

<400> 151

Gl n Asp Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Leu
1 5 10 15

<210> 152

<211> 16

<212> PRT

<213> Arti fici al Sequence

<220>

<223> Chemi cal ly Synthesi zed

<400> 152

Gl n Gl u Asp Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Leu
1 5 10 15

<210> 153

<211> 16

<212> PRT

<213> Arti fici al Sequence

<220>

<223> Chemi cal ly Synthesi zed

<400> 153

Gl n Gl u Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Leu
1 5 10 15

<210> 154

<211> 16

<212> PRT

<213> Arti fici al Sequence

<220>

<223> Chemi cal ly Synthesi zed

<400> 154

Lys Asp Asp Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Leu
1 5 10 15

<210> 155

<211> 16

<212> PRT

<213> Arti fici al Sequence

<220>

<223> Chemi cal ly Synthesi zed

<400> 155

Lys Asp Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Leu
1 5 10 15

<210> 156

<211> 16

<212> PRT

<213> Arti fici al Sequence

<220>

<223> Chemicaly Synthesized

<400> 156

Lys	Gl u	Asp	Cys	Gl u	Leu	Cys	Ile	Asn	Met	Al a	Cys	Thr	Gl y	Cys	Leu
1				5					10				15		

<210> 157

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<400> 157

Lys	Gl u	Gl u	Cys	Gl u	Leu	Cys	Ile	Asn	Met	Al a	Cys	Thr	Gl y	Cys	Leu
1				5					10				15		

<210> 158

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<400> 158

Gl u	Asp	Asp	Cys	Gl u	Leu	Cys	Ile	Asn	Met	Al a	Cys	Thr	Gl y	Cys	Ser
1				5					10				15		

<210> 159

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<400> 159

Gl u	Asp	Gl u	Cys	Gl u	Leu	Cys	Ile	Asn	Met	Al a	Cys	Thr	Gl y	Cys	Ser
1				5					10				15		

<210> 160

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemicaly Synthesized

<400> 160

Gl u	Gl u	Asp	Cys	Gl u	Leu	Cys	Ile	Asn	Met	Al a	Cys	Thr	Gl y	Cys	Ser
1				5					10				15		

<210> 161

<211> 16

<212> PRT

<213> Artificial Sequence

40737-513001W0_ST25. txt

<220>

<223> Chemically Synthesized

<400> 161

Gl u Gl u Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 162

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 162

Asp Asp Asp Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 163

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 163

Asp Asp Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 164

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 164

Asp Gl u Asp Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 165

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 165

Asp Gl u Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 166

<211> 16

<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 166

Gl n Asp Asp Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 167

<211> 16

<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 167

Gl n Asp Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 168

<211> 16

<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 168

Gl n Gl u Asp Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 169

<211> 16

<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 169

Gl n Gl u Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 170

<211> 16

<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 170

Lys Asp Asp Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 171
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 171

Lys Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
 1 5 10 15

<210> 172
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 172

Lys Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
 1 5 10 15

<210> 173
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 173

Lys Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
 1 5 10 15

<210> 174
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<220>
 <221> MISCFEATURE
 <222> (1)..(3)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
 <221> MISCFEATURE
 <222> (4)..(4)
 <223> wherein x is a cysteine, penicillamine homocysteine, or
 3-mercaptoproline

<220>
 <221> MISCFEATURE
 <222> (5)..(6)
 <223> x is natural, unnatural, analogue, L, D, or methylated amino acid
 or any combination

<220>
<221> MI SC FEATURE
<222> (7)..(7)
<223> where in x is a cysteine, penicillamine homocysteine, or
3-mercaptoproline

<220>
<221> MI SC FEATURE
<222> (8)..(11)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid
or any combination

<220>
<221> MI SC FEATURE
<222> (12)..(12)
<223> where in x is a cysteine, penicillamine homocysteine, or
3-mercaptoproline

<220>
<221> MI SC FEATURE
<222> (13)..(14)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid
or any combination

<220>
<221> MI SC FEATURE
<222> (15)..(15)
<223> where in x is a cysteine, penicillamine homocysteine, or
3-mercaptoproline

<400> 174

Xaa
1 5 10 15

<210> 175
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 175

Ser His Thr Cys Glu Ile Cys Ala Phe Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 176
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 176

Ser His Thr Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 177
<211> 15
<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 177

Ser His Thr Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 178

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 178

Ser His Thr Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 179

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 179

Ser His Thr Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 180

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 180

Ser His Thr Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 181

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 181

Ser His Thr Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 182

40737-513001W0_ST25. txt

<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 182

Ser His Thr Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 183
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 183

Ser His Thr Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 184
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 184

Ser His Thr Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 185
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 185

Ser His Thr Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 186
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 186

Ser His Thr Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

40737-513001W0_ST25. txt

<210> 187
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemical ly Synthesized

<400> 187

Ser His Thr Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 188
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemical ly Synthesized

<400> 188

Ser His Thr Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 189
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemical ly Synthesized

<400> 189

Ser His Thr Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 190
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemical ly Synthesized

<400> 190

Ser His Thr Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 191
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemical ly Synthesized

<400> 191

Ser His Thr Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
Page 66

<210> 192
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 192

Asn Asp Glu Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 193
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 193

Asn Asp Glu Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 194
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 194

Asn Asp Glu Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 195
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 195

Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 196
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 196

40737-513001W0_ST25. txt

Asn Asp Glu Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 197
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 197

Asn Asp Glu Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 198
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 198

Asn Asp Glu Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 199
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 199

Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 200
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 200

Asn Asp Glu Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 201
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

40737-513001W0_ST25. txt

<400> 201

Asn Asp Glu Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 202

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 202

Asn Asp Glu Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 203

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 203

Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 204

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 204

Asn Asp Glu Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 205

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 205

Asn Asp Glu Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 206

<211> 15

<212> PRT

<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<400> 206

Asn Asp Glu Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 207
<211> 15
<212> PRT
<213> Artifical Sequence

<220>
<223> Chemicaly Synthesized

<400> 207

Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15

<210> 208
<211> 17
<212> PRT
<213> Artifical Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(3)
<223> x is natural, unnatural, anal ogue, L, D, or methyl ated ami no aci d
or any combi nation

<220>
<221> MI SC FEATURE
<222> (4)..(4)
<223> wherein x is a cystei ne, peni ci ll ami ne homocystei ne, or
3-mercaptoprol i ne

<220>
<221> MI SC FEATURE
<222> (5)..(6)
<223> x is natural, unnatural, anal ogue, L, D, or methyl ated ami no aci d
or any combi nation

<220>
<221> MI SC FEATURE
<222> (7)..(7)
<223> wherein x is a cystei ne, peni ci ll ami ne homocystei ne, or
3-mercaptoprol i ne

<220>
<221> MI SC FEATURE
<222> (8)..(11)
<223> x is natural, unnatural, anal ogue, L, D, or methyl ated ami no aci d
or any combi nation

<220>
<221> MI SC FEATURE
<222> (12)..(12)
<223> wherein x is a cystei ne, peni ci ll ami ne homocystei ne, or
3-mercaptoprol i ne

<220>
<221> MI SC FEATURE
<222> (13)..(14)
<223> x is natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (15)..(15)
<223> x is none or a natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> x is none or a natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<220>
<221> MI SC FEATURE
<222> (17)..(17)
<223> x is any natural, unnatural, analogue, L, D, or methylated amino acid or any combination

<400> 208

Xaa
1 5 10 15

Xaa

<210> 209
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 209

Gl n Gl u Gl u Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Tyr
1 5 10 15

<210> 210
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 210

Gl n Gl u Gl u Cys Gl u Thr Cys Ile Asn Met Ala Cys Thr Gl y Tyr
1 5 10 15

<210> 211
<211> 15
<212> PRT
<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 211

Gln Asp Glu Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15

<210> 212

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 212

Gln Asp Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15

<210> 213

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 213

Gln Glu Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15

<210> 214

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 214

Gln Glu Glu Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15

<210> 215

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Chemically Synthesized

<400> 215

Gln Asp Glu Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15

<210> 216

<211> 15

<212> PRT

<213> Artificial Sequence

40737-513001W0_ST25. txt

<220>
<223> Chemicaly Synthesized

<400> 216

Gl n Asp Asp Cys Gl u Gl u Cys Ile Asn Met Ala Cys Thr Gl y Tyr
1 5 10 15

<210> 217
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<400> 217

Gl n Gl u Asp Cys Gl u Gl u Cys Ile Asn Met Ala Cys Thr Gl y Tyr
1 5 10 15

<210> 218
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<400> 218

Gl n Gl u Gl u Cys Gl u Tyr Cys Ile Asn Met Ala Cys Thr Gl y Tyr
1 5 10 15

<210> 219
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<400> 219

Gl n Asp Gl u Cys Gl u Tyr Cys Ile Asn Met Ala Cys Thr Gl y Tyr
1 5 10 15

<210> 220
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<400> 220

Gl n Asp Asp Cys Gl u Tyr Cys Ile Asn Met Ala Cys Thr Gl y Tyr
1 5 10 15

<210> 221
<211> 15

<212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 221

Gl n Gl u Asp Cys Gl u Tyr Cys Ile Asn Met Ala Cys Thr Gl y Tyr
 1 5 10 15

<210> 222
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 222

Gl n Gl u Gl u Cys Gl u Ile Cys Ile Asn Met Ala Cys Thr Gl y Tyr
 1 5 10 15

<210> 223
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 223

Gl n Asp Gl u Cys Gl u Ile Cys Ile Asn Met Ala Cys Thr Gl y Tyr
 1 5 10 15

<210> 224
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 224

Gl n Asp Asp Cys Gl u Ile Cys Ile Asn Met Ala Cys Thr Gl y Tyr
 1 5 10 15

<210> 225
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 225

Gl n Gl u Asp Cys Gl u Ile Cys Ile Asn Met Ala Cys Thr Gl y Tyr
 1 5 10 15

40737-513001W0_ST25. txt

<210> 226
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 226

Gln Glu Glu Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 227
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 227

Gln Asp Glu Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 228
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 228

Gln Asp Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 229
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 229

Gln Glu Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 230
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 230

Gln Glu Glu Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 231
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 231

Gl n Asp Gl u Cys Gl u Gl u Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 232
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 232

Gl n Asp Asp Cys Gl u Gl u Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 233
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 233

Gl n Gl u Asp Cys Gl u Gl u Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 234
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 234

Gl n Gl u Gl u Cys Gl u Tyr Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 235
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemically Synthesized

<400> 235

Gl n Asp Gl u Cys Gl u Tyr Cys Ile Asn Met Al a Cys Thr Gl y Cys Ser
 1 5 10 15

<210> 236
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 236

Gl n Asp Asp Cys Gl u Tyr Cys Ile Asn Met Al a Cys Thr Gl y Cys Ser
 1 5 10 15

<210> 237
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 237

Gl n Gl u Asp Cys Gl u Tyr Cys Ile Asn Met Al a Cys Thr Gl y Cys Ser
 1 5 10 15

<210> 238
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 238

Gl n Gl u Gl u Cys Gl u Ile Cys Ile Asn Met Al a Cys Thr Gl y Cys Ser
 1 5 10 15

<210> 239
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

<400> 239

Gl n Asp Gl u Cys Gl u Ile Cys Ile Asn Met Al a Cys Thr Gl y Cys Ser
 1 5 10 15

<210> 240
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Chemically Synthesized

40737-513001W0_ST25. txt

<400> 240

Gl n Asp Asp Cys Gl u Ile Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 241

<211> 16

<212> PRT

<213> Arti ficial Sequence

<220>

<223> Chemical ly Synthesi zed

<400> 241

Gl n Gl u Asp Cys Gl u Ile Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 242

<211> 22

<212> PRT

<213> Arti ficial Sequence

<220>

<223> Chemical ly Synthesi zed

<400> 242

Asn Ser Ser Asn Ser Ser Asn Tyr Cys Cys Gl u Lys Cys Cys Asn Pro
1 5 10 15

Al a Cys Thr Gl y Cys Tyr
20

<210> 243

<211> 16

<212> PRT

<213> Arti ficial Sequence

<220>

<223> Chemical ly Synthesi zed

<220>

<221> MI SC_FEATURE

<222> (1)..(1)

<223> wherein ASN is attached to polyethylene glycol

<220>

<221> MI SC_FEATURE

<222> (16)..(16)

<223> wherein TYR is attached to polyethylene glycol

<400> 243

Asn Phe Cys Cys Gl u Thr Cys Cys Asn Pro Al a Cys Thr Gl y Cys Tyr
1 5 10 15

<210> 244

<211> 16

<212> PRT

<213> Arti ficial Sequence

40737-513001W0_ST25. txt

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is attached to polyethylene glycol

<400> 244

Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 245
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is attached to polyethylene glycol

<400> 245

Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 246
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<400> 246

Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15

<210> 247
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Chemicaly Synthesized

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein ASN is a D amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein TYR is a D amino acid

<400> 247

Asn	Phe	Cys	Cys	Gl u	Tyr	Cys	Cys	Asn	Pro	Al a	Cys	Thr	Gl y	Cys	Tyr
1				5					10				15		

<210> 248

<211> 16

<212> PRT

<213> Arti fi ci al Sequence

<220>

<223> Chemical ly Synthesi zed

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherei n TYR i s a D ami no aci d

<400> 248

Asn	Phe	Cys	Cys	Gl u	Tyr	Cys	Cys	Asn	Pro	Al a	Cys	Thr	Gl y	Cys	Tyr
1				5					10				15		

<210> 249

<211> 16

<212> PRT

<213> Arti fi ci al Sequence

<220>

<223> Chemical ly Synthesi zed

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherei n ASN i s a D ami no aci d

<400> 249

Asn	Phe	Cys	Cys	Gl u	Tyr	Cys	Cys	Asn	Pro	Al a	Cys	Thr	Gl y	Cys	Tyr
1				5					10				15		

<210> 250

<211> 16

<212> PRT

<213> Arti fi ci al Sequence

<220>

<223> Synthesi zed pepti de

<220>

<221> MI SC FEATURE

<222> (1)..(2)

<223> wherei n Xaa i s absent or any natural , unnatural ami no aci d or anal ogue thereof

<220>

<221> MI SC FEATURE

<222> (3)..(3)

<223> wherei n Xaa i s any natural , unnatural ami no aci d or anal ogue thereof

<220>

<221> MI SC FEATURE
 <222> (5)..(11)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
 <221> MI SC FEATURE
 <222> (13)..(15)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
 <221> MI SC FEATURE
 <222> (16)..(16)
 <223> wherein Xaa is absent or any natural, unnatural amino acid or analogue thereof

<400> 250

Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
 1 5 10 15

<210> 251
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MI SC FEATURE
 <222> (1)..(1)
 <223> wherein Xaa is a pyroglutamic acid

<400> 251

Xaa Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Leu
 1 5 10 15

<210> 252
 <211> 15
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<400> 252

Pro Glu Thr Cys Glu Ile Cys Ala Tyr Ala Ala Cys Thr Glu Cys
 1 5 10 15

<210> 253
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MOD_RES

40737-513001W0_ST25. txt

<222> (3). . (3)
<223> Aad

<400> 253

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 254
<211> 15
<212> PRT
<213> Arti fici al Sequence

<220>
<223> Synthesi zed pepti de

<220>
<221> MOD_RES
<222> (2). . (2)
<223> Aad

<400> 254

Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 255
<211> 14
<212> PRT
<213> Arti fici al Sequence

<220>
<223> Synthesi zed pepti de

<220>
<221> MOD_RES
<222> (2). . (2)
<223> Aad

<400> 255

Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys
1 5 10

<210> 256
<211> 14
<212> PRT
<213> Arti fici al Sequence

<220>
<223> Synthesi zed pepti de

<220>
<221> MOD_RES
<222> (1). . (1)
<223> Aad

<400> 256

Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10

40737-513001W0_ST25. txt

<210> 257
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Aad

<400> 257

Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys
1 5 10

<210> 258
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> misc_feature
<222> (16)..(16)
<223> Xaa can be any naturally occurring amino acid

<400> 258

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 259
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC_FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC_FEATURE
<222> (16)..(16)

40737-513001W0_ST25. txt

<223> wherein Xaa is a dLeu

<400> 259

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 260

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein Xaa is a dAsn

<220>

<221> MI SC FEATURE

<222> (2)..(2)

<223> wherein Xaa is a dAsp

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein Xaa is a dLeu

<400> 260

Xaa Xaa Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 261

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein Xaa is a dAsn

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<400> 261

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

40737-513001W0_ST25. txt

<210> 262
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> mi sc_feature
<222> (6)..(6)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu

<400> 262

Xaa Asp Xaa Cys Glu Xaa Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 263
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<400> 263

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys
1 5 10 15

<210> 264
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein a PEG is conjugated at the N-terminus

40737-513001W0_ST25. txt

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu, and a PEG is conjugated at the C-terminus

<400> 264

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Xaa
1 5 10 15

<210> 265
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn, and a PEG is conjugated at the N-terminus

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu, and a PEG is conjugated at the C-terminus

<400> 265

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Xaa
1 5 10 15

<210> 266
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn, and a PEG is conjugated at the N-terminus

<220>
<221> MI SC FEATURE
<222> (2)..(2)
<223> wherein Xaa is a dAsp

<220>
<221> MOD_RES

40737-513001W0_ST25. txt

<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu and a PEG is conjugated at the C-terminus

<400> 266

Xaa Xaa Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 267
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu and a PEG is conjugated at the C-terminus

<400> 267

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 268
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein a PEG is conjugated at the N-terminus

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu

40737-513001W0_ST25. txt

<400> 268

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 269

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein Xaa is a dAsn and a PEG is conjugated at the N-terminus

<220>

<221> MI SC FEATURE

<222> (3)..(3)

<223> wherein Xaa is an Aad

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein Xaa is a dLeu

<400> 269

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 270

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein Xaa is a dLeu and a PEG is conjugated at the C-terminus

<400> 270

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 271

<211> 16

<212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MI SC FEATURE
 <222> (1)..(1)
 <223> wherein Xaa is a dAsn and a PEG is conjugated at the N-terminus

<220>
 <221> MI SC FEATURE
 <222> (2)..(2)
 <223> wherein Xaa is a dAsp

<220>
 <221> MOD_RES
 <222> (3)..(3)
 <223> Aad

<220>
 <221> MI SC FEATURE
 <222> (16)..(16)
 <223> wherein Xaa is a dLeu

<400> 271

Xaa Xaa Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
 1 5 10 15

<210> 272
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MI SC FEATURE
 <222> (1)..(1)
 <223> wherein Xaa is a dAsn

<220>
 <221> MI SC FEATURE
 <222> (2)..(2)
 <223> wherein Xaa is a dAsp

<220>
 <221> MOD_RES
 <222> (3)..(3)
 <223> Aad

<220>
 <221> MI SC FEATURE
 <222> (16)..(16)
 <223> wherein Xaa is a dLeu and a PEG is conjugated at the C-terminus

<400> 272

Xaa Xaa Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
 1 5 10 15

40737-513001W0_ST25. txt

<210> 273
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a D- 3-(2-naphthyl)alanine (dNal)

<400> 273

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 274
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Aib

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Aib

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu

40737-513001W0_ST25. txt

<400> 274

Xaa Asp Xaa Cys Glu Leu Cys Xaa Asn Xaa Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 275

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>

<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>

<221> MI SC FEATURE
<222> (7)..(7)
<223> wherein Xaa is an Asp, forms a lactam bridge with residue 15

<220>

<221> MOD_RES
<222> (15)..(15)
<223> Orn

<220>

<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu

<400> 275

Xaa Asp Xaa Cys Glu Leu Xaa Val Asn Val Ala Cys Thr Gly Xaa Xaa
1 5 10 15

<210> 276

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>

<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>

<221> MI SC FEATURE

40737-513001W0_ST25. txt

<222> (16)..(16)
<223> wherein Xaa is a dLeu

<400> 276

Xaa Asp Xaa Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 277
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu

<400> 277

Xaa Asp Xaa Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 278
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn and a PEG is conjugated at the N-terminus

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu and a PEG is conjugated at the C-terminus

<400> 278

Xaa Asp Xaa Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

40737-513001W0_ST25. txt

<210> 279
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn and a PEG is conjugated at the N-terminus

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu

<400> 279

Xaa Asp Xaa Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 280
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu and a PEG is conjugated at the C-terminus

<400> 280

Xaa Asp Xaa Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 281
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC_FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn and a PEG is conjugated at the N-terminus

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC_FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu and a PEG is conjugated at the C-terminus

<400> 281

Xaa Asp Xaa Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 282
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC_FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn and a PEG is conjugated at the N-terminus

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC_FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu

<400> 282

Xaa Asp Xaa Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 283
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC_FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>

40737-513001W0_ST25. txt

<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC_FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu and a PEG is conjugated at the C-terminus

<400> 283

Xaa Asp Xaa Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 284
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<400> 284

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 285
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC_FEATURE
<222> (1)..(1)
<223> wherein a PEG is conjugated at the N-terminus

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC_FEATURE
<222> (16)..(16)
<223> wherein a PEG is conjugated at the C-terminus

<400> 285

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 286
<211> 16
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein a PEG is conjugated at the N-terminus

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<400> 286

Asn	Asp	Xaa	Cys	Gl u	Leu	Cys	Val	Asn	Val	Al a	Cys	Thr	Gl y	Cys	Ser
1			5					10					15		

<210> 287

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<221> Synthesized peptide

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein a PEG is conjugated at the C-terminus

<400> 287

Asn	Asp	Xaa	Cys	Gl u	Leu	Cys	Val	Asn	Val	Al a	Cys	Thr	Gl y	Cys	Ser
1			5					10					15		

<210> 288

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<221> Synthesized peptide

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein a PEG is conjugated at the N-terminus

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> MI SC FEATURE

40737-513001W0_ST25. txt

<222> (16)..(16)

<223> wherein Xaa is a dSer and a PEG is conjugated at the C-terminus

<400> 288

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Xaa
1 5 10 15

<210> 289

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein a PEG is conjugated at the N-terminus

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein Xaa is a dSer

<400> 289

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Xaa
1 5 10 15

<210> 290

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein Xaa is a dSer and a PEG is conjugated at the C-terminus

<400> 290

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Glu Cys Xaa
1 5 10 15

<210> 291

<211> 16

<212> PRT

<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (5)..(6)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> MI SC FEATURE
<222> (8)..(10)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> mi sc_feature
<222> (11)..(11)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> MI SC FEATURE
<222> (13)..(14)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<400> 291

Asn Asp Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15

<210> 292
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(2)
<223> wherein Xaa is absent or any natural, unnatural amino acid or analogue thereof

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (5)..(6)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC FEATURE

<222> (8)..(11)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC FEATURE

<222> (13)..(14)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein Xaa is absent or any natural, unnatural amino acid or analogue thereof

<400> 292

Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15

<210> 293

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MI SC FEATURE

<222> (1)..(2)

<223> wherein Xaa is absent or any natural, unnatural amino acid or analogue thereof

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> MI SC FEATURE

<222> (4)..(4)

<223> wherein Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoprolidine

<220>

<221> MI SC FEATURE

<222> (6)..(6)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC FEATURE

<222> (7)..(7)

<223> wherein Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoprolidine

<220>

<221> MI SC FEATURE

<222> (12)..(12)

<223> where in Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoproline

<220>

<221> MI SC FEATURE

<222> (15)..(15)

<223> where in Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoproline

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> where in Xaa is absent or any natural, unnatural amino acid or analogue thereof

<400> 293

Xaa Xaa Xaa Xaa Glu Xaa Xaa Val Asn Val Ala Xaa Thr Gly Xaa Xaa
1 5 10 15

<210> 294

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MI SC FEATURE

<222> (1)..(2)

<223> where in Xaa is absent or any natural, unnatural amino acid or analogue thereof

<220>

<221> MOD_RES

<222> (1)..(2)

<223> Aad

<220>

<221> mi sc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<220>

<221> MI SC FEATURE

<222> (4)..(4)

<223> where in Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoproline

<220>

<221> MI SC FEATURE

<222> (5)..(6)

<223> where in Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC FEATURE

<222> (7)..(7)

<223> where in Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoproline

<220>

<221> MI SC FEATURE

<222> (8)..(11)

<223> where in Xaa is any natural, unnatural amino acid or analogue

thereof

<220>
 <221> MI SC FEATURE
 <222> (12)..(12)
 <223> wherein Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoproline

<220>
 <221> MI SC FEATURE
 <222> (13)..(14)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
 <221> MI SC FEATURE
 <222> (15)..(15)
 <223> wherein Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoproline

<220>
 <221> MI SC FEATURE
 <222> (16)..(15)
 <223> wherein Xaa is absent or any natural, unnatural amino acid or analogue thereof

<220>
 <221> mi sc_feature
 <222> (16)..(16)
 <223> Xaa can be any naturally occurring amino acid

<400> 294

Xaa
 1 5 10 15

<210> 295
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MOD_RES
 <222> (3)..(3)
 <223> Aad

<220>
 <221> MI SC FEATURE
 <222> (5)..(6)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
 <221> MI SC FEATURE
 <222> (8)..(8)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
 <221> MI SC FEATURE
 <222> (10)..(11)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> MI SC_FEATURE
<222> (13)..(14)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> MI SC_FEATURE
<222> (16)..(16)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<400> 295

Asn Asp Xaa Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15

<210> 296
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC_FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC_FEATURE
<222> (5)..(6)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> MI SC_FEATURE
<222> (8)..(8)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> MI SC_FEATURE
<222> (10)..(11)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> MI SC_FEATURE
<222> (13)..(14)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> MI SC_FEATURE
<222> (16)..(16)
<223> wherein Xaa is a D-form of any natural, unnatural amino acid or analogue thereof

<400> 296

Xaa Glu Xaa Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
 1 5 10 15

<210> 297

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein Xaa is a dAsn

<220>

<221> MI SC FEATURE

<222> (2)..(2)

<223> wherein Xaa is a dGlu

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> MI SC FEATURE

<222> (5)..(6)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC FEATURE

<222> (8)..(8)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC FEATURE

<222> (10)..(11)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC FEATURE

<222> (13)..(14)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein Xaa is D-form of any natural, unnatural amino acid or analogue thereof

<400> 297

Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
 1 5 10 15

<210> 298

<211> 16

<212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> wherein Xaa is a dAsn

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> wherein Xaa is a dAsp

<220>
 <221> MOD_RES
 <222> (3)..(3)
 <223> Aad

<220>
 <221> MISC_FEATURE
 <222> (5)..(6)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
 <221> MISC_FEATURE
 <222> (10)..(11)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
 <221> MISC_FEATURE
 <222> (13)..(14)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> wherein Xaa is D-form of any natural, unnatural amino acid or analogue thereof

<400> 298

Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
 1 5 10 15

<210> 299
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>

<221> MI SC FEATURE
 <222> (1)..(1)
 <223> wherein Xaa is a dAsn

 <220>
 <221> MI SC FEATURE
 <222> (2)..(2)
 <223> wherein Xaa is a dAsp

 <220>
 <221> MOD_RES
 <222> (3)..(3)
 <223> Aad

 <220>
 <221> MI SC FEATURE
 <222> (5)..(6)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue
 thereof

 <220>
 <221> MI SC FEATURE
 <222> (8)..(8)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue
 thereof

 <220>
 <221> MI SC FEATURE
 <222> (10)..(11)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue
 thereof

 <220>
 <221> MI SC FEATURE
 <222> (13)..(14)
 <223> wherein Xaa is any natural, unnatural amino acid or analogue
 thereof

 <220>
 <221> MI SC FEATURE
 <222> (16)..(16)
 <223> wherein Xaa is D-form of any natural, unnatural amino acid or
 analogue thereof

<400> 299

Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Tyr Xaa Xaa Cys Xaa Xaa Cys Xaa
 1 5 10 15

<210> 300
 <211> 18
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthesized peptide

<220>
 <221> MI SC FEATURE
 <222> (1)..(1)
 <223> wherein Xaa is a dAsn

<220>
 <221> MI SC FEATURE
 <222> (2)..(2)
 <223> wherein Xaa is a dGl u

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> mi sc_feature
<222> (4)..(4)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> MI SC FEATURE
<222> (5)..(6)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> mi sc_feature
<222> (7)..(7)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> MI SC FEATURE
<222> (8)..(8)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> MI SC FEATURE
<222> (10)..(11)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> mi sc_feature
<222> (12)..(12)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> MI SC FEATURE
<222> (13)..(14)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> mi sc_feature
<222> (15)..(15)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is D-form of any natural, unnatural amino acid or analogue thereof

<220>
<221> mi sc_feature
<222> (18)..(18)
<223> Xaa can be any naturally occurring amino acid

<400> 300

Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Tyr Xaa Xaa Cys Xaa Xaa
1 5 10 15

Cys Xaa

<210> 301
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(2)
<223> wherein Xaa is absent or any natural, unnatural amino acid or analogue thereof

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> mi sc_feature
<222> (4)..(4)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> MI SC FEATURE
<222> (5)..(11)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> mi sc_feature
<222> (12)..(12)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> MI SC FEATURE
<222> (13)..(15)
<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is absent or any natural, unnatural amino acid or analogue thereof

<400> 301

Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10

<210> 302
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE

40737-513001W0_ST25. txt

<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dLeu

<220>
<221> MOD_RES
<222> (16)..(16)
<223> AMI DATI ON

<400> 302

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 303
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dSer

<400> 303

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 304
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

40737-513001W0_ST25. txt

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dSer

<220>
<221> MOD_RES
<222> (16)..(16)
<223> AMI DATI ON

<400> 304

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 305
<211> 16
<212> PRT
<213> Arti fici al Sequence

<220>
<223> Synthesi zed pepti de

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein Xaa is a dTyr

<400> 305

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 306
<211> 16
<212> PRT
<213> Arti fici al Sequence

<220>
<223> Synthesi zed pepti de

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein Xaa is a dAsn

<220>
<221> MOD_RES
<222> (3)..(3)

40737-513001W0_ST25. txt

<223> Aad

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein Xaa is a dTyr

<220>

<221> MOD RES

<222> (16)..(16)

<223> AMI DATI ON

<400> 306

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 307

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein Xaa is a pyroglutamic acid

<220>

<221> MOD RES

<222> (3)..(3)

<223> Aad

<220>

<221> MI SC FEATURE

<222> (16)..(16)

<223> wherein Xaa is a dLeu

<220>

<221> MOD RES

<222> (16)..(16)

<223> AMI DATI ON

<400> 307

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15

<210> 308

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MI SC FEATURE

<222> (1)..(1)

<223> wherein Xaa is a pyroglutamic acid

<220>

40737-513001W0_ST25. txt

<221> MOD_RES
<222> (3)..(3)
<223> Aad

<400> 308

Xaa Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 309
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein a PEG is conjugated at the N-terminus

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<220>
<221> MI SC FEATURE
<222> (16)..(16)
<223> wherein a PEG is conjugated at the C-terminus

<400> 309

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 310
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> MI SC FEATURE
<222> (1)..(1)
<223> wherein a PEG is conjugated at the N-terminus

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Aad

<400> 310

Asn Asp Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 311
<211> 16
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> misc_feature

<222> (5)..(5)

<223> Xaa can be any naturally occurring amino acid

<220>

<221> MISCFEATURE

<222> (16)..(16)

<223> wherein a PEG is conjugated at the C-terminus

<400> 311

Asn	Asp	Glu	Cys	Xaa	Leu	Cys	Val	Asn	Val	Ala	Cys	Thr	Gly	Cys	Leu
1				5				10					15		

<210> 312

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> MISCFEATURE

<222> (1)..(2)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Aad

<220>

<221> MISCFEATURE

<222> (4)..(4)

<223> wherein Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoprolidine

<220>

<221> MISCFEATURE

<222> (5)..(6)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MISCFEATURE

<222> (7)..(7)

<223> wherein Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoprolidine

<220>

<221> MISCFEATURE

<222> (8)..(11)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC_FEATURE

<222> (12)..(12)

<223> wherein Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoproline

<220>

<221> MI SC_FEATURE

<222> (13)..(14)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<220>

<221> MI SC_FEATURE

<222> (15)..(15)

<223> wherein Xaa is a Cys, Penicillamine (Pen), homocysteine or 3-mercaptoproline

<220>

<221> MI SC_FEATURE

<222> (16)..(16)

<223> wherein Xaa is any natural, unnatural amino acid or analogue thereof

<400> 312

Xaa
 1 5 10 15

<210> 313

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> mi sc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 313

Gl u Asp Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
 1 5 10 15

<210> 314

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> mi sc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 314

40737-513001W0_ST25. txt

Gl u Gl u Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

<210> 315
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 315

Asp Asp Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

<210> 316
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 316

Asp Gl u Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

<210> 317
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 317

Gl n Asp Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

<210> 318
<211> 16
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 318

Gl n Gl u Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

<210> 319

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 319

Lys Asp Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

<210> 320

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 320

Lys Gl u Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Leu
1 5 10 15

<210> 321

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> misc_feature

40737-513001W0_ST25. txt

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 321

Gl u Asp Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 322

<211> 16

<212> PRT

<213> Arti fici al Sequence

<220>

<221> mi sc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 322

Gl u Gl u Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 323

<211> 16

<212> PRT

<213> Arti fici al Sequence

<220>

<223> Synthesi zed pepti de

<220>

<221> mi sc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 323

Asp Asp Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

<210> 324

<211> 16

<212> PRT

<213> Arti fici al Sequence

<220>

<223> Synthesi zed pepti de

<220>

<221> mi sc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 324

Asp Gl u Xaa Cys Gl u Leu Cys Val Asn Val Al a Cys Thr Gl y Cys Ser
1 5 10 15

40737-513001W0_ST25. txt

<210> 325
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> mi sc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 325

Gl n Asp Xaa Cys Gl u Leu Cys Val Asn Val Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 326
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> mi sc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 326

Gl n Gl u Xaa Cys Gl u Leu Cys Val Asn Val Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 327
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> mi sc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 327

Lys Asp Xaa Cys Gl u Leu Cys Val Asn Val Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 328
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> mi sc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 328

Lys Glu Xaa Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 329
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> mi sc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 329

Glu Asp Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 330
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> mi sc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 330

Glu Glu Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 331
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> mi sc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 331

40737-513001W0_ST25. txt

Asp Asp Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 332
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 332

Asp Glu Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 333
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 333

Gl n Asp Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 334
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 334

Gl n Glu Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 335
<211> 16
<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 335

Lys Asp Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 336

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 336

Lys Glu Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15

<210> 337

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 337

Gl u Asp Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 338

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> misc_feature

40737-513001W0_ST25. txt

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 338

Gl u Gl u Xaa Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 339

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 339

Asp Asp Xaa Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 340

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<400> 340

Asp Gl u Asp Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 341

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthesized peptide

<220>

<221> misc_feature

<222> (3)..(3)

<223> Xaa can be any naturally occurring amino acid

<400> 341

Asp Gl u Xaa Cys Gl u Leu Cys Ile Asn Met Ala Cys Thr Gl y Cys Ser
1 5 10 15

<210> 342

<211> 16

<212> PRT

<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 342

Gln Asp Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 343
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<400> 343

Gln Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 344
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 344

Gln Glu Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

<210> 345
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 345

Lys Asp Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15

40737-513001W0_ST25. txt

<210> 346
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthesized peptide

<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa can be any naturally occurring amino acid

<400> 346

Lys Glu Xaa Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15